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The brain has high energy demands, which are met by the complete oxidation of glucose, 
the obligatory energy substrate for the brain under physiological conditions.  Glucose 
oxidative metabolism consists of cytosolic processes that generate pyruvate, TCA cycle 
that provides reducing equivalents, and mitochondrial oxidative phosphorylation that 
converts energy to ATP. Consistent with the crucial role of energy metabolism in the 
maintenance of brain function, impaired glucose metabolism, and mitochondrial 
dysfunction have been implicated in the pathobiology of many brain disorders, including 
Alzheimer’s disease (AD) and diabetes. In this dissertation, the molecular mechanisms 
underlying altered glucose metabolism in the brains at genetic risk for AD and perturbed 
mitochondrial function in diabetes-associated brain dysfunction are studied.  
In the first study, the impact of human ApoE isoforms, which confer differential risk for 
AD, on brain glucose metabolism were investigated in human ApoE gene-targeted 
replacement mice (hApoE-TR). Gene expression profiling of the cortical RNA extracted 
from hApoE-TR mice revealed that ApoE2-bearing brains exhibited the most robust, 
while ApoE4 brains were associated with the most, deficient profile on both the uptake 
and metabolism of glucose. In particular, the three ApoE brains differed in the expression 
of hexokinase, which acts as the “gateway” enzyme by catalyzing the conversion of 
glucose to glucose-6-phosphate, a branch point metabolite that can be directed to 
glycolysis, glycogen synthesis, and the pentose phosphate pathway.  Ingenuity pathway 
analysis (IPA) predicted that PPAR-γ/PGC-1α signaling pathway could be enhanced in 
the ApoE2 brain and attenuated in the ApoE4 brain. In line with the prediction, PGC-1α 
overexpression ameliorated ApoE4-associated bioenergetic deficits. Furthermore, forced 
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expression of ApoE2 counteracted the detrimental effects induced by ApoE4 as 
demonstrated by the marked improvement in glycolytic function, mitochondrial 
respiration, and the concurrent increase in ATP levels in ApoE4-expressing cells 
transfected with ApoE2 as compared to those transfected with mock control. Taken 
together, in the first study, we discovered a key cytosolic point in glucose metabolism 
that is differentially modulated by human ApoE isoforms, which could serve as a 
potential mechanism underlying their discrete risk impact in AD. 
In the second study, the potential roles of cyclophilin D (CypD), a critical regulator of 
mitochondrial permeability transition (mPT), in diabetes-related mitochondrial 
abnormalities and cognitive dysfunction were investigated using mice injected with 
streptozotocin (STZ), a mouse model of type 1 diabetes. Brain mitochondria from STZ-
treated mice exhibited a significant increase in CypD expression, a marked decrease in 
mitochondrial respiratory function, as well as deficits in spatial learning and memory. 
Notably, genetic deletion of CypD significantly attenuated diabetes-associated defects in 
mitochondrial function and cognitive deficits. By contrast, upregulation of CypD and 
defects in mitochondrial respiration were greatly exacerbated in the brains of AD 
transgenic mice, suggesting AD and diabetes may have synergistic effects on CypD 
expression and mitochondrial dysfunction. As a result of an exacerbation of 
mitochondrial dysfunction, cognitive decline was greatly accelerated in AD transgenic 
mice injected with STZ. Collectively, results obtained from the second study provide new 
insights into the mechanisms underlying brain mitochondrial malfunction and cognitive 
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Alzheimer’s disease (AD) and diabetes are chronic disorders that have a rapidly 
increasing prevalence worldwide and place an enormous burden on the healthcare system 
and society. According to the World Health Organization, AD and diabetes will be the 
6th and 7th leading cause of death respectively by 2030 [1]. AD is a neurodegenerative 
disease clinically characterized by a progressive decline in memory and cognitive 
functions. Diabetes, characterized as a peripheral metabolic disorder, has been known to 
cause complications in the central nervous system, such as cognitive impairment and 
dementia [2-4]. Numerous epidemiological studies have shown that diabetes, and type 2 
diabetes in particular, significantly increased the risk of developing AD [5-9]. Of note, a 
clinical study reported that over 80% of AD patients had type 2 diabetes or exhibited 
abnormal glucose levels [10]. These findings implicate a close relationship between AD 
and diabetes. Mechanistic studies of this connection reveal that perturbed brain energy 
metabolism, including impaired glucose metabolism and mitochondrial dysfunction, may 
serve as the common link between AD and diabetes.  
Impaired glucose metabolism as a common pathological feature in AD and diabetes 
Diabetes is characterized by chronic hyperglycemia resulting from defects in insulin 
production, insulin action or both. While the mechanisms underlying diabetes-associated 
complications are complex and involve multiple factors, the biological basis that drives 
these complications is impaired glucose metabolism. The effects of diabetes on brain 
glucose transport and utilization remain largely unexplored. Increased brain glucose 
concentration has been observed in the individuals with type 1 diabetes, which was 
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thought to result from an increase in glucose transport across the blood-brain barrier 
(BBB) and/or reduced glucose metabolism [11, 12]. In type 2 diabetic patients, insulin 
resistance and reduced cerebral glucose metabolic rate have been observed in several 
AD-affected brain regions including parietotemporal, frontal, and cingulate cortices [13]. 
The abnormalities in brain glucose transport and metabolism were also observed in 
rodent models of experimental diabetes. Mice with type 1 diabetes induced by 
streptozotocin (STZ) exhibited a decrease in glucose transporter in the BBB, and an 
increase in brain glucose concentration and glucose utilization [14-17]. In line with these 
findings, the activities of several key enzymes involved in glucose metabolism were 
significantly elevated [18]. However, these alterations occurred within the first month of 
diabetes induction. In the late stage, a marked reduction in glucose metabolism was found 
in multiple brain regions [17]. Overall, these findings suggest diabetes causes 
perturbations in cerebral glucose transport and metabolism. Given that glucose is the 
obligatory fuel for the brain, the disrupted glucose supply, transport or utilization could 
lead to energy failure and brain damage. In support of this notion, both chronic 
hyperglycemia and repeated occurrences of severe hypoglycemia have been associated 
with impaired cognition [19-22]. Studies on diabetic animal models also point out a link 
between disrupted glucose metabolism and learning and memory deficits [23-26]. Taken 
together, these findings suggest that the dysregulated glucose transport and metabolism 
may, at least in part, underlie diabetes-associated cognitive dysfunction. 
Impaired glucose metabolism has also been observed in the preclinical and clinical AD 
brains. Positron emission tomographic studies with [18F] fluorodeoxyglucose (FDG-PET) 
in AD patients indicate severe glucose hypometabolism in the cerebral cortex, with 
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posterior cingulate and parietotemporal regions mostly affected [27-29]. Reduced glucose 
metabolism has also been detected in individuals with mild cognitive impairment (MCI), 
which is the prodrome to AD [30, 31]. In fact, cerebral glucose hypometabolism may 
precede the clinical symptoms for decades, as abnormally low measurements of glucose 
metabolic rate have been reported in the AD-typical regions including hippocampus, 
posterior cingulate, parietal, temporal, and prefrontal cortex in young and middle-aged 
adults at genetic risk for AD [32-36]. The impaired glucose metabolism may be 
associated with perturbed glucose transport. In support of this notion, the expression of 
two major brain glucose transporters, GLUT1, which is responsible for the uptake of 
glucose across BBB, and GLUT3, which mediates glucose entry into neurons, were 
significantly decreased in the AD brain [37-39].  In addition to the defects in glucose 
transport, impaired intracellular glucose catabolism has been observed. Altered activity of 
glycolytic enzymes including hexokinase, aldolase, pyruvate kinase, lactate 
dehydrogenase and glucose 6-phosphate dehydrogenase have been observed in the AD-
vulnerable brain regions [40, 41]. Decreased activity of two key enzymes in the 
tricarboxylic acid (TCA) cycle, pyruvate dehydrogenase, and α-ketoglutarate 
dehydrogenase were also documented in the AD brain [42, 43]. Similarly, reduced 
glucose metabolic rates, glucose transport dysfunction and disturbed intracellular glucose 
catabolism were detected in the brains of transgenic mouse models of AD [44-46]. The 
bioenergetic deficits resulting from perturbed glucose transport and metabolism may 
drive the molecular processes contributing to the formation of AD-related 
neuropathological hallmarks and cognitive decline [45-47].  
4 
 
In summary, accumulating evidence suggests abnormal glucose metabolism as the 
mechanistic link between AD and diabetes. Impaired cerebral glucose utilization due to 
insulin resistance or disturbed insulin signaling predisposes neurons to the energy crisis 
and functional deficits, which may contribute to the pathological alterations responsible 
for the cognitive dysfunction observed in the brains affected by AD and diabetes. 
Mitochondrial dysfunction and oxidative stress are commonly shared by AD and 
diabetes 
Apart from impaired glucose metabolism, mitochondrial dysfunction and oxidative stress 
have been implicated in AD- and diabetes-associated brain dysfunction. Multiple lines of 
evidence suggest mitochondrial dysfunction and oxidative stress are intimately involved 
in AD pathogenesis and progression. Reduced mitochondrial electron transport chain 
complex activity, particularly deficiency in cytochrome c oxidase activity, has been well 
documented [48-51]. As mitochondria are both the major source and direct victim of 
reactive oxygen species (ROS), mitochondrial dysfunction is usually associated with 
oxidative stress, as evidenced by the extensive lipid, protein, and nucleic acid oxidation 
observed in the AD brain [52-55]. While the cause of mitochondrial dysfunction in AD 
remains elusive, mounting evidence suggests amyloid beta peptide (Aβ) plays a crucial 
role. It has been shown that Aβ is imported into mitochondria via the translocase of the 
outer membrane (TOM) import machinery and localized to mitochondrial cristae [56], 
where it interacts with the mitochondrial proteins such as Aβ-binding alcohol 
dehydrogenase [57] and cyclophilin D [58], leading to mitochondrial respiratory 
dysfunction and mitochondrial reactive oxygen species (ROS) generation. Oxidative 
stress induces mitochondrial Ca2+ overload, resulting in mitochondrial membrane 
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potential collapse, ATP depletion, mitochondrial membrane permeability transition pore 
opening, cytochrome c leakage, and the activation of cell death signaling cascades [59-
61]. In addition to perturbations in mitochondrial function, alterations in mitochondrial 
morphology have been observed in the AD brain [62]. Aβ has been demonstrated to 
facilitate mitochondrial fragmentation by disrupting mitochondrial fission/fusion balance 
in AD-affected neurons [63, 64]. Further, AD brain also demonstrated impaired 
mitochondrial motility [65]. It has been shown that Aβ oligomers decreased axonal 
mitochondrial transport, resulting in reduced mitochondrial density in the axons and 
synaptic terminals [66-68]. Together, these Aβ-related impairments in mitochondrial 
bioenergetics, dynamics, and trafficking could contribute to the synaptic loss and 
functional deficits correlated with cognitive dysfunction in AD [69, 70].  
Emerging evidence suggests the involvement of mitochondrial dysfunction and oxidative 
stress in diabetes-induced brain damage. In an animal model of type 1 diabetes, brain 
mitochondria showed declines in oxidative phosphorylation, ATPase activity and ATP 
levels [71, 72]. Along with the defects in mitochondrial respiratory chain activities, levels 
of ROS, nitric oxide (NO), and mitochondrial nitric oxide synthase expression were 
found to be increased in the mitochondria, suggesting enhanced oxidative and nitrosative 
stress [73].  Additionally, STZ-induced diabetes promoted a reduction in glutathione 
(GSH) peroxidase activity and significant decreases in mitochondrial coenzyme Q9 and 
manganese superoxide dismutase (MnSOD) protein contents, suggesting impaired 
antioxidant capability [71-73]. Importantly, insulin treatment reversed diabetes-related 
mitochondrial alterations presumably via attenuating hyperglycemia-induced oxidative 
stress and improving oxidative phosphorylation efficiency. A similar decrease in 
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mitochondrial respiratory efficiency has been observed in the brains of Goto-Kakizaki 
rats, an animal model of type 2 diabetes [74]. Interestingly, diabetes-related 
mitochondrial dysfunction was exacerbated by aging and/or by the presence of Aβ, which 
supports the idea that diabetes and aging are risk factors for AD [74]. In addition to 
impaired mitochondrial respiratory function, diabetes has been associated with disrupted 
mitochondrial dynamics (imbalance of fission/fusion events). Reductions in 
mitochondrial density and mitochondrial length have been observed in the hippocampus 
of leptin receptor deficient mice (db/db), suggesting diabetes causes the balance shifting 
towards mitochondrial fission [75]. In line with the in vivo findings, treatment of human 
neuronal SK cell line with high glucose resulted in mitochondrial fragmentation by 
enhancing fission. Of note, restoration of mitochondrial dynamics ameliorated diabetes-
induced defects in mitochondrial respiratory function and deficits in synaptic plasticity, 
suggesting defects in mitochondrial function may be responsible for the cognitive 
dysfunction related to diabetes [75]. Additional evidence for the implications of 
mitochondrial bioenergetics and oxidative status in the cognitive decline came from the 
studies on type 1 diabetic patients experiencing recurrent hypoglycemia. It was found that 
both STZ-induced diabetes and insulin-induced hypoglycemia decreased mitochondrial 
respiratory efficiency, increased ROS generation and suppressed antioxidant defense in 
the cortical and hippocampal mitochondria [76]. Additionally, a higher release of 
glutamate was observed in the diabetic and hypoglycemic synaptosomes [77]. Therefore, 
mitochondrial dysfunction, oxidative stress, and higher release of excitatory 
neurotransmitters may act synergistically, contributing to neuronal injury and cognitive 
impairments in type 1 diabetic patients receiving insulin treatment. 
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As mitochondria are the major site where the complete oxidation of glucose takes place, 
their functional defects may constitute a downstream event of impaired glucose 
metabolism. Oxidative stress induced by poor glycemic control or Aβ promotes 
abnormalities in mitochondrial respiratory function, dynamics, and motility, contributing 
to synaptic dysfunction and cognitive impairment, both are prominent in the AD- and 
diabetes-affected brains. In conclusion, I briefly reviewed the evidence for the perturbed 
glucose metabolism and mitochondrial dysfunction as common pathological features of 
AD and diabetes. Further investigations aiming at uncovering the molecular mechanisms 
underlying AD and diabetes interrelation may lead to the discovery of novel therapeutic 




Purpose of the Dissertation 
Alzheimer’s disease and diabetes are aging-related chronic disorders affecting millions of 
people worldwide. The incidence of both has increased drastically in recent years due to 
the enhanced lifespan and population growth. Numerous epidemiological studies indicate 
that diabetes significantly increases the risk of dementia including the Alzheimer’s type 
[5, 78, 79]. A rapidly growing body of evidence suggests insulin resistance, the major 
defect in type 2 diabetes, and impaired insulin signaling may contribute to AD 
neuropathology and cognitive impairment [80-83]. These findings suggest a commonly 
shared mechanism may be responsible for AD- and diabetes-related cognitive impairment. 
One of the several common abnormalities shared by the two disorders is the perturbed 
brain energy metabolism, including impaired glucose metabolism and mitochondrial 
dysfunction. Uncovering the molecular intersection of AD- and diabetes-regulated brain 
energy metabolism may provide insights into the etiologies of cognitive dysfunction 
associated with these disorders and lead to the development of novel therapeutic 
interventions.  
Cognitively normal individuals at risk for AD, including those carrying ApoE4, showed 
reduced cerebral metabolism of glucose, the primary energy substrate for the brain [32, 
84]. Treatment with a ketogenic agent did not improve cognitive function in ApoE4 
carriers [85, 86], suggesting ApoE4 genetic status affects the brain’s capability of 
metabolizing ketone bodies, the secondary fuel for the brain. Utilizing mouse models 
expressing human ApoE isoforms, we found that ApoE2 brain is associated with a most 
robust profile in insulin-like growth factor 1 signaling and glucose transport [87]. 
Together, these findings suggest human ApoE genetic status influences brain energy 
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metabolism. However, what substrate and which metabolic pathway are specifically 
regulated by ApoE isoforms remain to be elucidated. Therefore, the purpose of the first 
part of my study is to identify the specific substrates and metabolic pathways in the brain 
that are differentially modulated by human ApoE isoforms. The intracellular oxidative 
catabolism of glucose includes glycolysis and pentose phosphate pathway in the cytosol, 
and TCA cycle and oxidative phosphorylation in the mitochondria. Previous research has 
been primarily focused on mitochondrial bioenergetics, in particular, the detrimental 
effects of ApoE4 on mitochondrial respiratory chain. Comparatively, few studies have 
looked at the cytosolic metabolism. However, metabolic pathways occur in the cytosol 
are crucial for ATP production and maintenance of mitochondrial function by providing 
reducing equivalents and antioxidant defense against oxidative stress. Therefore, my 
study focused on pinpointing the cytosolic metabolic pathways that are potentially 
affected by ApoE genetic status. 
To probe the metabolic pathways altered by ApoE genetic status, we first performed a 
gene expression profiling study on the brains of 6-month-old human ApoE gene-targeted 
replacement mice.  Specifically, the custom array examined the expression of 43 genes 
involved in the cytosolic processes from energy substrate transport to the major cytosolic 
metabolic pathways leading to the generation of acetyl-CoA. Based on the findings from 
gene array analysis, we carried out functional studies of ApoE modulation of energy 
metabolism using an in vitro cell culture model. To further understand the biological 
implications of gene expression changes, we used a bioinformatics computing program, 
IPA, and conducted a regulatory pathway and molecular network analysis. IPA predicted 
the enhanced activity of peroxisome proliferator-activated receptor gamma coactivator 1-
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alpha (PGC-1α) may underlie the bioenergetic robustness associated with ApoE2. 
Therefore, we proceeded with investigations of whether PGC-1α overexpression could 
ameliorate the detrimental effects induced by ApoE4 in brain energy metabolism using 
cell lines stably expressing human ApoE isoforms. Lastly, we examined whether the 
introduction of ApoE2 could counteract ApoE4-associated bioenergetic deficits.  
Diabetes has been associated with an increased risk of synaptic injury and cognitive 
dysfunction [88-91], however, the underlying mechanism is not clear. Emerging evidence 
suggests mitochondrial dysfunction and oxidative stress are common events in the brains 
of animal models of type 1 and type 2 diabetes [71, 72, 75]. In addition to reduced 
mitochondrial respiratory efficiency and lower ATP production, brain mitochondria 
isolated from diabetic animals also presented impaired capacity to accumulate Ca2+ [71, 
72]. A decrease in Ca2+ buffering capacity may lead to reduced threshold for 
mitochondrial permeability transition pore (mPTP) opening. In the presence of mPTP 
triggers, such as ROS generation, diabetic mitochondria may be more susceptible to the 
induction of mitochondrial permeability transition, which lead to loss of mitochondrial 
membrane potential, depletion of ATP, mitochondrial swelling, the rupture of the outer 
mitochondrial membrane and cell death. The structural and functional impairment of 
mitochondria may, in turn, promote ROS production, forming a vicious feedback loop. 
Therefore, mitochondrial mPTP may be implicated in mitochondrial dysfunction and 
oxidative stress observed in the diabetic brain. Previously, it has been shown that 
cyclophilin D (CypD), a critical regulator of Ca2+-mediated opening of mPTP, is 
significantly increased in the brains of AD patients and in a transgenic mouse model of 
AD [58]. Intriguingly, CypD-deficient mitochondria have improved calcium buffering 
11 
 
capacity and are resistant to Aβ- and Ca2+-induced mitochondrial permeability transition. 
Notably, genetic deletion of CypD protects neurons from oxidative stress-induced cell 
death. Further, the absence of CypD significantly attenuated synaptic injury and cognitive 
deficits in an AD mouse model. Given that mitochondrial dysfunction is a common 
abnormality in the AD- and diabetes-affected brain, we hypothesized that CypD 
deficiency attenuates diabetes-associated mitochondrial dysfunction and cognitive 
impairment.  
To test this hypothesis, I first verified the expression levels of CypD in the brains of STZ-
injected mice, a mouse model of type 1 diabetes. 3 month-old wild-type mice and CypD 
null mice were subjected to intraperitoneal injection of STZ for five consecutive days to 
induce diabetes. Then, I examined the effects of CypD deficiency on mitochondrial 
function by measuring mitochondrial electron transport chain (ETC) complex activities. 
Additionally, Morris water maze (MWM) task was performed to assess the effect of 
CypD deficiency on diabetes-induced learning and memory deficits. 
It has been shown that diabetes-associated mitochondrial dysfunction is exacerbated in 
the presence of Aβ. Additionally, the CypD expression is enhanced in an Aβ-enriched 
environment. Further, the expression level of CypD is positively correlated with the 
probability of mPTP opening. Therefore, I asked the question, whether enhanced CypD 
expression induced by AD exacerbates diabetes-associated mitochondrial dysfunction 
and cognitive decline.  
To address this question, we induced type 1 diabetes in an AD mouse model (J20) which 
has been demonstrated to express increased level of CypD in the brain. Then I evaluated 
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the synergistic effects of diabetes and AD on mitochondrial dysfunction by measuring 
mitochondrial ETC complex activities. Lastly, I performed MWM to determine whether 
diabetes and AD act synergistically to exacerbate cognitive impairment.  
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Chapter 1 Human ApoE Isoforms Differentially Modulate Brain Glucose and 
Ketone Metabolism: Implications for Alzheimer's Disease Prevention and Early 
Intervention 
1.1 Abstract 
Alzheimer’s disease (AD) is an irreversible neurodegenerative disorder characterized 
clinically by progressive loss of memory and cognitive decline. There are two types of 
AD: early-onset and late-onset (LOAD); LOAD accounts for over 95% of all AD cases. 
Humans possess three genetic isoforms of apolipoprotein E (ApoE)—ApoE2, ApoE3, 
and ApoE4—that confer differential risk for LOAD; however, the underlying 
mechanisms are poorly understood. This study sought to investigate the impact of human 
ApoE isoforms on brain energy metabolism, an area significantly perturbed in preclinical 
AD. A TaqMan custom array was performed to examine the expression of a total of 43 
genes involved in glucose and ketone body uptake, transport and cytosolic metabolism in 
the cortical tissues of human ApoE gene-targeted replacement mice (hApoE-TR). 
Consistent with our previous findings, ApoE2-bearing brains exhibited the most robust 
while ApoE4 brains were associated with the most deficient profile on both the uptake 
and metabolism of glucose, the primary energy substrate for the brain. In particular, the 
three ApoE genotypes significantly differed in the expression of facilitated glucose 
transporters, which mediate the entry of glucose into neurons, and hexokinase, which acts 
as the “gateway enzyme” in glucose metabolism by converting glucose to glucose-6-
phosphate, the initial step in the glycolysis, glycogen synthesis and pentose phosphate 
pathway.  Interestingly, on the uptake and metabolism of ketone bodies, the secondary 
energy source for the brain, ApoE2 and ApoE4 brains exhibited a similar level of 
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robustness, while ApoE3 brains presented a relatively deficient profile, which may 
provide a plausible explanation for the clinical observations that a ketogenic agent was 
found to benefit ApoE3 but not ApoE4 carriers. Moreover, Ingenuity Pathway Analysis 
predicted that PPAR-γ/PGC-1α signaling activity could be enhanced in the ApoE2 brain 
and attenuated in the ApoE4 brain. Consistent with the prediction, PGC-1α 
overexpression ameliorated ApoE4-associated deficits in glycolysis and mitochondrial 
respiration. Further, forced expression of ApoE2 counteracted the detrimental effects 
induced by ApoE4 as demonstrated by the significant improvement in glycolytic function, 
the elevation in mitochondrial respiration, and the concurrent increase in ATP production 
in ApoE4-expressing cells transfected with ApoE2 when compared to those transfected 
with mock control. Taken together, our data provide additional evidence that human 
ApoE isoforms differentially modulate brain energy metabolism, which could serve as a 
potential mechanism underlying their discrete risk impact in AD. Importantly, the 
introduction of ApoE2 may represent a promising therapeutic approach in AD prevention 
and early intervention by promoting bioenergetic robustness contributing to brain 





1.2.1 Alzheimer’s disease: current status 
As one of the most common forms of dementia, Alzheimer’s disease (AD) currently 
affects 35 million people worldwide, including 5.3 million Americans. By 2050, this 
number is predicted to nearly triple, projected to 13.8 million. This devastating disease 
creates a huge economic burden to the American society; an estimated overall payment 
for AD care in 2015 was $226 billion, which is projected to increase to more than $1 
trillion by 2050 [92].  
AD is manifested clinically as progressive loss of memory and cognitive function and is 
characterized pathologically by the formation of amyloid beta (Aβ) plaques and 
neurofibrillary tangles (NFT). Since its discovery in 1906, extensive research has been 
undertaken to delineate AD pathogenesis and to develop treatments; however, the cause 
of AD remains largely unknown and no success has been found from over 200 AD drug 
trials conducted in the past decade [93]. It has been estimated that a treatment that delays 
the onset of AD by just 5 years could reduce the number of individuals with the disease 
by 38% in 2050 [94]. Therefore, increased research should be directed to better 
understand AD-risk mechanisms that would allow the development of strategies aimed at 






1.2.2 Human apolipoprotein E (ApoE) in the brain: isoforms, expression, and 
function 
Apolipoprotein E (ApoE) is a component of a wide spectrum of plasma lipoproteins 
found in almost all mammals. Human ApoE was first described in 1973 by Shore and 
Shore as “arginine-rich protein” present in the very-low-density lipoproteins (VLDL) 
[95]. Later in 1975, it was proposed that the defect in the regulation or the structure of 
ApoE is responsible for the type III hyperlipoproteinemia, which is a familial disorder 
characterized by premature atherosclerosis and accumulation of plasma cholesterol [96, 
97]. In the half-century since its discovery, extensive research has been undertaken to 
delineate the role of the ApoE in cholesterol/lipid transport and metabolism under both 
physiological and pathological conditions. It is known that ApoE is a constituent of 
several plasma lipoproteins including chylomicrons, VLDL remnants, VLDL and a 
subclass of high-density lipoproteins (HDL). Lipoprotein-associated ApoE is a ligand for 
various members of the low-density lipoprotein (LDL) receptor family including LDL 
receptor, the very-low-density lipoprotein (VLDL) receptor, the ApoE receptor 2 
(ApoER-2) and the LDL-receptor-related protein (LRP). The transport of ApoE-
containing lipoproteins between the cells occurs through LDL receptor-mediated 
endocytosis. After internalization, ApoE can be degraded or recycled back to the cell 
surface.  
The human ApoE gene localizes to the long arm of chromosome 19q13.2, is 
approximately 3.7 kb in length and contains four exons separated by three introns [98] 
(Fig.1.2.1). The promoter sequence TATAATT occurs at 33 nucleotides upstream of the 
transcription initiation site [99]. Analysis of human ApoE cDNA indicates that the 
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corresponding mRNA contains 1157 nucleotides and the primary translation product is a 
317-amino acid precursor protein with an 18-amino acid signal peptide attached to the N-
terminal [100, 101]. The cleavage of the signal peptide results in the mature ApoE, which 
is a 299-amino acid protein with a molecular mass of 34 kDa.  
Human ApoE exists as three major isoforms, ApoE2, ApoE3 and ApoE4, which are the 
products of three alleles at a single gene locus. These isoforms differ structurally by two 
amino acid substitutions at residues 112 and 158: ApoE2 (Cys-112, Cys-158), ApoE3 
(Cys-112, Arg-158), and ApoE4 (Arg-112, Arg-158). The difference in amino acids 
arises from two single nucleotide polymorphisms (SNP) in the ApoE gene on codon 112 
(388 T > C) and 158 (526 C > T) (Fig. 1.2.1). ApoE consists of two major functional 
domains — an amino-terminal domain which has been shown to be a four-helix bundle 
that contains a highly positively charged receptor-binding region composed mainly of 
arginine and lysine residues and a carboxyl-terminal domain which includes a lipid-
binding region — and these two domains are joined by a flexible hinge region (Fig.1.2.1). 
The characterization studies of the receptor binding properties of ApoE suggest positively 
charged residues are essential since chemical modifications of either arginine or lysine 
residues in the vicinity of the recognition sites abolished the bindings of lipoproteins to 











Substitutions of two amino acid residues in the three ApoE isoforms significantly alters 
their structure and function, which is crucial for understanding their roles in AD 
pathogenesis [104]. Results from X-ray crystallography, fluorescence resonance energy 
transfer (FRET) and electron paramagnetic resonance (EPR) spectroscopy of human 
Fig.1.2.1 The schematic representation of the structural and functional domains 
of human ApoE isoforms. Human ApoE gene is composed of four exons interrupted 
by three introns (pattern box: coding region; open box: untranslated region). The 
ApoE2, ApoE3 and ApoE4 isoforms are coded by ԑ2, ԑ3 and ԑ4 alleles of the ApoE 
gene, respectively. The isoforms differ with each other in two amino acid substitutions 
at residues 112 or 158 resulting from C→T or T→ C point mutation in exon 4 as 
indicated. ApoE has two functional domains: the N-terminal domain containing the 
receptor-binding region (residues 134-150) and the C-terminal domain which includes 
the lipid-binding region (residues 244-272).  Adapted from Wu, Long, and Liqin Zhao 
(2016) Neural Regeneration Research 11(3): 412–413. 
19 
 
ApoE isoforms reveal that ApoE4 displays a distinct conformation resulting from 
intramolecular domain interaction [105-108] (Fig.1.2.2). Specifically, Arg-112 in the 
amino-terminal domain of ApoE4 forms a salt bridge with Glu-109 and causes the Arg-
61 side chain to extend away from the four-helix bundle, thus allowing an interaction 
with Glu-255 in the carboxyl-terminal domain, resulting in a more compact structure. In 
comparison, Cys-112 in ApoE2 and ApoE3 causes the Arg-61 side chain to be buried 
between two helixes, rendering it less accessible for the interaction with Glu-255 and 
resulting in a more extended structure. Indeed, in vitro studies indicate that mutation of 
Arg-61 to threonine or Glu-255 to alanine abolished domain interaction [106, 107]. 
Additionally, in mouse ApoE, which contains Arg-112 and Glu-255 that are equivalent to 
human ApoE4 but lacks Arg-61, substitution of Thr-61 with arginine introduced an 
ApoE4 domain interaction, making mouse ApoE to act like human ApoE4 [109]. This 
domain interaction appears to affect both the receptor- and lipid-binding affinities of 
ApoE. For instance, ApoE2 has a much lower binding affinity for LDL receptors 
compared to that of ApoE3 and ApoE4 [110]. While ApoE2 and ApoE3 preferentially 
bind to small, phospholipid-enriched HDL, ApoE4 preferentially binds to LDL and the 
large, triglyceride-enriched VLDL [106, 109]. Further, the structural difference renders 
ApoE4 more susceptible to protein misfolding and instability. It has been shown that 
ApoE2 is the most stable isoform whereas ApoE4 is the least stable and is prone to form 
a folding intermediate with the characteristics of a molten globule during guanidine-HCl, 
urea, and thermal denaturation [111, 112]. These altered properties of ApoE4 have been 
postulated to contribute to the neuropathological effects of ApoE4, including elevation in 
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Aβ production [113], increase in Aβ-induced lysosomal leakage and apoptosis [114], and 








ApoE is found in a variety of organs. In the periphery, ApoE is abundantly expressed in 
liver, kidney, and to a lesser extent in spleen, lung and adipose tissues. The liver is the 
major source of plasma ApoE [117-121]. Interestingly, although the intestine is involved 
in lipoprotein synthesis, ApoE was not detected in intestinal mucosa [118]. A substantial 
Fig.1.2.2 Influence of domain interaction on the structure of ApoE. In ApoE4, 
Arg-112 causes the Arg-61 side chain to extend away from the four-helix bundle, 
allowing an interaction with Glu-255. In ApoE3, Cys-112 causes the Arg-61 side chain 
to be tucked between helix 2 and helix 3, thus unable to interact with Glu-255.  The 
secondary structure of the amino-terminal domain of ApoE was shown. red, helix 1; 
blue, helix 2; green, helix 3; yellow, helix 4 and the connecting loop. Adapted from 




amount of ApoE mRNA was also detected throughout all regions of the brain. Initially, it 
was thought that ApoE is solely synthesized and secreted by glial cells, mainly astrocytes 
[122]. Later, it was found that neurons can produce ApoE in response to a variety of 
physiological or pathological stimuli, albeit at a much lower level compared to astrocytes 
[123-126]. Of note, ApoE is the major apolipoprotein in the human cerebrospinal fluid 
(CSF), where it may play an important role in mediating lipid transport and cholesterol 
metabolism in the central nervous system [127-129]. CSF ApoE concentration is only at 
5% - 10% of its concentration in the plasma and it has been shown to vary in 
inflammatory neurological disorders [130]. Currently, the clinical significance of CSF 
ApoE concentration in AD is still under debate. Some suggest the CSF level of ApoE is 
associated with pathogenesis and progression of AD [131-136] whereas others did not 
find such association [137-141]. Recently, a meta-analysis which includes a total of 1064 
AD patients and 1338 controls failed to identify a significant association between CSF 
ApoE levels and AD risk. However, the interpretation of the results may be confounded 
by the gender-specific and ApoE isoform-specific effects on ApoE level, the difference in 
age of onset as well as a lack of longitudinal CSF ApoE measurements [142]. Therefore, 
future studies, which take all the factors mentioned above into consideration, are 
warranted to address the clinical relevance of CSF ApoE concentrations in AD. 
One of the primary functions of ApoE in the brain is cholesterol transport, mainly from 
astrocytes to neurons. Cholesterol is an essential component in the membrane and myelin 
sheaths and is of critical importance in the synaptogenesis and synaptic function [143]. A 
role for ApoE in central nervous system (CNS) reinnervation after neural injury has been 
described [144-147]. In response to damage, such as neuronal loss or terminal 
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deafferentation, astrocytes synthesize and release ApoE, which presumably takes up the 
cholesterol and phospholipids released from cellular membrane and myelin debris. 
Following LDL receptor-mediated endocytosis, cholesterol is released into the cytoplasm 
and transported to the dendritic field for dendritic remodeling or to the terminals for 
synapse formation. Additionally, ApoE is also responsible for other brain lipid transport 
and metabolism. For instance, sulfatide, a class of oligodendrocyte-synthesized lipids 
which mediate neuronal plasticity and myelin sheath integrity, is carried by ApoE 
containing HDL-like lipoproteins in the human CSF [148].  
Accumulating evidence suggests ApoE interacts with LRP to modulate neurite 
outgrowth. The effect of ApoE-containing lipoproteins on neurite outgrowth has been 
shown to be isoform-specific with ApoE3-containing lipoproteins promoting neurite 
outgrowth whereas ApoE4-containing lipoproteins having no effect or suppressing 
neurite outgrowth [149-151]. Interestingly, the effects of ApoE-containing lipoproteins 
on neurite outgrowth is present only when β-migrating VLDL, which are cholesterol-
enriched remnants of chylomicrons, or HDL are utilized as lipoprotein carriers [150]. 
Further, these effects can be abolished by the inhibitors that prevent the ligand binding to 
LRP [151, 152]. Together, these findings indicate that the interaction between ApoE and 
certain lipoproteins may facilitate their internalization via the LRP-dependent pathway. 
Conflicting in vivo findings exist pertaining to the role of ApoE in synaptic integrity and 
plasticity. Results from some studies point out a critical role of ApoE in maintaining 
synaptic structure and function. Masliah et al. reported that ApoE null mice displayed an 
age-dependent loss of synapses and disruption of the dendritic cytoskeleton in the 
neocortex and limbic system [153]. Homozygous ApoE-deficient mice exhibited working 
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memory impairments in the MWM tasks, which has been correlated with cholinergic 
deficits in the basal forebrain [154-156]. Infusion of recombinant ApoE into the brain of 
ApoE-deficient mice resulted in a significant improvement in their learning capacity 
which was associated with the restoration of synapto-dendritic structure [157]. Others, 
however, suggest that ApoE is of no importance in the maintenance of normal synaptic 
integrity or plasticity. For instance, it has been shown that the ApoE-knockout mice have 
a normal cholinergic system during aging [158-160]. Additionally, mice lacking ApoE 
appear to be intact in spatial learning or reference memory as they performed similar to 
their wild-type littermates in the MWM tasks [161, 162]. Further, mice deficient in ApoE 
do not differ from aged-matched wild-type mice in synaptic plasticity, synaptic injury 
recovery or synaptic degeneration during aging [163-165]. One possible explanation for 
the lack of defects observed in ApoE-deficient mice could be that alternative 
apolipoproteins, for instance, apolipoprotein J (ApoJ), compensate for the loss of ApoE. 
ApoJ shares a number of similarities with ApoE: ApoJ is highly expressed in the brain 
and mainly synthesized and secreted by astrocytes. More importantly, like ApoE, ApoJ 
plays a role in synaptic remodeling, repair, and regeneration after brain injury [166-168]. 
Therefore, it is likely that ApoJ may replace the function of ApoE in the brain, although 




1.2.3 ApoE polymorphisms in AD: clinical evidence for the neuroprotective 
properties of ApoE2 
The genetic polymorphism of human ApoE was first discovered in 1977 from a German 
population, which was associated with the occurrence of type III hyperlipoproteinemia 
[169]. Three major ApoE alleles, ԑ2, ԑ3, and ԑ4, are determined by two single nucleotide 
polymorphisms. The expression of two of the three alleles gives rise to a total of six 
ApoE genotypes: three homozygous genotypes (ApoE ԑ2/ԑ2, ApoE ԑ3/ԑ3, and ApoE 
ԑ4/ԑ4) and three heterozygous genotypes (ApoE ԑ2/ ԑ3, ApoE ԑ3/ ԑ4, and ApoE ԑ2/ ԑ4). 
The allele frequencies of ApoE vary widely across the population with ApoE ԑ3/ԑ3 being 
the most common followed by ApoE ԑ3/ ԑ4 and ApoE ԑ2/ ԑ3. ApoE polymorphic alleles 
have been shown to confer differential susceptibility to AD [170]. As the most common 
allele, ApoE ԑ3 is present in approximately 75% of the population and is believed to play 
a neutral role in AD. ApoE ԑ2 is relatively rare, with only 5% incidence, and is 
recognized as a protective variant against AD. In contrast, as the most potent genetic risk 
factor for AD, ApoE ԑ4 exists in only about 20% of the population, however, it accounts 
for nearly 65% of total AD cases. Possession of ApoE4 not only increases the prevalence 
of AD but also lowers the age of onset in a gene dosage-dependent manner. It has been 
estimated that the mean age of onset is 84 years in individuals who do not have ApoE ԑ4, 
76 for individuals with one copy of ApoE ԑ4, and 68 in subjects with both copies of 
ApoE ԑ4 [171].  
ApoE4 was first identified as the major risk factor for developing late-onset AD in 1993 
[171]. Over the past few decades, a plethora of studies have been done to examine the 
role of ApoE in AD pathogenesis. Most studies have primarily focused on identifying 
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AD-risk mechanisms conferred by ApoE4 through comparisons between ApoE4 and 
ApoE3 and between ApoE4 carriers and non-carriers. Clinically, ApoE4 has been 
associated with an accelerated rate of cognitive decline in aging and AD. Healthy ApoE4 
homozygotes in their 60s have faster deterioration in several cognitive domains when 
compared to ApoE4 heterozygotes or non-carriers before the diagnosis of mild cognitive 
impairment (MCI), the prodromal stage of AD [172, 173]. Similarly, longitudinal studies 
reveal that ApoE4 carriers display memory decline even before the age of 60 and exhibit 
greater acceleration than non-carriers despite ongoing normal clinical status [174, 175]. 
ApoE4 carriers also show a higher rate of cognitive deterioration in verbal memory and 
abstract reasoning in the ninth decade of life [176]. More recently, it was found that 
ApoE4 exacerbated Aβ-related memory decline in cognitively normal older adults [177, 
178]. Notably, ApoE4 carriers with high Aβ concentration in the brain demonstrated the 
most pronounced decline in learning and working memory. In subjects with MCI, ApoE4 
was also associated with greater memory deficits and accelerated declines in the global 
measures of cognition [179-181]. Further, ApoE4 predicts a faster rate of cognitive 
decline in AD [182-185], although results obtained from some studies suggest no 
difference in the rate of deterioration in respect to ApoE4 genetic status [186-189]. These 
conflicting findings could be explained by methodologic differences in the measurements 
of cognitive function, subject’s stage of AD and length of follow-up time. Comparatively, 
few studies have explored the role of ApoE2 in relation to AD, and overall the results of 
these studies suggest that ApoE2 is neuroprotective. For instance, ApoE2 has been 
positively associated with cognitive function in aging [190]. A longitudinal study in a 
large cohort of elderly dementia-free subjects demonstrated that individuals who possess 
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at least one ApoE2 allele (ԑ2/ԑ2 and ԑ2/ԑ3) exhibit improved episodic memory 
performance, which may be attributed to increased functional connectivity in the 
entorhinal cortex region [191]. In contrast, a decrease in episodic memory performance 
was found in the subjects with the ApoE3 (ԑ3/ԑ3) genotype and a faster-deteriorating rate 
in those with at least one ApoE ԑ4 allele [192]. Additionally, ApoE2 has been found to 
slow AD progression [183, 184]. Possession of one copy of ApoE2 allele has been 
associated with slower rate of cognitive decline, whereas possession of an ApoE4 allele 
predicted an earlier and faster cognitive decline in patients with probable AD. Together, 
these findings point to a protective role of ApoE2 in maintaining cognitive function under 
both physiological and neurodegenerative conditions. 
Structural alterations may relate to cognitive impairments in the aging and AD brains. In 
subjects with MCI and AD, ApoE4 has been associated with an accelerated rate of 
hippocampal atrophy coupled with worsening memory performance [193-196]. In healthy 
non-demented individuals, possession of ApoE4 exacerbated the age-related decline in 
cortical thickness and hippocampal volume [197-199]. Recently, structural magnetic 
resonance imaging (MRI) of infants reveals that ApoE4 carriers have smaller gray matter 
volume in the brain areas that are most affected by AD, including precuneus, posterior 
middle cingulate, lateral temporal, and medial occipitotemporal regions [200]. It has been 
proposed that an age-related structural breaking down of myelin sheaths in the brain’s 
later-myelinating regions may lead to progressive interruption of neural impulse 
transmission and the subsequent degradation of the widely distributed neural network, 
contributing to cognitive dysfunction. Indeed, ApoE4 carriers demonstrate accelerated 
rate of myelin breakdown with age in late-myelinating regions as compared to non-
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carriers [201], which may underlie the faster rate of cognitive deterioration observed in 
the ApoE4 brain. In contrast, ApoE2 has been associated with the structural integrity of 
the brain during aging. For instance, ApoE2 carriers exhibit significantly less decline in 
age-related myelin breakdown [201]. Children and adolescents who possess ApoE2 have 
the thickest entorhinal and medial temporal cortex [202]. Results from the Alzheimer's 
Disease Neuroimaging Initiative (ADNI) study indicate that ApoE2 carriers have larger 
hippocampal volume and a reduced rate of hippocampal atrophy compared to non-
carriers [203]. Collectively, these findings suggest that ApoE2 may play a positive role in 
preserving the structural integrity of the brain which may set a foundation for its 
cognition-favoring properties during physiological aging and the development of AD.  
 
1.2.4 Brain energy substrate uptake and metabolism 
The brain has a surprisingly high energy demand, despite its small size. While it only 
represents 2% of the body mass, it utilizes up to 20% of the oxygen and 25 % of the 
glucose consumed by the body. It has been estimated that neurons consumed 80% of the 
energy to support the activity of ion pumps, such as  Na+/K+-ATPase, that re-establish the 
electrochemical gradients dissipated by signaling, namely action potentials, synaptic 
potentials and recycling of neurotransmitters [204-206]. In normal physiological 
conditions, glucose is the only significant energy substrate for the adult brain. However, 
under certain circumstances like starvation, ketone body can serve as a secondary energy 
source. Cerebral glucose metabolism includes glucose uptake, transport and intracellular 
oxidative catabolism (Fig.1.2.3). Brain glucose uptake and glucose entry into neurons are 
significantly dependent on the functions of glucose transporters. Intracellular oxidative 
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catabolism of glucose begins with the conversion of glucose to glucose-6-phosphate, 
which is a branch point metabolite that has different fates depending on the metabolic 
pathways. It is primarily processed via glycolysis, leading to the production of pyruvate, 
which can feed into TCA cycle and mitochondrial oxidative phosphorylation for the 
production of ATP. Alternatively, it is directed to the pentose phosphate pathway shunt 
for the generation of NADPH to support reductive biosynthesis, antioxidant defense and 
the synthesis of nucleic acids. In astrocytes, it is the precursor for glycogen. The entry of 
ketone bodies into neurons is mediated by monocarboxylate transporters. The metabolism 
of ketones occurs exclusively in the mitochondria. In the following sections, the 
transporters and major metabolic processes involving glucose and ketone bodies as 









Fig.1.2.3 The schematic representation of the brain energy metabolism. Brain 
energy substrates include: 1) Glucose as the primary energy source under most 
conditions, and 2) ketone bodies as the secondary energy source in times of glucose 
shortage. Brain glucose and ketone body uptake are strictly controlled by their 
respective transporters, GLUTs and MCTs. The substrate metabolism includes 
cytosolic metabolism and mitochondrial bioenergetics. Glucose-6-phosphate can be 
processed through several metabolic pathways including glycolysis and pentose 
phosphate pathway (PPP) in neurons and glycogen synthesis in astrocytes. GLUT: 
glucose transporters; MCT: monocarboxylate transporters; HK: hexokinase; PDH: 
pyruvate dehydrogenase; ACAT1: acetyl-CoA acetyltransferase; SCOT: succinyl-CoA: 




1.2.4.1 Glucose uptake and metabolism in the brain 
Brain glucose transporters  
In the brain, glucose transport across the cell membrane or tissue barrier is primarily 
mediated by the facilitated glucose transporters (GLUTs). Table 1.2.1 summarizes the 
major GLUTs, their locations and main substrates in the brain. The most characterized 
glucose transporter in the brain is glucose transporter 1 (GLUT1). Brain GLUT1 exists as 
two isoforms: a highly glycosylated, 55 kDa form, expressed in the blood-brain barrier 
(BBB) endothelial cells [207-209] and a less glycosylated, 45 kDa form, localized to 
astrocytes [210-212]. The relationship between the extent of glycosylation and protein 
function remains to be defined. It has been shown that glucose concentrations modulate 
GLUT1 protein expression in the BBB and the glucose uptake in cerebral microvessels 
directly correlates with GLUT1 protein levels, suggesting GLUT1 plays a crucial role in 
overall glucose supply for the brain [210, 213].  
Comparatively few studies have explored the role of glucose transporter 2 (GLUT2) in 
the CNS. To date, the expression pattern and function of GLUT2 in the brain remain 
controversial. Some studies reported that GLUT2 was exclusively expressed in the 
astrocytes in a limited number of brain nuclei including the paraventricular hypothalamic 
nucleus, the lateral hypothalamic area, and the arcuate nucleus, where it may function as 
a glucose sensor [214-216]. Other studies found that some cerebral neurons also 
expressed GLUT2 and may participate in glucose sensing, regulation of neurotransmitter 
release and glucose release by glial cells [217, 218]. Brant et al., however, found that 
GLUT2 was widely expressed in all brain regions, albeit at low levels [219]. Thus, 
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further investigations are warranted to validate the location and potential role of GLUT2 
in the regulation of cerebral glucose homeostasis. 
Apart from GLUT1, glucose transporter 3 (GLUT3) is another predominant transporter 
which mediates glucose uptake in the brain. It is recognized as a neuron-specific glucose 
transporter. GLUT3 is widely expressed throughout rat brain, including the cerebellum, 
striatum, cortex and hippocampus [210, 220]. A detailed examination of the location of 
GLUT3 by immunohistochemistry analysis revealed that GLUT3 was localized to 
neuropil and was largely absent from neuronal cell bodies [221, 222]. An additional 
electron microscopic study in rat brain further confirmed GLUT3 to be exclusively 
neuronal [211]. More importantly, on the subcellular level, GLUT3 was found localized 
mainly to the membranes of axon terminals, suggesting a functional role in energy supply 
that matched closely to synaptic transmission [211]. Despite its expression in neurons, 
how GLUT3 is regulated remains largely unknown. It has been shown that insulin 
facilitated GLUT3 translocation to the plasma membrane, and promoted neuronal glucose 
uptake [223].  
Glucose transporter 4 (GLUT4), the insulin-sensitive glucose transporter, is primarily 
expressed in discrete neuronal populations in several brain regions including cerebellum, 
hypothalamus, hippocampus and cortex [224-227]. At the subcellular level, GLUT4 
expression has been observed in neuronal cell bodies and dendrites [227].  Interestingly, 
there is a significant overlap between the cerebral areas where GLUT4 and insulin 
receptors are present [224, 228], suggesting GLUT4 may modulate the effects of insulin 
in the brain. In support of this hypothesis, altered cerebral expression of GLUT4 has been 
observed in rodent models with insulin resistance [225, 229, 230]. Additionally, it has 
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been shown that insulin induces the translocation of GLUT4 to the plasma membrane in 
human neuroblastoma cells [231]. Therefore, insulin may regulate neuronal glucose 
uptake by altering GLUT4 expressions on the cell surface. Further, since GLUT4 is 
highly expressed in the brain areas associated with motor function, such as sensorimotor 
cortex and cerebellum [227], GLUT4 may provide additional glucose to motor neurons 
under conditions of high energy demand. This notion is in line with the observation that 
heavy dynamic exercise markedly increased local cerebral glucose utilization in brain 
areas involved in motor function [232]. However, future studies are needed to delineate 
the molecular mechanisms by which GLUT4 modulates cerebral glucose homeostasis.  
Glucose transporter 5 (GLUT5) has been identified as the fructose transporter in the brain 
as it exhibits high affinity to fructose but displays significantly lower transporter activity 
for glucose [233]. In the human brain, GLUT5 has been found in microglial cells [210]  
and endothelial cells of the microvasculature [234]. Expression of GLUT5 was also 
observed in the Purkinje cells in the rat cerebellum [235]. Given that GLUT5 is localized 
to the BBB, it may mediate brain uptake of fructose since fructose can serve as an 
alternative energy source for the brain. In support of this notion, short-term fructose 
feeding increased brain expression of GLUT5 in both young and aging adult rats [236]. 
Recently, it was reported that rat neocortical cells took up and metabolized extracellular 
fructose in vivo [237]. Despite these advances, the physiological role of GLUT5 in the 
brain remains to be determined. 
Compared to the above-mentioned glucose transporters, other facilitative glucose 
transporters such as GLUT6, GLUT8, and GLUT10, are poorly studied. The exact 
location, biochemical characteristics, regulation and physiological functions of GLUT6 
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and GLUT10 remain to be determined. GLUT8, a novel insulin-sensitive glucose 
transporter, was found ubiquitously expressed in the rat brain, including hippocampus, 
hypothalamus, cortex, amygdala, and cerebellum [238-240]. Similar to GLUT4, the 
immunoreactivity of GLUT8 was detected exclusively in neurons, particularly in the 
neuronal cells bodies and the proximal apical dendrites [238, 240, 241]. Results from in 
vivo studies suggest insulin may stimulate the translocation of GLUT8 from the 
cytoplasm to the membranes of the rough endoplasmic reticulum (ER) in hippocampal 
neurons [242]. Notably, this subcellular trafficking was impaired in the diabetic rat 
hippocampus [243]. It was proposed that GLUT8 may control ER glucose homeostasis 
by transporting glucose molecules removed from glycoproteins during protein processing 
out of the rough ER lumen into the cytoplasm [242]. However, in vitro studies failed to 
show GLUT8 translocation in neurons in response to insulin, potassium- or glutamate-
induced depolarization [244, 245]. Therefore, future work is necessary to resolve the 










Table 1.2.1 GLUTs expressed in the central nervous system 
Protein  Expression sites Cell Types Substrates Comments 
























































Glycolysis is the first stage of cellular glucose metabolism. Through a series of metabolic 
processes in the cytosol, one molecule of glucose is broken down into two molecules of 
pyruvate, with the net gain of 2 molecules of ATP and production of NADH from NAD+ 
(Fig.1.2.4). The previously consumed NAD+ can be replenished through the reactions 
catalyzed by lactate dehydrogenase (LDH) or malate dehydrogenase (MDH) in the 
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malate-aspartate shuttle. Hexokinases act as the pacemaker of glycolysis by converting 
glucose into glucose-6-phosphate (Glc-6-p). Several hexokinase isoforms have been 
identified in the brain, with hexokinase I (HK1) being the major brain isoform 
responsible for glycolysis. HK1 has a low half-saturation constant (Km) thus possesses a 
high binding affinity for glucose and is able to metabolize glucose efficiently even when 
glucose concentration is low [246]. The activity of HK1 is feedback inhibited by high 
concentration of Glc-6-p. Another hexokinase isoform, HK2 is also expressed in the brain, 
albeit at a much lower level. HK2 also has low Km, thus may also be involved in glucose 
metabolism by promoting glycolysis. Recently, a protective role of HK2 in preventing 
mitochondrial death pathway and cell apoptosis has been proposed [247], suggesting 
HK2 may control neuronal survival in response to cellular stress. In addition to 
hexokinases, phosphofructokinase is another key enzyme that regulates glycolysis 
depending on the energy state [248]. The activity of phosphofructokinase is inhibited by 
signals for the high-energy state, such as increased ATP level, and reduced pH, which 
indicates the excessive formation of lactic acid, as well as enhanced citrate, an early 
intermediate in the TCA cycle. The inhibitory effect of ATP can be reversed by a high 
concentration of AMP, which suggests energy charge falls, or fructose 2, 6-bisphosphate, 
a potent activator of phosphofructokinase. A third key regulatory point in the glycolytic 
pathway is pyruvate kinase, which catalyzes the third committed step, yielding ATP and 
pyruvate. Fructose 1, 6-bisphosphate activates whereas ATP and alanine allosterically 
inhibit pyruvate kinase. Recently, brain aerobic glycolysis (AG), which describes non-
oxidative metabolism of glucose despite the presence of adequate oxygen, has received 
increasing attention. Regional differences in AG have been observed in the human brain 
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[249]. Local AG was found to increase when neuronal activity was elevated. Importantly, 
brain regions with high AG, showed upregulated expression of genes related to synapse 
formation and growth [250]. Further, AG has been found to play a role in synaptic 
plasticity during motor adaptation learning [251]. These findings point out the 




Fig.1.2.4 The glycolytic pathway.  Enzymes and metabolic intermediates in the 
glycolytic pathway were shown. Three key regulatory points in the glycolytic pathway 
were highlighted in red. GPI: glucose-6-phosphate isomerase; TPI: triose-phosphate 




Pentose Phosphate Pathway (PPP)  
Apart from being metabolized through the glycolytic pathway, Glc-6-p can be directed to 
the PPP shunt for the generation of NAPDH and five-carbon sugars, which are important 
for reductive biosynthesis, antioxidant defense, and nucleic acid synthesis. The PPP shunt 
consists of two phases: the oxidative phase and non-oxidative phase (Fig1.2.5). In the 
oxidative phase, glucose 6-phosphate is oxidized to ribose 5-phosphate, yielding NAPDH. 
In the non-oxidative phase, the interconversion of sugars with molecules containing 
different number of carbons occurs in a series of non-oxidative reactions, resulting in the 
synthesis of five-carbon sugars. Alternatively, excessive five-carbon sugars can be 
converted to the intermediates of glycolysis via transketolase and transaldolase. Glucose 
6-phosphate dehydrogenase (G6PD) catalyzes the rate-limiting step in the PPP, thus 
serving as a critical regulatory point [252]. The rate of PPP is also controlled by the 
concentration of NADP+ [252]. Low level of NADP+ inhibits the activity of G6PD, 
whereas the high level of NADP+ facilitates the oxidative phase of PPP shunt to replenish 
NADPH, which functions as a reductant for lipid and fatty acid synthesis. In the brain, 
the PPP shunt may represent an important antioxidant defense mechanism. It was 
suggested that NADPH generated by the PPP shunt can be used for regenerating 
antioxidant glutathione (GSH) from its oxidized form (GSSG) through a reaction 
catalyzed by glutathione reductase [253]. In support of this notion, oxidants such as 
hydrogen peroxide, cumene hydroperoxide, and peroxynitrite triggered a rapid activation 
of the PPP shunt and increased NADPH accumulation in both neurons and astrocytes 
[254-256]. Additionally, inhibition of glutathione peroxidase, GSH depletion, or the 
absence of glucose decreased oxidative stress-induced PPP activity and increased toxicity 
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[254, 255]. Further, D-glucose was found to protect rat cortical neurons against 
glutamate-mediated cell death likely through the stimulation of the PPP shunt, thus 
reversing glutathione oxidation and NADPH depletion induced by glutamate [257]. 
Together, these findings suggest the PPP shunt may play a major role in protecting brains 




Fig.1.2.5 The pentose phosphate pathway.  The PPP shunt includes both oxidative 
and non-oxidative branches. The glycolytic pathway and the PPP shunt are linked by 
transketolase and transaldolase (blue). Two major regulatory points are G6PD and 
NADPH/NAPD+ (red) GSH: glutathione; GSSG: oxidized glutathione. Adapted from 
David L. Nelson (2008) Lehninger Principles of Biochemistry, Fifth Edition.  
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Glycogen synthesis and utilization 
In astrocytes, Glc-6-p serves as a precursor for glycogen synthesis (Fig.1.2.6). 
Phosphoglucomutase catalyzes the conversion of Glc-6-p to glucose 1-phosphate (Glc-1-
p), which together with uridine triphosphate, is used for the synthesis of uridine 
diphosphate glucose (UDP-glucose) in a reaction catalyzed by UDP-glucose 
pyrophosphorylase. Glycogen synthase (GYS), the key regulatory enzyme 
in glycogen synthesis, catalyzes the transfer of glucose from UDP-glucose to the C-4 
hydroxyl group of a terminal residue in the growing glycogen molecule [258]. GYS 
exists in both active dephosphorylated (GYSa) and inactive phosphorylated (GYSb) 
forms, and the transformation of inactive GYSb to active GYSa is mediated by protein 
phosphatase 1 (PP1). On the contrary, GYSa can be phosphorylated at multiple sites by 
cAMP-dependent protein kinase A (PKA) or other kinases, leading to its inactivation. 
The breakdown of glycogen is catalyzed by glycogen phosphorylase (GP), during which 
Glc-1-p is released from glycogen through phosphorolysis [259]. In contrast to GYS, GP 
has the active phosphorylated form (GPa) and inactive dephosphorylated form (GPb) and 
the activation of phosphorylase kinase (PK) catalyzes the conversion of the b form into 
the a form. Like its substrate, the activity of PK can be modulated by phosphorylation of 
PK by PKA. PK contains Ca2+ binding sites and increased Ca2+ level can also activate PK 
[260]. In addition to covalent modification, GYS and GP are also regulated by 
noncovalent allosteric interactions depending on the energy state. For instance, GYSb can 
be activated by a high concentration of Glc-6-p. AMP may allosterically activate GPb by 
binding to its nucleotide-binding site and triggers a conformational change in GPb from a 
much less active tense (T) state into an active relaxed (R) state, which possesses similar 
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catalytic properties of the GPa phosphorylated form. By contrast, ATP may serve as a 
negative allosteric effector by competing with AMP and thus stabilizing the T 
confirmation [260]. Therefore, glycogen metabolism, which is reflected by the balance of 
glycogen synthesis and degradation, is tightly regulated by the activities of GYS and GP 
in response to changes in metabolic demand. 
 
 
Figure 1.2.6  
Fig.1.2.6 Glycogen synthesis and utilization.  The uptake of glucose in astrocytes is 
likely mediated by both GLUT1 and GLUT4. Glucose-6-phosphate, which is 
converted from glucose by hexokinase, serves as a precursor for glycogen synthesis. 
Key enzymes and intermediates involved in glycogen synthesis and degradation were 
shown.  HK: hexokinase; PGM: phosphoglucomutase; UDPGPP: UDP-glucose 
pyrophosphate; GYS: glycogen synthase; GYSa: active dephosphorylated form; 
GYSb: inactive phosphorylated form; PP1: protein phosphatase 1; GP: glycogen 
phosphorylase; GPa: active phosphorylated form; GPb: inactive dephosphorylated 
form; PK: phosphorylase kinase. Adapted from Falkowska, Anna et al. (2015) 
International Journal of Molecular Sciences 16(11): 25959–25981. 
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1.2.4.2 Ketone body uptake and metabolism in the brain 
Brain monocarboxylate transporters  
The brain uptake of ketone bodies is mediated by the monocarboxylate transporters 
(MCTs), which are a large transporter family containing 14 members. Only the first four 
members (MCT1 – MCT4) were identified as proton-linked transporters which facilitate 
the uptake of monocarboxylates such as lactate, pyruvate, and ketone bodies. Numerous 
studies have confirmed the expressions of MCT1, MCT2, and MCT4 in both rodent and 
human brains. A summary of major brain MCTs can be found in table 1.2.2. MCT1, the 
predominant form, is ubiquitously expressed throughout the brain. Immunohistochemical 
analyses of rat brain sections indicated that MCT1 was predominately expressed in both 
luminal and abluminal membranes of brain microvessel endothelial cells, suggesting 
MCT1 may play an important role in the brain uptake of ketone bodies and other 
monocarboxylates across the BBB [261, 262]. MCT1 immunoreactivity was also found 
in the astrocyte processes, particularly those of the glial limiting membrane [263-265]. 
The expression of MCT1 was also observed in a subset of neurons in several brain 
regions, particularly the hypothalamus, albeit at a much lower level [262, 266]. In 
contrast, MCT2 represents the major neuronal monocarboxylate transporter. The 
expression of MCT2 has been observed in the mouse brain regions including cortex, 
hippocampus, and cerebellum [265, 267]. At the subcellular level, MCT2 was found 
localized to postsynaptic densities and the expression of MCT2 appeared to correlate with 
synaptic development [265, 266, 268]. Specific populations of astrocytes in the white 
matter also exhibited MCT2 expression [266, 269]. Compared to MCT1 and MCT2, 
MCT4 has a more restricted cellular distribution. MCT4 has been found to be exclusively 
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expressed in the astrocytes in several brain regions including the cerebral cortex, 
hippocampus, cerebellum, and hypothalamus [266, 270, 271]. Given that astrocytes rely 
heavily on glycolytic metabolism, MCT4 may play a major role in the efflux of lactate.  
 
Table 1.2.2 MCTs expressed in the central nervous system 
Protein  Expression sites Cell Types Substrates Comments 































Brain ketone body metabolism 
Ketone bodies refer to three molecules: acetoacetate (AcAc), β-hydroxybutyrate (BHB) 
and acetone. Acetone is a minor product of spontaneous decarboxylation of AcAc. 
During glucose shortage, two predominant ketone bodies, AcAc and BHB, are generated 
in the liver, mainly from oxidation of fatty acids, serving as the alternative source of 
energy for the brain [272, 273].  It has been estimated that ketone bodies account for 
nearly two thirds of the brain's energy requirement during periods of prolonged fasting 
and starvation [273, 274]. As mentioned previously, MCT1 on the brain microvessels 
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mediates the transport of ketone bodies across the BBB and MCT2 regulates the neuronal 
uptake of ketone bodies. Within neurons, the metabolism of ketones occurs exclusively in 
the mitochondria and involves two steps, which is summarized in Fig.1.2.7. Briefly, β-
hydroxybutyrate dehydrogenase (BDH) catalyzes the first reversible step of ketolysis by 
converting BHB to AcAc.  The subsequent reconstitution of acetoacetyl coenzyme A 
(CoA) from AcAc is catalyzed by acetoacetyl succinyl-CoA transferase, which is also 
known as succinyl-CoA: 3-oxoacid CoA transferase (SCOT). The last step in ketolysis is 
the generation of 2 molecules of acetyl-CoA from acetoacetyl-CoA by the reversible 
enzyme acetoacetyl-CoA thiolase, also known as acetyl-CoA acetyltransferase (ACAT). 
Acetyl-CoA is then further metabolized to water and CO2 via the TCA cycle and 
mitochondrial oxidative phosphorylation. SOCT has been found to be a critical regulatory 
point for ketone body metabolism [273]. It is inhibited in the presence of high 







Figure 1.2.7  
Fig.1.2.7 Ketone body uptake and metabolism. The uptake of ketone boides in the 
brain is mediated by MCT1 and MCT2. Ketone bodies can freely enter mitochondria 
where they are converted to acetyl-CoA through ketolysis.  Key enzymes and 
intermediates involved in ketolysis are shown. BDH1: β-hydroxybutyrate 
dehydrogenase, mitochondrial; SCOT: succinyl CoA: 3-oxoacid CoA transferase; 
ACAT1: acetyl-CoA acetyltransferase, mitochondrial. 
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1.2.5 ApoE polymorphisms and perturbed brain energy metabolism  
ApoE genetic status influences glucose metabolism and mitochondrial function 
It has been shown that the preclinical development of AD begins 10-20 years prior to its 
clinical manifestation. One of the major changes that typically occur in the preclinical AD 
brain is the severe reduction of the cerebral glucose metabolic rate (CMRglc) as 
measured by FDG-PET scans [275].  Several longitudinal FDG-PET studies of non-
demented elderly subjects indicate that reduction of CMRglc in AD-vulnerable regions 
during normal aging predicted cognitive decline years in advance of the clinical diagnosis 
[31, 276, 277]. In patients with MCI, which is considered a prodrome to AD, the extent of 
CMRglc reduction was in parallel to the severity of cognitive deficits [278, 279]. 
Additionally, CMRglc reductions were observed in individuals at genetic risk for AD. 
FDG-PET studies on cognitively normal middle- and late-middle-aged individuals 
bearing ApoE4 demonstrated similar region-specific patterns of glucose hypometabolism. 
The most significant deficit occured in the posterior cingulate cortex (PCC), the brain 
region which serves as a central node in the default mode network (DMN) and 
consistently shows early metabolic alterations in AD [280, 281]. Similar regional 
CMRglc reductions were also observed in cognitively normal young ApoE4 carriers, at 
an age several decades before the possible onset of dementia or clinical manifestations of 
AD [32]. Notably, in ApoE4 carriers, the gene dose of ApoE4 alleles was negatively 
correlated with values of CMRglc in the same brain regions as patients with probable AD 
[84]. Despite these observations, the cause and precise mechanisms underlying glucose 
hypometabolism in the preclinical AD brain remain largely unknown.  
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In the past decade, emerging evidence suggests ApoE isoforms differentially modulate 
mitochondrial respiration and cellular bioenergetics. A microarray analysis of 
hippocampal tissue from AD patients indicated that expression of ApoE4, in comparison 
to ApoE3, was associated with downregulation of gene transcripts involved in 
mitochondrial oxidative phosphorylation and energy metabolism [282]. Similarly, studies 
on the post-mortem cortical tissues from ApoE4 carriers showed abnormalities in the 
expressions of transcripts that regulate mitochondrial respiratory chain activity [283]. In 
young ApoE4 carriers, significantly lower mitochondrial cytochrome c oxidase activity 
was observed in PCC, a brain region later vulnerable to AD [284, 285]. A more detailed 
examination revealed extensive alterations in the uptake of brain energy substrates and 
their metabolism. It was found that young ApoE4 carriers exhibited enhanced protein 
expression of complexes I, II and IV of the mitochondrial electron transport chain 
compared to non-carriers [286]. Despite the increase in protein levels, the functional 
activities of these subunits may be decreased. Therefore, the upregulation of protein 
expression can be interpreted as a compensatory response to dysfunction.  
Consistent with clinical findings, mice expressing ApoE4 also displayed mitochondrial 
structural alterations and functional abnormalities [287, 288]. While the precise 
mechanism by which ApoE4 induces mitochondrial dysfunction is not well understood, 
results obtained from in vitro studies suggest that a carboxyl-terminal-truncated form of 
ApoE4 (1-272), produced by proteolysis of ApoE via a chymotrypsin-like serine 
protease, may be responsible for the detrimental effects of ApoE4 on mitochondrial 
respiratory function [289].  Specifically, ApoE4(1-272) fragments were found to 
mislocalize to mitochondria [290] and bind to subunits of mitochondrial electron 
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transport chain complex III and complex IV, leading to impaired respiratory chain 
activity [291]. Recently, it was reported that ApoE4-containig lipoprotein particles 
significantly upregulate endoplasmic reticulum (ER)-mitochondrial communication and 
mitochondria-associated ER membranes (MAM) function in human fibroblasts [292]. 
Since the crosstalk between mitochondria and ER regulates mitochondrial homeostasis 
with MAM serving as the platform, the perturbations in ER-mitochondrial 
communication and MAM function may contribute to ApoE4-associated mitochondrial 
dysfunction. Collectively, these findings suggest ApoE genetic status influences 
mitochondrial bioenergetics, with ApoE4 adversely affecting mitochondrial functions. 
While there is an abundance of research demonstrating the negative impact of ApoE4 on 
cerebral bioenergetics, few studies have explored the effects of ApoE2.  To address this 
research gap, our laboratory has initiated a series of studies to identify the molecular 
differences in brain energy metabolism that separate ApoE2 brains from ApoE3 and 
ApoE4 brains. Our analyses demonstrated that human ApoE isoforms differentially 
modulate brain insulin-like growth factor 1 (Igf1) signaling and downstream glucose 
uptake and metabolism. Compared to ApoE3 and ApoE4 brains, ApoE2 brains exhibited 
the most bioenergetically robust profiles, providing a possible mechanism by which 
ApoE2 promotes neuroprotection [87]. Additionally, we have recently demonstrated for 
the first time that three ApoE isoforms differentially modulate a key component of the 
catalytic domain of the V-type H+-ATPase, a proton pump that mediates the concentration 
of neurotransmitters into synaptic vesicles and thus plays a crucial role in synaptic 
transmission. Specifically, our data indicate that ApoE2 brains express significantly 
higher levels of the β subunit of V-type H+-ATPase when compared to both ApoE3 and 
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ApoE4 brains, providing a mechanistic rationale for the positive impact on cognitive 
function conferred by ApoE2 [293]. Collectively, our data indicate that the three ApoE 
brains are significantly different in two major areas — bioenergetically and synaptically 
— and that a more efficient and robust status in both areas may underlie the 
neuroprotective and cognition-favoring properties associated with ApoE2.    
 
ApoE4 genetic status modifies the efficacy of a ketogenic agent 
The clinical application of a high-fat and low-carbohydrate ketogenic diet on patients 
with CNS disorders, starting with epilepsy, has been established almost a century ago 
[294, 295], whereas the mechanisms by which a ketogenic diet confers neuroprotection 
remain unknown. Preclinical studies indicate that enhanced mitochondrial respiration and 
ATP generation may underlie the neuroprotective effects of a ketogenic diet [296-299]. In 
patients with probable AD or mild cognitive impairment, treatment with a ketogenic 
agent, which is primarily composed of medium-chain triglycerides, resulted in a 
significant improvement in the cognitive function.The ketogenic agent induced a marked 
elevation in plasma ketone body (BHB) concentration and a positive correlation was 
found between BHB level and cognitive performance. Notably, the positive response was 
confined to ApoE4 non-carriers, whereas ApoE4 carriers showed no effect or even a 
minor deterioration [86]. The results obtained from this acute dosing study were 
replicated in a 90-day study of the same ketogenic compound, AC-1202 [85, 300]. In this 
randomized, double-blind, placebo-controlled study involving 152 probable AD subjects 
with mild to moderate cognitive impairment, the effects of AC-1202 on cognitive 
function were evaluated by the AD Assessment Scale-Cognitive subscale (ADAS-Cog). 
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Among participants who did not carry ApoE4, daily administration AC-1202 significantly 
improved scores of ADAS-Cog relative to placebo on day 45 and the effects were 
maintained throughout the study. In contrast, no difference was observed among subjects 
who were detected to be ApoE4 positive. Additional analyses revealed that some SNPs in 
genes of insulin degrading enzyme and a proinflammatory cytokine interleukin 1 beta 
may enhance the therapeutic efficacy of the ketogenic agent in ApoE4 non-carriers [301]. 
In contrast, such effects of SNP genotype were not detected on ApoE4 carriers. Despite 
these findings, it is unclear why ApoE4 carriers do not benefit from ketosis. While 
ApoE4-induced mitochondrial dysfunction may contribute to an impaired ability in 
metabolizing ketone bodies, abnormalities in the brain ketone body uptake and transport 
could also lead to a deficiency in ketone body utilization. Future studies are necessary to 
examine these possibilities. 
 
The goals of the first chapter are to pinpoint the specific substrate and metabolic pathway 
that are differentially regulated by ApoE genetic status. We performed a custom gene 
expression profiling of the major metabolic pathways involved in brain energy substrate 
transport and cytosolic metabolism in human ApoE gene-targeted replacement mice. 
Utilizing Neuro2a cells expressing human ApoE isoforms, we validated our findings from 
the gene array analysis and further examined the mechanisms by which ApoE isoforms 
modulate glucose metabolism, particularly focused on hexokinase and glycolysis. Our 
data provide additional evidence that human ApoE isoforms exert differential impact on 
brain energy metabolism, which could serve as a potential mechanism underlying their 
discrete risk impact in AD.    
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1.3 Materials and Methods 
1.3.1 Animals 
All the animal work presented has been approved by the Institutional Animal Care and 
Use Committee (IACUC) of the University of Kansas and followed National Institutes of 
Health (NIH) guidelines for the care and use of laboratory animals. 6 month-old human 
ApoE2, ApoE3, and ApoE4 gene-targeted replacement (hApoE2-TR, hApoE3-TR, and 
hApoE4-TR) mice were obtained from Taconic Biosciences (Hudson, NY, USA). These 
mice express human ApoE at physiological levels in the same temporal and spatial 
patterns observed in humans [302], which allows the direct comparison of human ApoE 
isoform-specific effects in vivo.  
 
1.3.2 Plasmids  
Human ApoE2, ApoE3 and ApoE4 cDNA expressed in the mammalian vector pCMV6 
with C-terminal Myc-DDK Tag were procured from OriGene Technologies (Rockville, 
MD, USA). ApoE3 cDNA clone (NM_000041) was directly purchased from OriGene. 
ApoE2 and ApoE4 cDNA clones were generated by genetic modification of the ApoE3 
cDNA sequence. Specifically, an ApoE2 cDNA clone was obtained by mutating 388 T to 
C, resulting in a Cys to Arg substitution in codon 112. ApoE4 cDNA clone was obtained 
by mutating 526 C to T, which resulted in an Arg to Cys substitution in codon 158. 
Mouse PGC-1α cDNA clone (NM_008904) expressed in the vector pCMV6 was 
purchased from OriGene. For all the experiments, the empty pCMV6 vector was used as 
the control plasmid. 100 ng plasmid DNA was transformed into DH5α competent cells 
(Invitrogen) for amplification. The purification of plasmid DNA was performed using 
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Plasmid Midi Kit (Qiagen, Hilden, Germany) according to manufacturer's manual.  
 
1.3.3 Cell Culture  
Mouse neuroblastoma cell line Neuro-2a (N2a) was purchased from American Type 
Culture Collection (ATCC, Manassas, VA, USA). N2a cells were grown in Dulbecco's 
Modified Eagle Medium (DMEM, High Glucose) (Thermo Fisher Scientific, Waltham, 
MA, USA) supplemented with 10% Fetal Bovine Serum (FBS) (Thermo Fisher 
Scientific). Cells were sub-cultivated every 3-4 days and maintained at 37 °C in a 
humidified atmosphere with 5% CO2. A new vial of frozen cell stock was recovered when 
the passage number exceeds 25.  
 
1.3.4 Generation of Neuro-2a Cells Stably Expressing Human ApoE isoforms 
N2a cells stably expressing human ApoE2, 3 and 4 were generated as described below. In 
brief, a kill curve assay was performed on N2a cells to determine the optimal 
concentration of Geneticin (G418, Thermo Fisher Scientific). Cells were then transfected 
with 2 μg hApoE2-pCMV6, hApoE3-pCMV6 or hApoE4-pCMV6 using Lipofectamine 
3000 according to the manufacturer’s instructions. 48 hours after transfection, the 
medium containing transfection complexes was replaced with N2a culture medium 
containing 600 μg/mL G418. Cells stably transfected were selected for 10 days, then 
dissociated from the plates and subjected to limited dilution on 96-well plates. Wells 
containing a single cell were marked and colonies formed in those wells were considered 
to be monoclonal. Cells were maintained in a humidified 37°C, 5% CO2 environment and 
media containing 600 μg/mL G418 were changed every 3-4 days. An individual colony in 
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each well was transferred to one well in 24-well plates for further expansion. Cell lines 
stably expressing ApoE2 or ApoE4 at similar levels, as determined by qRT-PCR and 
Western blotting, were used in the study. 
 
1.3.5 Transfection  
Transient transfection of human ApoE isoforms in N2a cells N2a cells were transfected 
with 2 μg human ApoE2, ApoE3 and ApoE4 cDNA and empty vector using 
Lipofectamine 3000 transfection reagent (Thermo Fisher Scientific). Cells were 
incubated with plasmid DNA-transfection reagent complex for 48 hours prior to further 
experiments. The transfection efficiency was determined by measuring the protein and 
gene expression levels of ApoE. 
PGC-1α overexpression in N2a cells stably expressing human ApoE4 Cells stably 
expressing human ApoE4 were plated at a density of 3 × 105 /well in a 6-well plate in 
DMEM without G418 the day before transfection. A reaction containing 500 ng of either 
PGC-1α-pCMV or empty pCMV vector and Lipofectamine 3000 reagent in Opti-MEM 
(Thermo Fisher Scientific) was prepared for each transfection. Cells were incubated with 
the prepared reaction mix for 24 hours at 37°C, 5% CO2.  Then DMEM containing 
transfection reagents were replaced with fresh culture medium and cells were grown for 
additional 24 hours before protein extraction, mitochondrial and glycolytic function 
assays. 
The introduction of human ApoE2 to N2a cells expressing human ApoE4 2 μg human 
ApoE2 cDNA and empty vector were introduced into N2a cells stably expressing human 
ApoE4 using Lipofectamine 3000. 48 hours post transfection, mRNA level and protein 
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expression of ApoE were determined in the transfected cells to evaluate the transfection 
efficiency.  
 
1.3.6 Immunoblotting Analysis 
Cells were washed twice with cold Dulbecco's phosphate-buffered saline (dPBS) and 
lysed with Neuronal Protein Extraction Reagent (N-PER) (Thermo Fisher Scientific) 
supplemented with protease and phosphatase inhibitors (Thermo Fisher Scientific). 
Cortical tissue homogenates were prepared from 6-month-old hApoE-TR mice using 
Tissue Protein Extraction Reagent (T-PER) (Thermo Fisher Scientific) containing 
protease and phosphatase inhibitors. Protein concentrations of the cell extracts and tissue 
homogenates were determined by BCA protein assay kit (Thermo Fisher Scientific). 
Immunoblotting analyses were carried out as previously published [293]. The following 
primary antibodies were used: goat anti-Apolipoprotein E (1:5000, EMD Millipore), 
rabbit anti-hexokinase I (1:3000, Cell Signaling Technology, Danvers, MA), rabbit anti-
hexokinase II (1:2000, Cell Signaling Technology), rabbit anti-PGC-1α (1:1000, Santa 
Cruz Biotechnology, Dallas, TX), mouse anti-PGC-1α (1:1000, EMD Millipore), rabbit 
anti-β-actin (1:5000, Thermo Fisher Scientific), mouse anti-β-tubulin (1:5000, Thermo 
Fisher Scientific). Secondary antibodies were species-specific horseradish peroxidase-
conjugated immunoglobulins purchased from Thermo Fisher Scientific. Protein bands 
were visualized using chemiluminescence (BioRad) on C-Digit Blot Scanner (LI-COR). 
Band densities were quantified using the Image Studio Version 4.0 image digitizing 
software with signal normalized to loading control protein. 
1.3.7 ATP Levels 
54 
 
Cells were plated at 1 x 104 / well in white opaque 96-well culture plate the day before 
experiments. ATP levels were measured using CellTiter-Glo Luminescent Cell Viability 
Assay (Promega, Madison, WI, USA) according to the manufacturer's instructions. The 
luminescence level was normalized to the protein content in each individual well. 
 
1.3.8 RNA Extraction from Cells 
Total RNA was extracted from stable N2a-hApoE4 cells transfected with human ApoE2-
pCMV. In brief, 350 μL Trizol reagent (Thermo Fisher Scientific) was added to each well 
in a 6 well plate to lyse the cells. 100 μL chloroform was added to the cell lysates and 
samples were inverted vigorously several times to mix thoroughly. The samples were 
centrifuged for 15 minutes at 12,000 × g at 4°C. The upper aqueous phase containing 
RNA was carefully transferred to a new tube. Subsequent purification of RNA was 
performed using PureLink RNA Mini Kit (Thermo Fisher Scientific) following 
manufacturer's instructions. RNA concentration was measured by Qubit Assay Kit 
(Invitrogen). The quality of RNA was evaluated by 2200 TapeStation system (Agilent, 
Santa Clara, CA, USA). 
 
1.3.9 Gene Expression Analysis 
The gene expression of ApoE after transfection was measured by real-time PCR as 
previously described [303]. Genomic DNA was extracted from N2a cells transfected with 
human ApoE2, ApoE3, ApoE4 cDNA and mock vector using PureLink Genomic DNA 
Mini Kit (Thermo Fisher Scientific). For measurement of gene expression of human 
ApoE2 in N2a-hApoE4 cells transfected with hApoE2-pCMV, cDNA was synthesized 
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from RNA extracted from the transfected cells using High Capacity RNA-to-cDNA 
Master Mix (Applied Biosystem). The primers were synthesized and purchased from 
Integrated DNA Technologies (Coralville, IA, USA). The sequences of the primers were: 
5’- CGGACATGGAGGACGTGT -3’ (Forward) and 5’- CTGGTACACTGCCAGGCA -
3’ (Reverse) for ApoE2, 5’- CGGACATGGAGGACGTGT -3’ (Forward) and 5’- 
CTGGTACACTGCCAGGCG -3’ (Reverse)  for ApoE3, 5’- 
CGGACATGGAGGACGTGC -3’ (Forward) and 5’- CTGGTACACTGCCAGGCG -3’ 
(Reverse) for ApoE4. DNA amplification was performed on 100 ng of genomic DNA or 
20 ng cDNA mixed with 1× Power SYBR Green PCR Master Mix (Applied Biosystems) 
and 0.3 μM of each primer under the following protocol: stage 1: AmpErase UNG 
activation at 50°C for 2 min; stage 2: AmpliTaq Gold DNA Polymerase activation at 
95 °C for 10 min; stage 3: denature at 95 °C for 15 s followed by annealing/extension at 
60 °C for 1 min, for 40 cycles. Negative controls contained the same reaction mixture 
without DNA. Mouse GAPDH served as loading control. The fluorescence was detected 
on QuantStudio 7 Flex Real-Time PCR System (Applied Biosystems) and data were 
analyzed by the comparative Ct (ΔCt) method.  
 
1.3.10 TaqMan Gene Expression Profiling 
TaqMan gene expression array cards (96-well plate format, which enables analysis of 2 
samples against 48 genes) were custom manufactured at Applied Biosystem. A list of 43 
genes and 5 candidate control genes examined in the array can be found in Table 1.4.1. 
Total RNA was extracted from cortex tissues of 6-month-old hApoE-TR mice using 
PureLink RNA Mini Kit. RNA quantity was determined using Qubit Assay Kits and RNA 
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quality was analyzed using Agilent RNA 6000 Nano Kit on Agilent 2100 Bioanalyzer 
system (Agilent). The integrity of RNA samples was assessed by RNA integrity number 
(RIN). RNA samples with RIN greater than 8.0 proceeded to cDNA synthesis. The 
conversion of RNA to cDNA was performed using the High Capacity RNA-to-cDNA 
Master Mix on T100 thermocycler (Bio-Rad Laboratories, Hercules, CA, USA). Taqman 
qRT-PCR reaction was carried out on QuantStudio 7 Flex Real-Time PCR System under 
the following thermal cycling conditions: AmpErase UNG activation at 50°C for 2 min; 
AmpliTaq Gold DNA Polymerase activation at 95 °C for 10 min followed by 40 cycles of 
denaturation at 95 °C for 15 s and annealing/extension at 60 °C for 1 min. Each reaction 
mixture contained 10 ng cDNA samples mixed with 1× TaqMan Universal PCR Master 
Mix (Applied Biosystems).  
Data were analyzed using the PCR Array Data Analysis Software (Qiagen, Hilden, 
Germany). Relative gene expression levels or fold change (FC) relative to the comparison 
group were calculated by the comparative Ct (ΔΔCt) method, with Ct denoting threshold 
cycle. Normalization factor calculation based on the geometric mean of multiple control 
genes was performed for selection of the endogenous control gene for normalization 
[304]. Samples collected from 4 animals per ApoE genotype group were included in the 
analysis. For each sample, ΔCt was calculated as the difference in average Ct of the target 
gene and the endogenous control gene. For each ApoE genotype, mean 2-ΔCt was 
calculated as the arithmetic means of 2-ΔCt of the 4 samples in the group. FC was then 
calculated as mean 2-ΔCt (ApoE genotype group) divided by mean 2-ΔCt (comparison 
group). The 2-ΔCt values for each target gene between two ApoE genotype groups were 
statistically compared using Student’s t-test; p < 0.05 was considered statistically 
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significant. The p-values were adjusted by Bonferroni correction.  
The heat map graphically demonstrated the hierarchical clustering of gene expression 
data. Distances between samples and target genes were calculated based on ΔCt values 
using Pearson’s correlations. The volcano plot displayed FC in the X-axis versus p-values 
in the Y-axis, which enabled the overview of gene fold regulation and identification of 
genes with fold change to the statistical significance level. 
 
1.3.11 IPA Network Analysis 
Data containing gene identifiers and corresponding FC relative to the comparison group 
(ApoE3) were uploaded to Ingenuity Pathway Analysis (IPA, Qiagen Bioinformatics). 
IPA upstream regulator analysis identified transcriptional regulators upstream of the 
genes in the dataset which potentially explained the observed gene expression changes. A 
prediction is made about the activation state of an upstream molecule when most of the 
target genes changed in the direction that is consistent with a particular activation state of 
the transcriptional regulator. Activation z-score was calculated to predict the state of the 
upstream regulator: activating (z-score ≥ 2) or inhibiting (z-score ≤ -2). 
 
1.3.12 Hexokinase Activity Assay 
Hexokinase activity assay was performed as previously described [305]. The assay is 
based on the reduction of nicotinamide adenine dinucleotide (NAD+) through a coupled 
reaction with glucose-6-phosphate dehydrogenase. Briefly, 150 μL solution containing 
13.3 mM MgCl2, 0.112 M glucose, 0.55 mM adenosine 5' triphosphate, 0.227 mM NAD
+ 
and 1 IU/mL glucose-6-phosphate dehydrogenase in 0.05 M Tris-HCl buffer, pH 8.0 was 
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loaded in each well of 96-well microplate. The plate was incubated at room temperature 
for 6 - 8 minutes to achieve temperature equilibration. 20 μg whole cell lysates from 
transfected cells were added to start the reaction. Hexokinase solution prepared by 
dissolving hexokinase in 0.05 M Tris-HCl buffer, pH 8.0 served as positive control. 
Assay buffer without sample served as negative control. The increase in absorbance (A) 
at 340 nm was recorded every 1 min for 30 minutes at 30 °C. ΔA/min from an initial 
linear portion of the curve was used to calculate the enzyme activity.  
 
1.3.13 Analysis of Mitochondrial respiration and Glycolysis 
The XF96 Extracellular Flux Analyzer (Agilent Technologies), which measures oxygen 
consumption rate (OCR) and extracellular acidification rate (ECAR) was used to assess 
mitochondrial respiration and glycolytic function in N2a cells expressing human ApoE 
isoforms. Transfected cells were seeded at a density of 3.1 × 105 cells/cm2 in the 96-well 
culture plate provided with the flux pack (Agilent Technologies) the day before the 
experiments. Both the Mito Stress Test and the Glycolysis Stress Test were performed 
according to manufacturer’s instructions.  
For the Mito Stress Test, cell growth media was replaced with pre-warmed assay medium 
(XF base medium supplemented with 5.5 mM glucose, 2 mM glutamine and 1 mM 
sodium pyruvate, pH 7.4) and incubated in 37°C incubator without CO2 for 1 hour prior 
to the test. OCR was measured under basal condition followed by sequential injection of 
the compounds:  ATP coupler oligomycin (2 μg/mL), ETC accelerator FCCP (1 μM), and 
a mix of mitochondrial electron transport chain (ETC) complex inhibitors rotenone (1 
μM) and antimycin A (1 μM) to measure ATP-linked respiration, maximal respiration, 
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and non-mitochondrial respiration, respectively.  
For the Glycolytic Stress Test, cell growth media was replaced with pre-warmed assay 
medium (XF base medium containing 2 mM glutamine, pH 7.4) and incubated at 37°C in 
the absence of CO2 for 1 hour before the assay. ECAR was measured under basal 
condition followed by sequential addition of compounds. The initial injection was a 
saturating concentration of glucose (10 mM), which allows the measurement of 
glycolysis rate under basal conditions. The addition of oligomycin (2 μg/mL) results in 
the inhibition of mitochondrial ATP generation and thus shunting the energy production 
to glycolysis, with the subsequent increase in ECAR revealing the maximum glycolytic 
capacity of the cells. The final injection was 2-Deoxy-D-glucose (50 mM), a glucose 
analogue that competitively binds to hexokinase and inhibits the conversion of glucose to 
glucose-6-phosphate thereby terminating the glycolysis.  
To examine the impact of human ApoE isoforms in cells’ ability to metabolize ketone 
bodies, FCCP-induced maximal mitochondrial respiration rates were measured in ApoE-
expressing cells sequentially injected with β-hydroxybutyrate (5 mM) and mitochondrial 
inhibitors oligomycin (5 μg/mL). OCR and ECAR values were normalized to the total 
protein content in each well. Data were analyzed using Seahorse XF Cell Mito\Glycolysis 
Stress Test Report Generator. 
 
1.3.14 Statistical Analyses 
Each experiment was performed independently at least three times. Data are presented as 
mean ± standard error of the mean (SEM). All statistical analyses were performed using 
GraphPad Prism 6 (GraphPad Software, La Jolla, CA, USA). All data were analyzed by 
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Student’s t-test or one-way ANOVA. Post-hoc tests were performed using the Holm–
Bonferroni method. A p-value < 0.05 was considered statistically significant and the 




1.4.1 Human ApoE isoforms differentially modulate brain energy substrate uptake 
and cytosolic metabolism 
To probe the metabolic pathways that are differentially regulated by human ApoE 
isoforms, a TaqMan gene expression profiling was conducted on the cortical tissues 
collected from 6-month-old human ApoE gene-targeted replacement mice (hApoE-TR).  
A complete list of the 48 genes grouped according to functional class is provided in Table 
1.4.1. We focused on the genes involved in the molecular processes from energy 
substrate uptake to cytosolic metabolic pathways leading to the generation of acetyl-CoA 
(Fig. 1.4.1A). The fold changes (FC) relative to gene expression levels in the comparison 
group (ApoE2 or ApoE3) with the corresponding p-value are indicated in Table 1.4.2. 
Both distinct and consistent patterns among the three ApoE brains were observed in the 
gene expression analysis. More specifically, the group heatmap demonstrated that the 
profile associated with ApoE4 appeared most distinct from those of ApoE2 and ApoE3 









1.4.2 ApoE2 brain exhibited the most robust whereas ApoE4 brain displayed the 
most deficient gene expression profile in glucose uptake and glycolytic pathway 
We first examined the gene expression profiles on brain uptake and cytosolic metabolism 
of glucose, the primary brain fuel. The volcano plots illustrate the FC and p-values for 
significant differences in ApoE2 brains (Fig. 1.4.2B) and ApoE4 brains (Fig. 1.4.2C) 
compared to ApoE3 brains. Of the 12 genes analyzed, 2 genes exhibited significantly 
higher levels in ApoE2 brains versus ApoE3 brains, including solute carrier family 2, 
member 4 (Slc2a4, FC = 2.05, p = 0.039) and hexokinase 2 (Hk2, FC = 1.19, p = 0.022); 
In contrast, a comparison between ApoE4 and ApoE3 brains yielded 3 genes that were 
significantly downregulated in ApoE4 brains: solute carrier family 2, member 3 (Slc2a3, 
FC = 0.68, p = 0.037), hexokinase 1(Hk1, FC = 0.73, p = 0.042) and hexokinase 2 (Hk2, 
FC = 0.66, p = 0.004). The results of the gene array studies were further validated using 
independent mRNA quantitation and immunoblotting analysis.  Among the 4 genes that 
significantly changed among three ApoE genotype groups, we were particularly 
interested in hexokinases for the following reasons: 1) the expression levels of 
hexokinase 1 and hexokinase 2 were significantly higher in the ApoE2 brain when 
Fig. 1.4.1 Human ApoE isoforms differentially modulate brain energy substrate 
uptake and cytosolic metabolism. A) Schematic illustration of brain energy substrate 
uptake and the generation of acetyl-CoA. Hexokinase 1/2 catalyze the conversion of 
glucose to glucose-6-phosphate, a “branch-point” metabolite that has alternative 
metabolic fates. Acetyl-CoA is a critical point of convergence of glucose and ketone 
body metabolism. Brain uptake of glucose and ketone body are strictly controlled by 
their respective transporters, glucose transporters (GLUTs) and monocarboxylate 
transporters (MCTs). Key enzymes involved in the glucose and ketones metabolic 
pathways are shown. B) Gene expression profiles on energy substrate uptake and 
cytosolic metabolism in the brains of 6-month-old hApoE-TR mice. n=4 per group. 
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compared to the ApoE4 brain; 2) hexokinase acts as the “gateway” enzyme that catalyzes 
the first step in intracellular glucose metabolism; 3) hexokinase is the “pacemaker” of 
glycolysis. Consistent with the findings in the gene array study, significantly lower levels 
of mRNA (Fig. 1.4.2D) and protein (Fig. 1.4.2E) of hexokinase 1 were found in ApoE4 
brains (p < 0.05) when compared to both ApoE2 and ApoE3 brains. Similarly, mRNA 
level (Fig. 1.4.2F) and protein expression (Fig. 1.4.2G) of hexokinase 2 were 
significantly reduced in ApoE3 brains (p < 0.05) and ApoE4 brains (p < 0.01) when 
compared to ApoE2 brains. These results suggest that ApoE2 brains possess the most 
robust expression profile in both glucose uptake and glycolysis, whereas ApoE4 brains 








1.4.3 ApoE2 brain demonstrated a more robust expression profile in other glucose 
metabolic pathways 
Next, we sought to examine the gene expression profile in other glucose metabolic 
pathways including pyruvate metabolism, pentose phosphate pathway (PPP), 
gluconeogenesis and glycogenesis. Unlike the one generated for glucose uptake and 
glycolytic pathway, no distinct pattern was observed in the heat map when comparing the 
three ApoE genotype groups (Fig. 1.4.3A). However, the volcano plots indicated trends 
in gene upregulation/downregulation. Out of 18 genes examined, 14 were upregulated in 
ApoE2 brains compared to ApoE3 brains (Fig. 1.4.3B). In comparison, 10 out of 18 
genes were downregulated in ApoE4 brains compared to ApoE3 brains (Fig. 1.4.3C). 
Genes significantly changed include dihydrolipoamide S-acetyltransferase (Dlat, FC = 
1.16, p = 0.033) and phosphogluconate dehydrogenase (Pgd, FC = 0.85, p = 0.021).  
Together, these data suggest that the ApoE2 brain exhibited the most metabolically 
robust profile in other glucose metabolic pathways. By contrast, the ApoE4 brain 
displayed some deficits in the PPP shunt and glycogen utilization.  
Fig. 1.4.2 ApoE2 brains exhibited the most robust metabolic profiles in glucose 
uptake and glycolytic pathway. A) The heat map showed the expression of genes 
involved in glucose transport and glycolytic pathways for all three ApoE genotypes. 
B-C) The volcano plots illustrated fold changes (X-axis) and p-values (Y-axis) 
between (B) ApoE2 brains versus ApoE3 brains and (C) ApoE4 brains versus ApoE3 
brains; Highlighted significantly altered expression – Hk1/2: hexokinase 1/2; Slc2a3: 
solute carrier family 2 facilitated glucose transporter 3 (Glut3) ; Slc2a4: solute carrier 
family 2 facilitated glucose transporter member 4 (Glut4). D-E) Gene and protein 
expression levels of hexokinase 1 were significantly lower in ApoE4 brains compared 
to ApoE2 and ApoE3 brains. F-G) ApoE2 brains exhibited significantly higher levels 
of mRNA and protein expression of hexokinase 2.  Results were normalized to ApoE3 
group. Statistical analysis was performed using One-way ANOVA with Bonferroni’s 










Fig. 1.4.3 ApoE2 brains displayed a more robust expression profile in other 
glucose metabolic pathways. A) The heat map showed the expression of key genes 
involved in the metabolic pathways including pyruvate metabolism, gluconeogenesis, 
glycogenesis and pentose phosphate pathways for all three ApoE genotypes. B-C) The 
volcano plots demonstrated fold changes (X-axis) and p-values (Y-axis) between (B) 
ApoE2 brains versus ApoE3 brains and (C) ApoE4 brains versus ApoE3 brains; 
Highlighted significantly altered expression – Dlat:  Dihydrolipoamide S-
Acetyltransferase; Pgd: 6-Phosphogluconate dehydrogenase. 
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1.4.4 ApoE2-expressing neurons had significantly higher protein levels and 
enzymatic activity of hexokinase  
Based on our findings in the gene array analysis, we moved to a cell model to investigate 
how the three human ApoE isoforms modulate glucose and ketone body metabolism. 
Mouse N2a cells were transfected with empty vector or vectors encoding human ApoE2, 
ApoE3, and ApoE4. As shown in Fig. 1.4.4A and 1.4.4C, mRNA and protein levels of 
ApoE were comparable in cells transfected with human ApoE isoforms. The primers used 
for PCR amplification for each genotype were highly specific as the difference in 
threshold cycle (Ct) value between positive and negative was at least 11, which indicates 
that the specific amplifications are 2048-fold more efficient compared to the non-specific 
ones (Fig. 1.4.4B). We first validated the results from gene array study by measuring 
protein expression levels of hexokinase 1/2 in N2a cells expressing human ApoE 
isoforms (N2a-hApoE2, N2a-hApoE3, and N2a-hApoE4). Consistent with our findings in 
the brain of hApoE-TR mice, N2a cells transfected with ApoE2 exhibited a significantly 
higher level of hexokinase 2 compared with ApoE3 transfected group (FC = 1.20, p = 
0.022) (Fig. 1.4.4E). The protein expression level of hexokinase 1 was also higher in 
ApoE2-transfected cells, however, it did not reach statistical significance (FC = 1.14, p = 
0.205) (Fig. 1.4.4D). Cells transfected with ApoE4 showed a markedly lower levels of 
protein expression of both hexokinase 1 (FC = 0.71, p = 0.016) and hexokinase 2 (FC = 
0.69, p = 0.002) as compared to those transfected with ApoE3 (Fig. 1.4.4D-E). 
Additionally, hexokinase enzyme activity was determined in whole cell lysates collected 
from transfected cells. In line with the protein expression data, N2a-hApoE2 cells 
demonstrated significantly higher (FC = 1.25, p = 0.0002) whereas N2a-hApoE4 cells 
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exhibited significantly lower (FC = 0.85, p = 0.026) hexokinase activity when compared 
to N2a-hApoE3 cells (Fig. 2.4.4F). These results suggest that human ApoE isoforms 
differentially modulate hexokinase expressions in N2a cells, with ApoE2-expressing cells 









1.4.5 ApoE2-expressing neurons exhibited the most robust glycolysis and 
mitochondrial respiration 
Given that the three human ApoE isoforms differentially modulate hexokinase expression 
and hexokinase is a critical regulator of glycolysis, we next performed the glycolytic 
stress test to assess ApoE isoform-specific effect on glycolytic function in N2a cells (Fig. 
1.4.5A-B). Extracellular acidification rate (ECAR) is measured before and after glucose 
injection which provides the basal glycolytic rate. Subsequent addition of oligomycin 
inhibits ATP synthase which drives glycolysis to produce more ATP to compensate, 
allowing the measurement of maximal and reserve glycolytic capacity. Finally, 2-Deoxy-
D-glucose (2-DG) shuts down glycolysis by binding to hexokinase which provides the 
measurement of non-glycolytic acidification. As shown in Fig. 1.4.5A, basal glycolysis 
was significantly lower in ApoE4-expressing cells compared to ApoE2- (FC = 0.65, p 
<0.0001) and ApoE3- (FC = 0.76, p = 0.017) expressing cells. Oligomycin induced a 
Fig. 1.4.4 ApoE2-expressing neurons exhibited higher protein levels and 
enzymatic activity of hexokinase. A) Gene expression levels of ApoE were 
determined in N2a cells transfected with human ApoE cDNA by real time PCR. 
Amplification plots of 3 ApoE genotypes in transfected cells were shown. NC: 
negative control. Four replicates each group. B) Genomic DNA extracted from N2a 
cells transfected with human ApoE cDNA or empty vector were amplified with 
specific primers for ApoE2, ApoE3 and ApoE4 reactions. Three replicates per group. 
C) ApoE protein expression in the transfected cells were confirmed by 
immunoblotting analyses. ApoE levels were comparable among the three transfected 
groups. D-E) Protein expressions of hexokinase1/2 were assessed in N2a cells 
transfected with vectors encoding human ApoE isoforms. ApoE2-expressing cells 
displayed the highest whereas ApoE4-expressing cells exhibited the lowest protein 
expression levels of both hexokinase 1 and hexokinase 2. F) Hexokinase activity was 
determined in the cell lysates of N2a-hApoE cells. Results were normalized to ApoE3 
group. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by ANOVA with Bonferroni’s 
post hoc test. n=4-5 per group. 
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significantly larger ECAR increase, suggesting a significant higher cellular maximum 
glycolytic capacity, in ApoE2-expressing cells than that in ApoE3-expressing cells (FC = 
1.17, p = 0.012). In comparison, the glycolytic capacity was significantly lower in 
ApoE4-expressing cells (FC = 0.74, p < 0.0001). Similarly, the glycolytic reserve was 
markedly higher in ApoE2- (FC = 1.19, p = 0.008) whereas lower in ApoE4- (FC = 0.95, 
p = 0.001) expressing cells when compared to ApoE3-expressing cells.  
We also performed the mitochondrial stress test on N2a-hApoE cells to evaluate the 
impact of human ApoE isoforms on mitochondrial respiration (Fig. 1.4.5C-F). The basal 
respiration rate is established by measuring oxygen consumption rate (OCR) before the 
sequential injections of compounds. The difference in OCR before and after oligomycin 
injection provides a measure of ATP-linked respiration. FCCP induces the collapse of the 
proton gradient across the inner mitochondrial membrane resulting in the maximal 
mitochondrial respiration. The spare respiratory capacity is calculated by subtracting 
basal respiration from maximal respiration. The basal mitochondrial respiration was 
significantly higher in cells expressing ApoE2 than that in cells expressing ApoE3 (FC = 
1.13, p = 0.004). ApoE4-expressing cells had significantly lower basal respiration when 
compared to ApoE2 cells (FC = 0.81, p < 0.0001). FCCP response was significantly 
higher in cells expressing ApoE2 compared to that in cells expressing ApoE3 (FC = 1.11, 
p = 0.021). ApoE4-expressing cells showed a significantly lower maximal respiratory 
capacity when compared to that of ApoE3- (FC = 0.85, p = 0.001) and ApoE2- (FC = 
0.76, p < 0.0001) expressing cells. Additionally, N2a-hApoE4 cells exhibited a 
significantly lower spare respiratory capacity compared with both N2a-hApoE3 (FC = 
0.77, p = 0.0001) and N2a-hApoE2 (FC = 0.71, p < 0.0001) cells.  ATP generation was 
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determined in the cell lysates of N2a-hApoE to evaluate the level of cellular energy 
metabolism. In line with the results from mitochondrial and glycolytic stress tests, N2a-
hApoE2 displayed significantly higher levels of ATP compared to N2a-hApoE3 cells (FC 
= 1.25, p < 0.0001). ATP levels were significantly lower in N2a-hApoE4 cells (FC = 0.81, 
p < 0.0001). These data indicate that ApoE2-expressing cells are the most robust whereas 











1.4.6 ApoE2 and ApoE4 brains displayed similar robustness in ketone body 
metabolism 
In addition to glucose, we also examined gene expression profile on the uptake and 
metabolism of ketone bodies, the secondary brain energy source, on the brain tissues 
from the three ApoE genotypes. Previous clinical studies reported that ApoE4 carriers did 
not benefit from a ketogenic agent [85, 86], suggesting that individuals with ApoE4 
might be deficient in the transporters which mediate the cellular uptake of ketone bodies 
or/and key enzymes which convert the ketone bodies to their metabolites. Surprisingly, 
both ApoE2 and ApoE4 brains demonstrated the similar extent of robustness in the gene 
expression profile of ketone body utilization (Fig. 1.4.6A). More specifically, all 5 genes 
examined were upregulated in ApoE2 and ApoE4 brains compared to ApoE3 brains (Fig. 
1.4.6B-C). 2 genes exhibited significantly higher levels in ApoE2 brains versus ApoE3 
brains, including 3-hydroxybutyrate dehydrogenase, type 1 (Bdh1, FC = 1.31, p = 0.0004) 
and solute carrier family 16, member 1 (Slc16a1, FC = 1.18, p = 0.019). 
 
Fig. 1.4.5 ApoE2-expressing neurons displayed significantly enhanced glycolytic 
function and mitochondrial respiration.  A-B) Glycolytic stress tests were 
performed using the Seahorse XF96 Extracellular Flux Analyzer to measure the basal 
glycolysis, glycolytic capacity and glycolytic reserve in N2a-hApoE cells. n= 18-20 
per group. *p<0.05, **p<0.01 vs N2a-ApoE3 group. ### p<0.001, #### p< 0.0001 vs 
N2a-ApoE2 group. C-E) Mitochondrial stress tests were performed using the Seahorse 
XF96 Extracellular Flux Analyzer to measure mitochondrial basal respiration, 
maximal respiration capacity and ATP-linked respiration in N2a-hApoE cells. n= 18-
20 per group. F) ATP level was determined in the cell lysates of N2a-hApoE cells. 
n=5 per group. Results were compared using one-way ANOVA with Bonferroni post 
hoc test. *p<0.05, ** p<0.01, ***p<0.001, ****p<0.0001 vs N2a-ApoE3 group. 
#p<0.05, ###, p<0.001, ####p<0.0001 vs N2a-ApoE2 group. 
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To validate the results from gene array study on cerebral ketone body utilization, we 
assessed the impact of human ApoE isoforms on the cells’ capability of metabolizing β-
hydroxybutyrate (BHB) in N2a cells. Specifically, N2a cells were transfected with 
vectors encoding three human ApoE isoforms. 48 hours post transfection, cells were 
treated with vehicle control or BHB and mitochondrial respiration was measured. 
Compared to vehicle-treated groups, the FCCP-induced response was markedly larger in 
BHB-treated groups, suggesting that N2a cells are capable of metabolizing ketone bodies 
for energy supply (Fig. 1.4.6D-F). For each genotype, when normalized to its 
corresponding vehicle-treated group, maximal mitochondrial respiration rate after FCCP 
injection was significantly higher in cells expressing ApoE2 and ApoE4 compared to 
cells expressing ApoE3 (Fig. 1.4.6D-F). The maximal respiration rates in BHB-treated 
cells divided by those in vehicle-treated cells in each ApoE genotype were compared 
using one-way ANOVA with Bonferroni correction (Fig. 1.4.6G). In line with the 
observations from the OCR data, statistical analysis revealed that both ApoE2- and 
ApoE4-expressing cells had significantly higher maximal mitochondrial OCR in response 
to FCCP upon BHB treatment as compared to ApoE3-expressing cells. Our data indicate 
that ApoE2 and ApoE4 brains possess a similar level of robustness whereas ApoE3 brain 








1.4.7 Upstream regulator PGC-1α was upregulated in the ApoE2 brain 
To further understand the biological relevance of the changes in gene expressions, we 
conducted a regulatory pathway and molecular network analysis using Ingenuity Pathway 
Analysis (IPA). IPA predicted that PPARGC1A, which encodes peroxisome proliferator-
activated receptor gamma coactivator 1 alpha (PGC-1α), was activated in the ApoE2 
brain when compared to the ApoE3 brain (Fig. 1.4.7A) (z-score = 2.507, p-value of 
overlap = 1.13E-12). Consistent with our previous findings, IPA predicted that 
peroxisome proliferator-activated receptor gamma (PPAR-γ) was inhibited in the ApoE4 
brain compared to the ApoE2 brain (z-score = -2.146, p-value of overlap = 1.46E-09) 
[49]. To validate the results from bioinformatics analysis, mRNA and protein levels of 
PGC-1α were determined in the brains of hApoE-TR mice. In accordance with the 
prediction, ApoE2 brains exhibited significantly higher level of PGC-1α mRNA when 
compared to ApoE3 (FC = 1.13, p = 0.009) and ApoE4 brains (FC = 1.25, p = 0.0003) 
(Fig. 1.4.7B). Similarly, protein expression levels of PGC-1α was significantly lower in 
Fig. 1.4.6 ApoE2 and ApoE4 brains presented a similar level of robustness in 
ketone body utilization. A) The heat map showed the expression of genes implicated 
in brain ketone body uptake, transport and metabolism. B-C) The volcano plots 
illustrated fold changes and p-values between (B) ApoE2 brains versus ApoE3 brains 
and (C) ApoE4 brains versus ApoE3 brains; Highlighted significantly altered 
expression – Bdh1:β-hydroxybutyrate dehydrogenase, Slc16a1: monocarboxylate 
transporter 1; D-G) Mitochondrial oxygen consumption rate (OCR) was measured in 
in N2a-hApoE cells receiving sequential injection of substrate (BHB or vehicle), 
oligomycin and FCCP. The ketone body-metabolizing capacity of each ApoE 
genotype group was assessed by the maximum OCR measurements after FCCP 
injection.  FCCP-induced OCR in BHB-treated cells was normalized to their vehicle-
treated counterparts. n=8 per group. Results were compared using one-way ANOVA 




ApoE4 brains compared to ApoE3 brains (FC = 0.70, p = 0.026) (Fig. 1.4.7C). PGC-1α 
protein expression was also significantly lower in ApoE4-expressing cells as compared to 
ApoE2-expressing cells (FC = 0.75, p =0.025) (Fig. 1.4.7D). These results suggest the 
activation of PGC-1α may underlie the bioenergetic robustness associated with ApoE2, 
whereas the lower protein levels of PGC-1α observed in ApoE4 brains and ApoE4-







1.4.8 PGC-1α overexpression ameliorated bioenergetic deficits in N2a cells stably 
expressing human ApoE4 
To investigate the long-term effect of human ApoE expression in neurons, we transfected 
N2a cells with expression vectors encoding human ApoE isoforms and selected stable 
cell lines expressing matched levels of ApoE2, ApoE3, and ApoE4. Interestingly, N2a 
cells stably transfected with human ApoE isoforms exhibited similar metabolic features 
as those observed in the transient transfections. Specifically, neurons stably expressing 
ApoE2 demonstrated significantly higher protein expressions of hexokinase 1 and 
hexokinase 2 compared to neurons stably expressing ApoE3. By contrast, cells stably 
expressing ApoE4 exhibited the lowest expression of both hexokinase isoforms among 
the three ApoE genotype groups. In accordance with the protein expression levels, 
hexokinase activity was markedly higher in ApoE2-expressing neurons but was 
significantly lower in ApoE4-expressing neurons compared to ApoE3-expressing neurons. 
In fact, ApoE4 stably-transfected cells displayed altered cellular morphology (elongated, 
spindle-shaped with neurite outgrowth) at passage 10 and massive cell death after 13 
passages whereas ApoE2 and ApoE3 stably-transfected cells were predominantly round 
shaped and remain healthy even after 20 passages. The aberrant morphological changes 
Fig. 1.4.7 PGC-1α as an upstream regulator in energy metabolism was activated 
in ApoE2 brains. A) IPA predicted the activation of PPARGC1A in the ApoE2 brain 
when compared to the ApoE3 brain. B) qRT-PCR was performed to examine the gene 
expression levels of PGC-1α in the brains of hApoE-TR mice. C-D) Protein 
expressions of PGC-1α were determined in cortex tissues of hApoE-TR mice (C) and 
N2a cells expressing human ApoE isoforms (D). Results were normalized to ApoE3 
group. *p<0.05, **p<0.01, ***p<0.001 by ANOVA with Bonferroni post hoc test, 




and cell death observed in ApoE4-expressing cells were likely attributed to inherited 
defects in glucose metabolism and the resultant energy failure. Further characterization of 
the cell lines stably expressing ApoE isoforms will help to explain these observations.  
Data presented in this section and the following, unless specified otherwise, were 
generated on the stable cell lines.  
Given that PGC-1α activation may underlie the bioenergetic robustness in ApoE2-
expressing cells, we hypothesized that PGC-1α overexpression could ameliorate ApoE4-
induced bioenergetic deficits. To test this hypothesis, ApoE4-expressing cells were 
transfected with empty vector or vectors encoding mouse PGC-1α for 48 hours, and 
hexokinase expressions, enzymatic activity, and ATP levels were assessed in the whole 
cell lysates. ApoE2-expressing cells served as positive control. Interestingly, we found 
that PGC-1α differentially modulated hexokinase expressions. Specifically, PGC-1α 
overexpression significantly increased hexokinase 1 expression (FC = 1.32, p = 0.001) 
but decreased hexokinase 2 expression (FC = 0.73, p = 0.004) in ApoE4-expressing cells 
(Fig. 1.4.8.1A-B). Additionally, the enzymatic activity of hexokinase was significantly 
improved by PGC-1α overexpression (FC = 1.23, p <0.0001) (Fig.1.4.8.1C), which is 





Fig. 1.4.8.1 PGC-1α overexpression differentially modulate hexokinase 
expression. A-B) Protein expressions of hexokinase 1 (A) and hexokinase 2 (B) were 
measured in ApoE4-expressing cells transfected with expression vectors encoding 
mouse PGC-1α or mock control.  Hexokinase 1 and hexokinase 2 expressions were 
significantly lower in ApoE4-expressing cells compared to ApoE2-expressing cells.  
PGC-1α overexpression upregulated hexokinase 1 whereas downregulated hexokinase 
2 in cells expressing ApoE4. C) Hexokinase activity was determined in the whole cell 
lysates for the indicated groups.  PGC-1α overexpression improved hexokinase 
activity in ApoE4-expresssing cells. D) ATP levels were measured in ApoE4-
expressing cells transfected with PGC-1α or empty vectors. Results were normalized 
to ApoE2 group. **p<0.01, ***p<0.001, ****p<0.0001 by ANOVA with Bonferroni 




Although both hexokinase isoforms are expressed in a variety of cell types, cells that are 
sensitive to insulin, such as adult muscle cells, express primarily hexokinase 2, whereas 
cells that rely heavily on glycolysis for energy production, such as neurons, express 
predominantly hexokinase 1. Additionally, it has been proposed that hexokinase 1 
remains associated with mitochondria to promote glycolysis whereas hexokinase 2 
dynamically translocates between cytosol and mitochondria where it directs the metabolic 
fate of glucose between anabolic (glycogen synthesis and pentose phosphate shunt) and 
catabolic (glycolysis) metabolism [246, 306]. To examine the functional consequence of 
the differential regulation of hexokinase expression by PGC-1α, the glycolytic stress test 
was performed in ApoE4-expressing cells transfected with PGC-1α. Sequential injections 
of glucose, oligomycin, and 2-DG measured basal glycolysis, glycolytic capacity, and 
non-glycolytic acidification. The glucose-induced increase in ECAR was significantly 
lower in ApoE4-expressing cells compared to ApoE2-expressing cells, suggesting 
ApoE4-expressing cells had a lower basal glycolytic rate (Fig.1.4.8.2A). Unexpectedly, 
PGC-1α overexpression did not increase basal glycolysis in ApoE4-expressing cells. 
However, defects in maximum glycolytic rate induced by ApoE4 was significantly 
ameliorated by PGC-1α overexpression (FC = 1.33, p = 0.003) (Fig.1.4.8.2B). 
Importantly, PGC-1α overexpression completely reversed ApoE4-induced defects in 
glycolytic reserve capacity (FC = 1.9, p <0.0001) (Fig.1.4.8.2B). These results suggest 
that hexokinase 1 is mainly responsible for promoting glycolysis in N2a cells and that 
improved glycolytic function by PGC-1α is primarily attributed to increased expression 








Because PGC-1α is well recognized as a mediator for mitochondrial biogenesis and 
oxidative phosphorylation, we examined the effect of PGC-1α overexpression on 
mitochondrial respiration in ApoE4-expressing cells (Fig. 1.4.8.2C-E). Higher levels of 
basal and maximal mitochondrial respiratory rates following FCCP injection were 
observed in ApoE4-expressing cells transfected with PGC-1α than those transfected with 
mock control (Fig 1.4.8.2C). Quantitative analysis confirmed that PGC-1α 
overexpression significantly improved basal (FC = 1.36, p = 0.0002) and maximal 
mitochondrial OCR (FC = 1.51, p < 0.0001) in ApoE4-expresssing cells. Similarly, PGC-
1α overexpression resulted in a marked elevation in the spare respiratory capacity in 
ApoE4-expressing cells (FC = 1.80, p = 0.012). Consistent with results shown in Fig. 
1.4.8.1, ATP-linked respiration was significantly improved by PGC-1α expression in N2a 
cells expressing ApoE4 (FC = 1.44, p = 0.0003). Further, PGC-1α overexpression 
markedly increased ATP levels (FC = 1.24, p = 0.0002) in ApoE4-expresing cells, which 
Fig. 1.4.8.2 PGC-1α overexpression ameliorated defects in glycolysis and 
mitochondrial respiration in ApoE4-expressing cells. A) ECAR was measured 
following sequential injections of glucose (10 mM), oligomycin (2 µM), and 2-
deoxyglucose (2-DG) (50 mM) in ApoE4-expressing cells transfected with mouse 
PGC-1α. B) Individual parameters for glycolysis, glycolytic capacity and glycolytic 
reserve were calculated for the indicated groups. PGC-1α overexpression significantly 
enhanced glycolytic capacity and glycolytic reserve in ApoE4-expressing cells. C) 
Mitochondrial OCR was measured in ApoE4-expressing cells transfected with mouse 
PGC-1α after sequential additions of oligomycin (2 µM), FCCP (1 µM), as well as 
antimycin A & rotenone (1 µM), as indicated. D) Quantification of individual 
parameters for basal respiration, maximal respiration, spare respiratory capacity, and 
ATP-linked respiration. PGC-1α overexpression markedly improved mitochondrial 
respiratory function in ApoE4-expresssing cells. Results were compared using one-
way ANOVA with Bonferroni post hoc test. *p<0.05, ***p<0.001, ****p<0.0001 vs 
ApoE2 group. #p<0.05, ##p<0.01, ###p<0.001, ####p<0.0001 vs ApoE4 group. Data 




may result from improvements in glycolysis and mitochondrial respiration (Fig.1.4.8.1D). 
Collectively, these results indicate that enhanced expression of PGC-1α is able to 
ameliorate mitochondrial respiratory deficits induced by ApoE4 in N2a cells. 
 
1.4.9 De novo expression of ApoE2 reversed bioenergetic deficiencies in ApoE4-
expressing cells 
Given that ApoE2 is associated with a robust energy metabolic phenotype, we 
hypothesized that forced expression of ApoE2 could reverse bioenergetic defects induced 
by ApoE4. To test this hypothesis, ApoE4-expressing cells were transfected with 
mammalian expression vector encoding human ApoE2 or empty vector. 48 hours post 
transfection, gene expression, and protein levels were measured to determine the 
transfection efficiency. Then hexokinase protein expression, enzymatic activity, and ATP 
levels were measured in whole cell lysates collected from ApoE4-expressing cells 
transfected with ApoE2 or mock control. ApoE2-expressing cells served as a positive 
control. We first examined ApoE2 expression by real-time PCR and immunoblotting 
analysis. As shown in Fig. 1.4.9.1A, transfection of ApoE2 resulted in abundant gene 
expression of ApoE2 in ApoE4-expressing cells. The ApoE protein levels in ApoE4 + 
ApoE2 group were two-fold higher than non-transfected (ApoE2) or mock-transfected 
(ApoE4) groups (Fig.1.4.9.1B). The weak correlation between changes in the mRNA 
level (30-fold difference) and protein contents (2-fold difference) is likely due to 
regulatory processes at the transcriptional level, RNA processing, and RNA stability, as 
well as rapid protein turnover rate [307]. Intriguingly, introduction of ApoE2 resulted in a 
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marked increase in the expression of hexokinase 2 (FC = 1.42, p = 0.002) and hexokinase 
1 (FC = 1.55, p = 0.015) (Fig. 1.4.9.1C-D). Hexokinase activity in ApoE4-expressing 









We next investigated whether the introduction of ApoE2 could counteract or rescue the 
detrimental effects of ApoE4 on glycolysis and mitochondrial respiratory function. 48 
hours after transfection with ApoE2 or mock control, ApoE4-expressing cells were 
subjected to glycolytic and mitochondrial stress tests. Real-time glycolytic and 
mitochondrial respiratory rates were measured by a Seahorse extracellular flux analyzer. 
As shown in Fig. 1.4.9.2A, baseline glycolysis induced by high concentration of glucose 
was significantly lower in ApoE4-expressing cells compared to ApoE2-expressing cells 
(FC = 0.61, p < 0.0001), which is consistent with our previous findings. Intriguingly, 
introduction of ApoE2 increased basal glycolysis by 47% in ApoE4-expressing cells (FC 
= 1.47, p <0.0001) (Fig.1.4.9.2B). Similarly, the maximal glycolytic rate after oligomycin 
injection was markedly enhanced by ApoE2 expression. The quantitative analysis further 
confirmed that ECAR was significantly higher in ApoE4-expressing cells transfected 
with ApoE2 than those transfected with mock control (FC = 1.27, p <0.0001) (Fig. 
1.4.9.2B). The introduction of ApoE2 also resulted in an increase in glycolytic reserve, 
Fig. 1.4.9.1 Forced expression of ApoE2 increased protein expression and 
enzymatic activity of hexokinase. A) ApoE2 mRNA level was determined in 
ApoE4-expressing cells transfected with empty vector or vectors encoding human 
ApoE2 by real time PCR. ApoE2-expressing cells served as positive control. 
Amplification plots for both ApoE2 and ApoE4 genotypes were shown. GAPDH was 
used as loading control. Three replicates each group. B) Protein expression of ApoE 
was confirmed with immunoblotting analysis. ApoE levels were comparable between 
ApoE2 and ApoE4 groups. C-D) Protein expressions of hexokinase1 (C) and 
hexokinase 2 (D) were assessed in ApoE2- or mock-transfected cells. Expression 
levels of both hexokinase isozymes were markedly elevated in ApoE4-expressing 
cells transfected with ApoE2 compared to those transfected with mock control E-F) 
Hexokinase activity (E) and ATP levels (F) were determined in the cell lysates of 
transfected cells. Results were normalized to ApoE2 group. *p<0.05, **p<0.01, 




although the difference was not significant.  Strikingly, forced expression of ApoE2 
almost completely reversed mitochondrial bioenergetic defects induced by ApoE4. 
(Fig.1.4.9.2C-D). In addition to Basal OCR (FC = 1.58, p <0.0001), ATP-coupled 
respiration represented by oligomycin-sensitive OCR was significantly higher in ApoE4-
expressing cells transfected with ApoE2 than those transfected with mock control (FC = 
1.56, p <0.0001). Similarly, the introduction of ApoE2 resulted in a nearly 2-fold increase 
in the maximal mitochondrial respiration determined by FCCP-stimulated OCR in 
ApoE4-expressing cells (FC = 1.99, p <0.0001). Further, the spare respiratory capacity 
was also markedly improved by ApoE2 expression (FC = 8.22, p <0.0001). In line with 
the improvements in glycolysis and mitochondrial respiration, total ATP levels were 
significantly elevated by ApoE2 expression (FC = 1.41, p = 0.005) (Fig.1.4.9.1F). 
Collectively, our data indicate that de novo expression of ApoE2 could rescue the 




















Fig. 1.4.9.2 Forced expression of ApoE2 improved glycolysis and mitochondrial 
respiration in ApoE4-expresssing cells. A) Kinetic ECAR responses of ApoE4-
expressing cells transfected with ApoE2 to sequential injections of glucose (10 mM), 
oligomycin (2 µM), and 2-DG (50 mM) B) Quantitative analysis of basal glycolysis, 
glycolytic capacity and glycolytic reserve. ApoE2 expression significantly enhanced 
all the parameters for glycolysis in ApoE4-expressing cells. C) Kinetic OCR response 
of ApoE4-expressing cells transfected with ApoE2 to sequential additions of 
oligomycin (2 µM), FCCP (1 µM), as well as antimycin A & rotenone (1 µM). D) 
Calculated parameters including basal respiration, maximal respiration, spare 
respiratory capacity, and ATP production. Introduction of ApoE2 markedly improved 
mitochondrial respiratory function in ApoE4-expresssing cells. Results were 
compared using one-way ANOVA with Bonferroni post hoc test. *p<0.05, 
***p<0.001, ****p<0.0001 vs ApoE2 group. ####p<0.0001 vs ApoE4 group. n=15-
18 per group. 
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Table 1.4.2 Changes in gene expression in ApoE2 and ApoE4 brains compared to ApoE3 brain 
Gene 
Symbol 


















































































































































































































Human ApoE isoforms (ApoE2, ApoE3, and ApoE4) have been shown to confer 
differential risk impact in late-onset AD, which comprises 95% of the total AD cases. 
While an immense amount of work has been done to examine the role of ApoE in AD 
pathogenesis, most studies have focused on identifying AD risk mechanisms conferred by 
ApoE4. In contrast, few studies have explored the role of ApoE2 in relation to AD, 
despite the fact that many of these studies suggest that ApoE2 is neuroprotective [308]. 
However, the underlying mechanisms by which ApoE2 confers neuroprotection remain 
largely unexplored.  
Our previous gene array analysis on the hippocampal tissues from 6-month-old hApoE-
TR mice revealed that the three human ApoE isoforms differentially regulate brain 
bioenergetics. Intriguingly, compared to ApoE3 and ApoE4 brains, the ApoE2 brain is 
associated with a more robust insulin/IGF1 signaling and downstream glucose utilization 
[87]. In the current study, we examined the potential differences in brain metabolic 
pathways involving glucose and ketone bodies as energy substrates. We focused 
primarily on substrate uptake metabolic pathways leading to the generation of acetyl-CoA 
among the three human ApoE genotypes using 6-month-old hApoE-TR mice. Our data 
demonstrated that three ApoE brains differentially express transporters that mediate the 
uptake of energy substrates and the enzymes that are involved in the cytosolic 
metabolism. These data provide potential mechanistic rationales for the protective effects 
associated with ApoE2 and the detrimental effects linked to ApoE4 in the aging and AD 
brain. 
Under normal physiological conditions, glucose is the obligatory energy substrate for the 
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brain. As neurons have a high energy requirement, their function is heavily dependent on 
glucose availability and utilization [309].In this study, we initially examined the gene 
expression profile of glucose transporters and enzymes involved in glucose metabolism, 
in particular, glycolysis. The facilitative glucose transport proteins mediate the transport 
of glucose from the blood to the brain across the blood-brain barrier (BBB) and the 
uptake of glucose into the neuron and glial cells [310]. Here we focused on the main 
glucose transporters in the brain: glucose transporter 1 (GLUT1), which is abundantly 
detected in the BBB, glucose transporter 3 (GLUT3), the major isoform in neurons, and 
the insulin-sensitive glucose transporter 4 (GLUT4). Postmortem studies of the brains of 
AD patients demonstrated a marked decrease in protein levels of GLUT1 and GLUT3 in 
the AD-affected brain regions, particularly in the cerebral cortex, with a significant loss 
of GLUT3 [37, 311]. Reduced levels of GLUT1 and GLUT3 has been correlated with a 
decrease in O-GlcNAcylation and to the hyperphosphorylation of tau [39]. The 
underlying mechanisms implicated downregulation of the hexosamine biosynthesis 
pathway [47]. Therefore, abnormalities in glucose transport may lead to impaired brain 
glucose metabolism, contributing to the development of neuropathological hallmarks of 
AD. In the current study, we did not observe a significant difference in the mRNA level 
of GLUT1 among the three ApoE genotypes. However, studies on human AD brain 
tissues indicate markedly lower protein expression of GLUT1 with no change in mRNA 
level of GLUT1, suggesting post-transcriptional regulation [312]. Further, compared to 
hApoE2-TR and hApoE3-TR mice, hApoE4-TR mice showed reduced glucose transport 
across the BBB without altered levels of mRNA or protein of GLUT1, suggesting the 
function of GLUT1 may involve post-translational modification [313]. Therefore, 
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GLUT1 protein expression and/or function may be altered despite no detectable 
difference in mRNA levels. Future studies are necessary to clarify the role of GLUT1 in 
brain glucose uptake in the three ApoE brains. Additionally, we observed a significantly 
lower mRNA level of GLUT3 in ApoE4 brains than ApoE3 brains. The GLUT3 glucose 
transporter is the predominant isoform in the neurons [314, 315]. Compared to GLUT1 
and GLUT4, GLUT3 has both a higher affinity for glucose and significantly greater 
transport capacity, making it uniquely suited to match the energy needs of the highly 
metabolic neurons [316]. In support of this notion, the protein expression of GLUT3 
decreased in parallel with reduced cerebral glucose metabolism in AD-vulnerable brain 
regions [37]. Further, it has been shown that synaptic activity induced surface expression 
of GLUT3 following elevated rates of glucose import into neurons [317]. Therefore, the 
diminished GLUT3 expression could lead to insufficient energy supply during intense 
neuronal activity, resulting in deficits in neurotransmission in the ApoE4 brain. Of note, 
no changes in GLUT4 protein levels have been observed in the brains of AD patients 
[39]. Similarly, decreases in the expression levels of GLUT1 and GLUT3, but not 
GLUT4 were found in the brains of AD transgenic mice [318]. Here we reported that 
ApoE2 brains exhibited significantly higher levels of GLUT4 mRNA compared to both 
ApoE3 and ApoE4 brains, consistent with our previous findings [87]. The regional 
distribution of GLUT4 correspond to those of the insulin receptors, indicating that insulin 
may induce GLUT4 translocation and promote neuronal glucose transport, thus providing 
additional glucose to neurons under energy challenging conditions [319]. GLUT4 is also 
expressed in the synaptic terminals of some hippocampal neurons where it may play a 
critical role in memory processes [320]. While the mechanisms by which insulin 
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signaling regulates GLUT4 expression and neuronal glucose transport remain to be 
elucidated, upregulation of GLUT4 by insulin-like growth factor-1 (IGF1) could serve as 
a potential mechanism contributing to the neuroprotective properties conferred by 
ApoE2. 
Intracellular glucose metabolism includes glycolysis in the cytosol, TCA cycle and 
oxidative phosphorylation in the mitochondria. Defects in the glycolytic pathway, 
particularly in the initial step, has been reported in the AD brain. For instance, markedly 
reduced glucose phosphorylation was found in the AD-affected brain regions, including 
parietal and temporal cortex [321]. Diminished activity of hexokinase, which catalyzes 
the phosphorylation of glucose, was observed in the brains of AD patients [41, 322]. In 
the current study, we reported that three ApoE isoforms differentially modulate 
hexokinase 1 (HK1) and hexokinase 2 (HK2). Specifically, ApoE2 brains exhibited 
higher expression of HK2 compared to ApoE3 brains. In contrast, ApoE4 brains 
displayed the lowest expressions of both HK1 and HK2 among the three ApoE 
phenotypes.  In line with the in vivo data, compared to ApoE3-expressing cells, ApoE2-
expressing cells showed higher whereas ApoE4-expressing cells demonstrated lower 
expression of both hexokinase isoforms and hexokinase activity. Accordingly, the 
glycolytic capacity was significantly higher in cells expressing ApoE2, but markedly 
lower in cells expressing ApoE4. Within the brain, ATP consumption primarily occurs at 
the synapses [323]. It has been shown that synaptic vesicle recycling requires 
considerable energy that could be met by ATP synthesis driven by neuronal activity [324]. 
In support of this notion, blockade of the activity-stimulated ATP synthesis results in 
severe impairment in synaptic functions [324].  While ATP generated by glycolysis only 
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accounts for a small percentage of total energy consumed by synaptic transmission [323], 
emerging evidence suggests that glycolysis plays a crucial role in the maintenance of 
synaptic function. Several glycolytic enzymes have been found in nerve terminals [325]. 
It has been shown that these enzymes interact with the subunits of vacuolar H+-ATPase 
(V-ATPase), a proton pump that mediates the concentration of neurotransmitters into 
synaptic vesicles thereby regulating synaptic transmission [326, 327]. Additionally, it has 
been reported that V-ATPase activity at the steady state and glucose-dependent V-ATPase 
reassembly are controlled by glycolytic flux [328]. These findings suggest an intimate 
relationship between glycolysis and V-ATPase in regulating synaptic function and 
behavior. Previously, we have reported that three ApoE isoforms differentially modulate a 
key component of the catalytic domain of the V-ATPase. Specifically, our data 
demonstrated that ApoE2 brains express significantly higher levels of the β-subunit of V-
ATPase when compared to ApoE3 and ApoE4 brains [293]. Here we showed that ApoE2 
brains also possess the most robust glycolytic profile among the three ApoE brains. 
Therefore, the robustness in both glycolysis and V-ATPase expression may underlie the 
cognition-favoring properties associated with ApoE2. 
In addition to defects in brain glucose transport and perturbed glycolysis, impaired 
mitochondrial function has been thought to contribute to the development of brain 
hypometabolism [329]. Results from both clinical and pre-clinical studies indicate a close 
link between mitochondrial dysfunction and AD pathophysiology [330, 331]. 
Additionally, it has been reported that ApoE4 carriers had reduced mitochondrial function 
in the hippocampus and posterior cingulate cortex [282, 285], brain regions that are most 
affected by AD. While the mechanisms of ApoE4-induced mitochondrial dysfunction 
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remain largely unknown, several in vitro studies suggest that a carboxyl-terminal-
truncated form of ApoE4 mislocalizes to mitochondria and binds to subunits of 
mitochondrial respiratory chain complexes, leading to impaired electron transport chain 
activity and defects in mitochondrial oxidative phosphorylation [290, 291]. In line with 
these findings, we observed ApoE4-induced deficits in mitochondrial respiratory function 
in N2a cells. Specifically, the basal mitochondrial respiration, spare and maximal 
respiration capacities were all significantly lower in ApoE4-expressing cells compared to 
ApoE3-expressing cells. By contrast, ApoE2-expressing cells exhibited improved 
mitochondrial respiration. Apart from the mechanism mentioned above, reduced 
mitochondrial respiration may be secondary to impaired glycolysis. As less pyruvate is 
generated from glucose, lower levels of acetyl-CoA will enter the TCA cycle, resulting in 
decrease in mitochondrial oxidative phosphorylation. Similarly, the enhanced 
mitochondrial function associated with ApoE2 could be attributed to its increased rate of 
glycolysis. Additionally, compared to ApoE3 and ApoE4 brains, ApoE2 brains exhibited 
enhanced mRNA levels of dihydrolipoamide acetyltransferase (DLAT), a central 
component of pyruvate dehydrogenase complex (PDC), which mediates the conversation 
of pyruvate to acetyl-CoA. Therefore, increased expression of DLAT could also 
contribute to the elevated mitochondrial respiration in ApoE2-expressing cells by 
providing more acetyl-CoA for feeding into the TCA cycle.  
In addition to glucose, we also examined the metabolic profile of ketone bodies, the main 
alternative fuel for the brain under glucose limiting conditions. Brain uptake and 
transport of ketone bodies are mediated by monocarboxylate transporters (MCTs), which 
are proton-linked membrane carriers that transport a range of monocarboxylate 
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metabolites such as lactate, pyruvate, and ketone bodies [332]. Although clinical studies 
have shown that a ketogenic agent improved cognitive performance in AD patients, the 
therapeutic benefits appear to be confined to ApoE4 non-carriers [85, 86, 333]. This led 
us to hypothesize that ketone body transport is defective or/and key enzymes that 
metabolize ketone bodies are impaired in the ApoE4 brain. We examined the gene 
expression of several brain MCTs, including MCT1, which is widely expressed in the 
endothelial cells of brain BBB, MCT4, whose expression appears to be restricted to 
astrocytes, and MCT2, the predominant neuronal monocarboxylate transporter [332] as 
well as the enzymes involved in ketolysis.  Surprisingly, we found that ApoE2 and ApoE4 
brains displayed a similar expression profile of ketone body uptake and metabolism. 
Compared to ApoE3 brains, MCTs and metabolic enzymes were upregulated in both 
ApoE2 and ApoE4 brains. Of note, mRNA levels of MCT1 and β-hydroxybutyrate 
dehydrogenase were significantly higher in the brains or hApoE2-TR mice than those of 
hApoE3-TR mice. These results suggest that ApoE2 and ApoE4 brains are capable of 
taking up and metabolizing ketone bodies more efficiently than ApoE3 brains.  In support 
of this notion, maximal mitochondrial respiration rates upon BHB treatment were 
significantly higher in ApoE2- and ApoE4-expressing neurons compared to ApoE3-
expressing neurons. Intriguingly, our data indicate a relatively robust, rather than 
defective, metabolic profile for ketone body utilization in the ApoE4 brain relative to the 
ApoE3 brain, which could explain, in part, the clinical observation that a ketogenic agent 
provides a more meaningful benefit in ApoE3 than in ApoE4 carriers. In the AD context, 
as the ApoE4 brain is associated with glucose hypometabolism, increased ketone body 
metabolism could serve as an adaptive response to compensate for the bioenergetic 
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defects. We hypothesized that there is an upper limit of ketone body transport and 
metabolism in the ApoE4 brain and that the maximal capacity of ketone utilization has 
been reached as a result of this compensatory response. Hence, when supplied with 
exogenous ketone bodies, the ApoE4 brain would be unable to further metabolize ketones 
for energy production, therefore do not show amelioration in cognitive function. 
Additionally, enhanced ketone body metabolism may be another important contributor to 
the intact cognition associated with ApoE2. 
To further understand the biological implications of gene changes, we utilized Ingenuity 
Pathway Analysis (IPA) to conduct a regulatory pathway and molecular network analysis. 
The results generated from IPA suggest that an upstream regulator, peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), is activated in the 
ApoE2 brain. Studies on adipose tissue, liver, and skeletal muscle have pointed out a 
central role of PGC-1α in modulating mitochondrial biogenesis and oxidative 
phosphorylation [334]. Comparatively fewer studies have examined its function in the 
brain.  A marked decrease in the expression of PGC-1α has been observed in the brains of 
patients with neurodegenerative diseases [335-338]. PGC-1α downregulation has been 
associated with extensive alterations in several metabolic pathways, particularly in 
oxidative phosphorylation and the mitochondrial electron transport chain [337, 338]. 
Additionally, gene expression analysis of PGC-1α null mouse brain indicated significant 
downregulation of genes associated with neuronal functions [339, 340]. These findings 
suggest a pivotal role of PGC-1α in maintaining neuronal functions by controlling 
mitochondrial oxidative metabolism and energy homeostasis. In this study, we found 
significantly higher mRNA levels of PGC-1α in ApoE2 brains compared to ApoE3 and 
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ApoE4 brains. Protein levels of PGC-1α were significantly lower in ApoE4 brains 
compared to both ApoE2 and ApoE3 brains. It has been reported that forced expression 
of ApoE4 reduced mRNA and protein levels of sirtuin 1 (Sirt1) [341], an enzyme which 
mediates NAD+-dependent deacetylation of PGC-1α [342]. As the deacetylation of PGC-
1α results in enhanced PGC-1α transcriptional activity, the lower expression of Sirt1 may 
lead to reduced PGC-1α transcriptional activity. Therefore, lower protein expression and 
activation of PGC-1α may contribute to the bioenergetic deficits associated with the 
ApoE4. To date, there is no report on Sirt1 expression and transcriptional regulation in 
the ApoE2 genotype. However, ApoE2 may modulate PGC-1α activity through a similar 
mechanism. Given that PGC-1α is a master regulator of mitochondrial oxidative 
metabolism, the elevated expression and/or activity of PGC-1α may underlie the 
bioenergetic robustness associated with ApoE2. 
The role of PGC-1α in glycolysis has been examined in the liver, heart, muscle and 
several types of cancer cells. In cultured hepatocytes, PGC-1α overexpression suppressed 
glycolysis by downregulating glucokinase and pyruvate kinase [343]. Reduced 
expression of PGC-1α has been postulated to promote aerobic glycolysis in some most 
aggressive types of cancer, such as breast cancer [344] and colon cancer [345]. In the 
neonatal cardiac myocytes, PGC-1α expression was strongly induced, which directed the 
metabolic switch from glycolysis to mitochondrial oxidative metabolism [346, 347]. In 
skeletal muscles, conflicting findings exist. Muscle-specific overexpression of PGC-1α 
significantly increased expression of glucose transporters and hexokinase, which 
contribute to elevated glucose uptake and utilization [348]. In line with this finding, 
activation of AMP-activated protein kinase (AMPK), which has been shown to promote 
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PGC-1α expression and enhance PGC-1α activity by phosphorylation, significantly 
increased the expression of HK2 and GLUT4, the major hexokinase isoform and glucose 
transporter in the skeletal muscle [349]. However, a recent study indicates that HK2 may 
be regulated independently of PGC-1α upon AMPK activation [350]. To date, no study 
has explored the role of PGC-1α in the glycolytic pathway in the brain. Here we show, 
for the first time, that PGC-1α differentially modulates hexokinase isozymes in neurons. 
Specifically, overexpression of PGC-1α increased the protein expression of HK1, 
decreased HK2 expression. While both hexokinase isozymes catalyze the conversion of 
glucose into glucose-6-phosphate (Glc-6-p), they appear to direct glucose to different 
metabolic fates depending on their subcellular locations. The idea that HK1 functions 
primarily in a catabolic role derived from the findings that the inhibition of HK1 by Glc-
6-p can be overcome by increased cellular phosphate (Pi) [351, 352], which is a signal for 
increased energy demand. In contrast, Pi does not antagonize but enhances the inhibitory 
effect of glucose-6-phosphate on HK2 [353, 354]. Both hexokinase isozymes were found 
to bind to mitochondria. HK1 binds to mitochondrial via the interaction with voltage-
dependent anion channel (VDAC), which controls metabolite exchange across the 
mitochondrial outer membrane [355, 356]. Additionally, it has been demonstrated that 
HK1 preferentially utilized ATP generated by oxidative phosphorylation within the 
mitochondria for phosphorylating glucose [357, 358]. Therefore, a picture has emerged 
that HK1 is mainly catabolic by shuttling Glc-6-p to glycolysis with the terminal stage of 
glucose oxidative metabolism occurring in the mitochondria. In contrast to HK1, HK2 
has been suggested to dynamically translocate between cytoplasm and mitochondria. 
When bound to mitochondria, HK2 fulfills a similar function as HK1; when localized to 
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cytosol, HK2 channels Glc-6-p into glycogen synthesis and other anabolic pathways such 
as the pentose phosphate shunt to provide NADPH for lipid synthesis [246, 306, 359, 
360]. Taken together, these findings suggest HK1 is primarily responsible for glycolysis 
whereas HK2 may play multiple roles in response to different metabolic conditions. 
Therefore, increased HK1 may facilitate glycolysis whereas decreased HK2 may lead to 
inhibition of glucose anabolic metabolism, thus promoting the overall glucose 
catabolism.  Indeed, PGC-1α overexpression resulted in a significant improvement in 
glycolytic capacity, which is likely attributed to the enhanced HK1 expression.  
In the present study we found that three ApoE isoforms differentially modulate brain 
energy metabolism, however, the underlying mechanism remains to be elucidated.  A 
recent study cast the lipid-binding ApoE in an entirely new light by showing that ApoE 
could act as a transcription factor [362]. Human recombinant ApoE, specifically ApoE3 
and ApoE4, were found to translocate to the nucleus and bind to double-stranded DNA 
with high affinity. Chromatin immunoprecipitation and high-throughput DNA sequencing 
(ChIP-seq) analyses revealed ApoE4 targeted the promoter regions of over 1700 genes, of 
which 76 have been implicated in AD pathogenesis [362]. These genes can be broadly 
grouped into several functional classes including neuronal signaling, glucose metabolism 
and energy homeostasis, inflammation, and neuronal cell death.  Both ApoE3 and ApoE4 
were found to bind to the promoter region of Sirt1, but only ApoE4 suppressed its 
transcriptional activity [362]. Importantly, ApoE-Sirt1 interaction was also observed in 
fibroblasts from AD patients that possess ApoE ε3/ε4, suggesting ApoE may regulate 
Sirt1 activity in vivo [362]. As mentioned previously, Sirt1 directly affects PGC-1α 
activity through deacetylation. Therefore, suppression of Sirt1 activity by ApoE4 may 
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result in increased acetylation of PGC-1α and a decrease in its transcriptional activity, 
which could ultimately lead to downregulation of the genes involved in glucose 
metabolism and mitochondrial function. In contrast to ApoE4, which functions as a 
transcriptional repressor, ApoE2 may serve as a positive transcriptional regulator. Thus, 
ApoE2 may increase Sirt1 activity transcriptionally, leading to the deacetylation of PGC-
1α and the upregulation of genes involved in glucose metabolism and mitochondrial 
bioenergetics. Further, ApoE may also target other metabolic pathways known to regulate 
glucose oxidative metabolisms, such as AMPK [342] and hypoxia-inducible factor -1 
(HIF-1) [363]. Further investigations are warranted to delineate the mechanisms by which 
different ApoE isoforms achieve their diverse impacts on multiple energy metabolic 
processes, particularly glycolysis. 
In summary, our data indicate that the ApoE2 brain exhibits the most robust while the 
ApoE4 brain displays the most deficient profile for the uptake and metabolism of 
glucose. In particular, these two ApoE genotypes differ significantly in the expression of 
facilitated glucose transporters and hexokinases. While the uptake and metabolism of 
ketone bodies was similar between ApoE2 and ApoE4 brains, ApoE3 brain display a 
more deficient profile. These findings are supported by both molecular and functional 
studies. Importantly, we discovered that the glycolytic pathway is differentially 
modulated by the three ApoE genotypes. The significantly higher hexokinase protein 
expression and activity could contribute to the overall bioenergetic robustness associated 
with ApoE2. In contrast, the remarkably lower expression and activity of hexokinase may 
be responsible for the bioenergetic deficits associated with ApoE4. Therefore, a 
therapeutic approach that could circumvent the defects in the cytosolic metabolism of 
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glucose by providing glucose metabolizing intermediates, e. g. pyruvate may hold 
benefits for ApoE4 carriers. Importantly, we also provide preliminary evidence that 
introduction of ApoE2 could elicit protective effects in ApoE4 and AD brains. The 
numerous failures in AD clinical trials suggest a loss in translation from pre-clinical 
research to humans and the possibility that we are aiming at the wrong targets. Thus it has 
been proposed that instead of focusing on reducing Aβ, treatment should target processes 
preceding plaque formation or appearance of AD pathology. In this context, strategies 
that target the neuroprotective mechanism could hold promise for preventing, reducing 
risk or delaying the onset of AD by increasing the brain’s internal defense against aging 
and AD-related insults. Therefore, the introduction of ApoE2 may represent a promising 





1.6 Future Directions 
There are a couple of opportunities for the future studies. We have shown that PGC-1α 
overexpression ameliorated ApoE4-induced deficits in glycolysis and mitochondrial 
respiration. To further validate the role of PGC-1α in the bioenergetic robustness 
associated with ApoE2, we will evaluate the effects of shRNA-mediated PGC-1α 
knockdown on hexokinase protein expressions, glycolytic function and mitochondrial 
respiration in the cell line stably expressing human ApoE2. Additionally, a further in-
depth investigation is necessary to elucidate the molecular mechanisms by which PGC-1α 
modulates hexokinase expression. As PGC-1α overexpression improved glycolysis, 
mitochondrial respiration may be improved due to increased availability of substrates and 
reducing equivalents. However, given that PGC-1α is the master regulator of 
mitochondrial oxidative metabolism, the amelioration in mitochondrial respiratory 
dysfunction may be also attributed to enhanced mitochondrial biogenesis and improved 
respiratory capacity. Examination of mitochondrial mass and the expression levels of 
several transcription factors that regulate the expression of mitochondrial genes, such as 
nuclear respiratory factor 1 (NRF1), transcription factor A, mitochondrial (TFAM) and 
estrogen-related receptors (ERRs), could provide insights into the mechanisms 
underlying PGC-1α-mediated protective effects against ApoE4-induced defects in 
mitochondrial function.   
In the present study, PGC-1α overexpression decreased HK2 expression, whereas the 
introduction of ApoE2 significantly increased HK2 expression, suggesting other 
upstream regulators also modulate HK2 expression in the ApoE2 brain. A gene 
expression profiling of the major upstream and downstream signaling pathways with 
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HK2 serving as the node will help to delineate the molecular mechanisms by which 
ApoE2 regulates HK2 expression.  
Another opportunity worth exploring is the potential benefit of pyruvate supplementation 
in ApoE4 carriers. It has been reported that oxidative stress-induced activation of poly 
(ADP-ribose) polymerase-1 (PARP-1) resulted in the depletion of cytosolic NAD+ 
followed by inhibition of glycolysis, leading to sustained energy failure and ultimately 
cell death [364]. As a direct substrate for mitochondrial metabolism, pyruvate can be 
oxidized in the absence of cytosolic NAD+, therefore, it can bypass the restrictions 
imposed by PARP-1 and thus restore energy  efficiency [365]. Consistent with this 
concept, administration of pyruvate significantly improved neuron survival in the brains 
of rats subjected to insulin-induced hypoglycemia [364]. These findings and results from 
our study indicate that pyruvate may benefit ApoE4 brain by circumventing a sustained 
impairment in neuronal glucose utilization due to defects in glycolysis. More work is 
necessary to examine the potential therapeutic effects of pyruvate in the pre-clinical AD 
brain, particularly in those bearing ApoE4. 
Further, results obtained from our in vitro studies suggest that forced expression of 
ApoE2 reversed bioenergetic deficits induced by ApoE4. In future studies, the 
neuroprotective effects of ApoE2 will be evaluated in in vivo studies using hApoE4-TR 
mice. Specifically, the E-cadherin peptides will be used to disrupt the BBB and facilitate 
the delivery of ApoE2 into the ApoE4 brain. Then the effects of ApoE2 introduction on 
ApoE4-induced bioenergetic deficits and other AD-related neuropathological features 
such as synaptic dysfunction, neuronal loss, and cognitive impairment, will be evaluated 




In the current study, we explored the potential differences in the brain energy metabolic 
pathways involving glucose and ketones as substrates, among the three human ApoE 
genotypes.  Our data demonstrated that compared to the ApoE3 brain, the ApoE2 brain 
was associated with a more metabolically robust profile, whereas the ApoE4 brain 
demonstrated a relatively deficient profile in the transport and metabolism of glucose, the 
primary brain energy source (Fig. 1.7.1). Importantly, our data indicated that human 
ApoE isoforms differentially modulate the expression and activity of hexokinase, the 
“gateway” enzyme in glucose metabolism and the “pacemaker” for glycolysis. Enhanced 
glucose metabolism associated with ApoE2 sets a foundation for an increased defense 
against aging and AD-risk-related stress, which may underlie its cognition-favoring 
properties. By contrast, the deficit in glucose metabolism associated with ApoE4 renders 
the brain vulnerable to aging and neurodegeneration, which could contribute to its 
increased susceptibility to AD. Pertaining to the capability of utilizing ketones, the 
secondary fuel for the brain, surprisingly, ApoE2 and ApoE4 brains showed a similar 
level of robustness (Fig. 1.7.1). The vigorous metabolic utilization of ketone bodies in the 
ApoE4 brain could be an adaptive response to compensate for energy deficiency resulting 
from impaired glucose metabolism. Additionally, it may provide a mechanistic rationale 
for the clinical observations that ApoE4 carriers do not benefit from ketogenic therapy. 
Moreover, a bioinformatic analysis suggests the potentiation of an upstream regulator, 
PGC-1α, may be responsible for the bioenergetic robustness associated with ApoE2. In 
support of this prediction, PGC-1α overexpression significantly improved glycolytic 
function and mitochondrial respiration in the cell line stably expressing ApoE4.  More 
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importantly, we provide preliminary evidence that de novo expression of ApoE2 could 
counteract the detrimental effects in glycolysis and mitochondrial respiratory function 
induced by ApoE4 (Fig. 1.7.1). While in vivo studies and in-depth mechanistic 
investigations are warranted, the introduction of ApoE2 could hold promise for 
preventing or delaying the onset of AD by enhancing the overall bioenergetic robustness 















Fig.1.7.1 Conclusion: human ApoE isoforms differentially modulate brain energy 
metabolism. ApoE2 brain exhibits the most metabolically robust while ApoE4 brain 
associates with the most deficient profile on both the uptake and metabolism of 
glucose. In particular, these two ApoE genotypes differs significantly in the expression 
of GLUTs and hexokinases. On the uptake and metabolism of ketones, ApoE2 and 
ApoE4 brains present similar levels of robustness, while ApoE3 brain displays a most 
deficient profile. The activation of PGC-1α may be responsible for the bioenergetic 
robustness associated with ApoE2 as PGC-1α overexpression and forced expression of 
ApoE2 reversed the bioenergetic defects induced by ApoE4. 
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Chapter 2 Cyclophilin D-Mediated Mitochondrial Perturbation Underlies Diabetes-
Associated Cognitive Dysfunction 
2.1 Abstract 
Diabetes mellitus is a heterogeneous metabolic disorder associated with an increased risk 
of synaptic injury and cognitive dysfunction. Diabetic patients have a greater prevalence 
of dementia including Alzheimer’s Disease (AD). However, the underlying mechanisms 
of diabetes-associated cognitive deficits remain to be elucidated. Emerging evidence 
indicates mitochondrial dysfunction is a common pathological feature in diabetes-
affected brains, however, the precise underlying mechanisms are not clear. Brain 
mitochondria isolated from streptozotocin (STZ)-injected mice, a mouse model of type 1 
diabetes, demonstrated reduced calcium buffering capacity and increased reactive oxygen 
species (ROS) generation, suggesting an increased susceptibility to the induction of 
mitochondrial permeability of transition (mPT) and mitochondrial dysfunction. Here, we 
show that Cyclophilin D (CypD), a critical regulator of mPT, plays a major role in 
diabetes-induced mitochondrial abnormalities and related cognitive dysfunction in a type 
1 diabetic mouse model. Compared with vehicle-treated mice, STZ treatment resulted in 
a significant increase in CypD expression and marked decrease in mitochondrial 
respiratory function in the brain, as well as impaired spatial learning and memory 
abilities. Intriguingly, genetic deletion of CypD significantly attenuated diabetes-induced 
cognitive deficits. Compared with STZ-treated non-transgenic mice, CypD null mice 
injected with STZ exhibited substantial improvement in the cognitive function assessed 
by the Morris Water Maze task. In contrast, diabetes-associated upregulation in CypD 
and defects in mitochondrial respiration were greatly exacerbated in the brains of AD 
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transgenic mice made diabetic, suggesting a synergistic effect of diabetes and AD on the 
regulation of CypD expression and mitochondrial dysfunction. In accordance with the 
aggravated mitochondrial perturbation, the diabetes-related cognitive decline was greatly 
accelerated. Therefore, our results provide new insights into the role of CypD-mediated 
mPT in brain mitochondrial malfunction and cognitive impairment related to diabetes. 
Inhibition of the induction of mPT by blocking CypD may represent a promising 






2.2.1 Diabetic encephalopathy 
Diabetes mellitus is a metabolic disorder that affects 422 million people worldwide, 
including 29.1 million in the US [366]. The vast majority of cases of diabetes fall into 
two broad classifications. Type 1 diabetes, comprises only 5-10% of diabetic cases and 
primarily results from autoimmune destruction of the β-cells in the pancreas. Type 2 
diabetes accounts for 90-95% of total cases and is associated with insulin resistance and 
relative insulin deficiency. Diabetes is a chronic illness associated with a number of 
complications including cardiovascular disease, nephropathy, retinopathy, and 
neuropathy. In addition to these peripheral complications, diabetes may also cause 
pathological alterations in the brain. The relationship between diabetes and cognitive 
impairment was noted as early as 1922 [367]. Later in 1950, the term diabetic 
encephalopathy was introduced to describe cognitive impairment as a central nervous 
system (CNS) complication of diabetes [368]. While the clear definition and diagnostic 
criteria of diabetic encephalopathy remains to be established, increasing interest has been 
drawn to investigate the cognitive impairment in relation to diabetes in recent years. A 
number of epidemiological studies indicate that the presence of diabetes significantly 
increases the risk of dementia including the Alzheimer’s type [5, 369-372]. Additionally, 
longitudinal analyses from population-based studies reveal that diabetes is associated 
with an accelerated cognitive decline in aging [373, 374]. In line with these findings, 
compared to age-matched healthy control subjects, diabetic patients exhibited worse 
performance in the cognitive screening tests involving multiple brain regions [2, 375, 
376]. In accordance with clinical evidence, synaptic injury and cognitive dysfunction 
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were observed in animal models of type 1 and type 2 diabetes [90, 91, 377-381]. For 
instance, rats injected with streptozotocin (STZ), a toxin which causes the destruction of 
pancreatic β cells and insulin deficiency, exhibited poor performance in the Morris water 
maze task, suggesting deficits in spatial learning and memory [377, 379]. Consistent with 
these observations, hippocampal long-term potentiation (LTP), which is believed to be 
linked to the cellular mechanisms of learning and memory, was severely impaired in the 
diabetic rats [377, 379, 382]. Similar defects in synaptic plasticity and memory formation 
were also detected in leptin receptor-deficient rodents, the Zucker rats and db/db mice, 
which are characterized by insulin resistance [88, 379]. Collectively, these findings point 
out an intimate association between cognitive impairment and diabetes. 
In contrast to the well-characterized vascular complications, the mechanisms underlying 
diabetic encephalopathy remain largely unexplored.  Several animal studies suggest the 
molecular mechanisms of diabetic encephalopathy differ between type 1 and type 2 
diabetes [383]. In type 2 diabetic encephalopathy, insulin resistance and an increased 
level of cholesterol appear to play significant roles in facilitating amyloidogenesis, tau 
hyperphosphorylation, oxidative stress and neuronal degeneration [384, 385]. In type 1 
diabetic encephalopathy, however, insulin deficiency and hyperglycemia play major roles 
in contributing to neuronal loss and cognitive dysfunction [386, 387]. Therefore, further 
mechanistic studies should be conducted separately on animal models of type 1 and type 
2 diabetes to advance our understandings on the etiology of diabetes-associated CNS 
complication. 
Diabetic encephalopathy has been estimated to occur in 40% of the total diabetic cases, 
primarily in patients with a long diabetic history and/or poorly controlled hyperglycemia 
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[388]. The cognitive deficits are generally mild to moderate, however, they could lead to 
poor self-management, worse glycemic control and lower quality of life [389]. Moreover, 
conventional therapeutic strategies were found to be less effective for diabetic CNS 
complications [390]. With the significantly increasing prevalence of both type 1 and type 
2 diabetes, more research should be directed to uncover the pathophysiological basis of 
diabetic encephalopathy and to find a novel therapeutic approach to prevent or slow 
down the progression of cognitive impairment. 
 
2.2.2 Mitochondrial dysfunction in diabetes 
Mitochondrial dysfunction has long been implicated in the pathogenesis, progression, and 
complications of diabetes [391]. A genetic mutation in mitochondrial DNA (A3243G) 
results in mitochondrial diabetes, a rare form of diabetes characterized by decreased 
glucose-induced insulin release but not insulin resistance [392]. It was proposed that 
mitochondrial dysfunction in the pancreatic β cells, hyperglycemia-induced ROS 
generation, and subsequent oxidative damage play significant roles in the progression of 
the disease [393]. The pathophysiological impacts of mitochondrial dysfunction in type 1 
and type 2 diabetes involve both insulin sensitivity and insulin secretion. While a cause-
effect relationship between perturbed mitochondrial function and insulin resistance 
remains to be established, it is without doubt that alterations in mitochondrial 
morphology [394-396], dynamics (fission/fusion) [397, 398], reduced mitochondrial 
biogenesis [399, 400] and oxidative phosphorylation [396, 400, 401] are all associated 
with impaired insulin actions in the target organs. Additionally, mitochondrial 
dysfunction leads to decreased insulin secretion due to insufficient ATP production and 
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consequently diminished ratio of ATP/ADP [402, 403]. High glucose and fatty acid flux 
into mitochondria elicit ROS generation, presumably from the mitochondrial respiratory 
chain [404, 405]. Mounting evidence suggests mitochondrial oxygen radicals cause 
damage to a number of cell types and tissues, such as vascular endothelial cells [406], 
retinal endothelial cells [404, 407] and renal mesangial cells [408, 409], which may 
underlie the development of diabetes-related complications. Comparatively, few studies 
have explored the role of mitochondrial dysfunction in diabetic encephalopathy. 
Mitochondrial dysfunction in diabetic CNS complication 
Given that brain has high energy requirements and mitochondria are the main source of 
ATP production, it is not surprising that mitochondrial dysfunction is implicated in 
diabetes-associated defects in the brain. Functional impairments of mitochondria, as 
evidenced by a significant reduction in mitochondrial respiration, membrane potential, 
and energy levels, have been observed in the brains of type 2 diabetic mice [410]. 
Additionally, levels of transcription factors involved in mitochondrial biogenesis were 
markedly decreased [410]. Importantly, mitochondrial dysfunction is accompanied by a 
loss of synaptic integrity [410, 411], which may contribute to the cognitive deficits. 
Interestingly, it has been shown that aging facilitated diabetes-related mitochondrial 
dysfunction. Moreira et al. reported a reduction in mitochondrial respiratory chain 
activity and an uncoupling of oxidative phosphorylation in the brain mitochondria 
isolated from Goto-Kakizaki diabetic rats [74]. These defects in mitochondrial 
bioenergetics were greatly exacerbated by aging. The accelerated mitochondrial 
dysfunction could partially explain the increased prevalence of diabetic encephalopathy 
in the elderly [412]. 
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Apart from the defects in mitochondrial respiratory function, several studies suggest that 
oxidative stress plays a major role in the pathology of diabetic encephalopathy. 
Previously, it has been shown that acute hyperglycemia-induced oxidative damage in the 
rat brain [413], with mitochondria being the major target [414]. Indeed, ROS levels, nitric 
oxide production, and mitochondrial nitric oxide synthase expression were found to be 
increased in the brain mitochondria isolated from diabetic rats [73, 415]. Alongside 
elevated oxidative stress, deficits in antioxidant defense such as diminished activity of 
glutathione peroxidase and manganese superoxide dismutase (MnSOD), a lower content 
of coenzyme Q, as well as a reduced ratio of glutathione to glutathione disulfide 
(GSH/GSSG) were also noted [72, 73, 415]. Consequently, nitrosative and oxidative 
stress-induced damage to mitochondrial proteins and DNA may contribute to the 
pathological alterations in mitochondrial structure and function.  
In addition to impairments in mitochondrial function, altered mitochondrial morphology 
resulting from perturbed mitochondrial dynamics has been implicated in type 2 diabetes 
and its complications [416]. Previous studies have shown that hyperglycemia facilitates 
mitochondrial fragmentation by promoting mitochondrial fission or suppressing 
mitochondrial fusion in a variety of cell types, including pancreatic β cells [417, 418], 
skeletal muscle cells [419], cardiomyocytes [420], endothelial cells [421, 422], and dorsal 
root ganglia (DRG) neurons [423-425]. However, the role of mitochondrial dynamics in 
diabetes-induced brain mitochondrial dysfunction and cognitive impairment remains 
unexplored. To address this research gap, mitochondrial dynamics was evaluated in the 
brain of a mouse model of type 2 diabetes (db/db) [75]. A significant decrease in 
mitochondrial density and increased mitochondrial fragmentation were observed in the 
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hippocampus of diabetic mice compared with age-matched nondiabetic littermates [75]. 
The perturbation in mitochondrial dynamics was accompanied by defects in the 
mitochondrial respiratory chain and reduced ATP levels. Consistent with the findings 
from the in vivo studies, a human neuronal SK cell line treated with high concentrations 
of glucose also showed mitochondrial fragmentation and respiratory dysfunction [75]. 
Intriguingly, restoration of mitochondrial fission/fusion balance markedly ameliorated 
diabetes-induced defects in respiratory function and impairment in synaptic plasticity 
[75]. Taken together, these findings indicate that alterations in mitochondrial morphology 
and function due to perturbation in mitochondrial dynamics contribute to diabetes-
associated deficits in synaptic plasticity and cognitive function.  
 
2.2.3 Mitochondrial permeability transition pore (mPTP) 
mPTP in physiological and pathological conditions  
Previous studies have demonstrated a decrease in the capacity of mitochondria to 
accumulate Ca2+ in the brain of diabetic rats, suggesting an increased susceptibility to 
induction of the mitochondrial permeability transition (mPT) [72, 74]. In physiological 
conditions, mitochondria are impermeable and the mitochondrial permeability transition 
pore (mPTP) exists in a low-conductance state, which only allows for the exchange of 
small metabolites between the cytosol and mitochondrial matrix [426]. In the presence of 
some inducers, such as excessive ROS or Ca2+ overload, the formation and opening of the 
mPTP results in a sudden increase in the permeability of mitochondrial inner membrane 
(IMM) to solutes with molecular weight up to 1,500 Da [427]. The high-conductance 
pore allows the entry of small solutes into the mitochondrial matrix, leading to osmotic 
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swelling of the mitochondrial matrix, eventually resulting in the rupture of outer 
mitochondrial membrane (OMM). The subsequent release of cytotoxic proteins, such as 
cytochrome c or apoptosis-inducing factor (AIF), could trigger cellular apoptosis in both 
caspase-dependent and independent pathways. Additionally, the dissipation of 
mitochondrial membrane potential due to the disruption of proton gradient in the IMM 
will lead to uncoupling of oxidative phosphorylation, resulting in ATP depletion and ROS 
generation (Fig.2.2.1). Multiple studies have demonstrated that mPT is involved in tissue 
injuries under certain pathological conditions such as traumatic brain injury [428, 429], 
ischemia-reperfusion injury [430-432], as well as stroke [433]. mPT has also been 
associated with tissue damage in diabetic complications. A number of studies have shown 
that diabetic mitochondria exhibit greater sensitivity to mPTP opening and augmented 
susceptibility to cell dysfunction in heart [434, 435], liver [436] and kidney [437, 438] 
than non-diabetic counterparts. However, it remains unknown whether the mPT 
contributes to diabetes-related brain mitochondrial abnormalities and cognitive 
dysfunction. 
The molecular composition of mPTP 
Despite the considerable efforts to delineate the molecular composition of mPTP, its exact 
structure remains elusive. The old model [439] proposed that mPTP consists of three 
major proteins:  the voltage-dependent anion channel (VDAC) in the OMM, the adenine 
nucleotide translocator (ANT) in the IMM, and cyclophilin D (CypD) as a regulatory 
component in the mitochondrial matrix. It was suggested that CypD binds to VDAC/ANT 
complex, forming a tunnel-like structure at the junction between the inner and outer 
mitochondrial membranes [439]. The crucial role of CypD in mPTP and cell death have 
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been confirmed in a number of in vivo and in vitro studies (discussed in details in section 
2.2.4). However, several genetic knockout experiments raise the question as to whether 
other major components of mPTP are dispensable. For instance, Ca2+- and oxidative 
stress-induced mPT and apoptosis were unaltered or even exacerbated in mitochondria 
lacking all three VDAC isoforms [440, 441], suggesting VDAC may not be an essential 
component for mPTP. Liver mitochondria lacking the two most abundant ANT isoforms 
(Ant1 and Ant2) were still able to undergo mPT, albeit more Ca2+ than usual was required 
[442]. However, it cannot be ruled out that other isoforms, such as Ant4, may compensate 
for the loss of Ant1 and Ant2. Thus, more work is needed to determine whether ANT is 
an essential component of mPTP and the potential role of ANT in the induction of mPT. 
Recent studies suggest the involvement of other molecules in the modulation of mPTP 
activity, including mitochondrial phosphate carrier (PiC) in the IMM. Overexpression of 
PiC has been shown to induce apoptosis [443]. Additionally, PiC was found to associate 
with ANT and binds to CypD [444]. Although the reduction in protein level of PiC did 
not prevent mPTP opening, genetic deletion of PiC in cardiomyocytes blunted mPTP 
opening in response to Ca2+ challenge [445]. Collectively, these findings suggest PiC may 
not be a requisite component of mPTP, but it could regulate its activity.  
In addition to PiC, Bcl-2 family member proteins Bax and Bak, which are central players 
in apoptotic cell death, have also been implicated in mPT regulation by enhancing the 
permeability of the OMM [446]. Indeed, loss of Bax and Bak reduced OMM 
permeability, resulting in resistance to Ca2+ overload-induced mPTP opening and necrotic 
cell death [447, 448]. Further, reconstitution of Bax/Bak-deficient mitochondria with Bax 
mutants not capable of oligomerization or forming apoptotic pores enhanced OMM 
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permeability, restored mPTP opening [447, 448]. These findings suggest Bax/Bak 
facilitate mPT induction and the resulting mitochondrial swelling and organelle rupture. 
Evidence for mitochondrial F1F0 ATP synthase as a core component of mPTP is just 
beginning to emerge. Previously, CypD was found to modulate the catalytic activity of 
F1F0 ATP synthase via binding to the oligomycin sensitivity-conferring protein (OSCP) 
subunits of the lateral stalk [449]. Later, the same group reported that dimers of the F1F0 
ATP synthase incorporated into lipid bilayers formed Ca2+-activated channels with the 
key features of the mPTP [450]. It was found that the c subunit in the F0 domain played a 
critical role in the opening of mPTP induced by cytosolic Ca2+ overload [451]. In line 
with these findings, purified subunit c, when reconstituted to artificial bilayer lipid 
membranes, formed a high-conductance voltage-sensitive channel [452]. Importantly, 
siRNA-mediated downregulation of the c subunit inhibited Ca2+-mediated mPT, 
abolished mitochondrial fragmentation and prevented mPT driven cell death [451]. More 
recently, it was proposed that the c subunit associated with inorganic polyphosphate 
(polyP) and polyhydroxybutyrate (PHB) to form ion channels with properties 
recapitulating those of the native mPTP [453]. Taken together, these findings indicated 
that F1F0 ATP synthase is required for the assembly and function of mPTP, however, 










Fig. 2.2.1 mPTP in physiological and pathological conditions. Key components of 
the mPTP include mitochondrial phosphate carrier (PiC), adenine nucleotide 
translocator (ANT) and F1F0 ATP synthase in the inner mitochondrial membrane 
(IMM), and cyclophilin D (CypD) in the mitochondrial matrix. In physiological 
conditions, mitochondria exhibit high mitochondrial transmembrane potential (Δψm), 
which is generated by proton extrusion from the respiratory chain, and is used to drive 
ATP generation.  In response to some cellular stress, such as excessive ROS 
generation and Ca2+ overload, mPTP opens, resulting in the influx of small solutes 
into the mitochondrial matrix driven by the electrochemical forces. Pro-apoptotic 
proteins Bax and Bak aid in the mPT process by enhancing the permeability of outer 
mitochondrial membrane (OMM). The opening of mPTP results in the loss of the 
Δψm, ATP depletion, mitochondrial swelling, and eventually the rupture of OMM. 
Subsequent release of cytotoxic proteins such as cytochrome c and apoptosis-inducing 
factor could lead to cell death via both caspase-dependent and independent pathways. 
Adapted from Fulda et al. (2010) Nature Reviews Drug Discovery 9, 447-464. 
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2.2.4 CypD and CypD-mediated mPT  
CypD: history, domain, and structure 
Cyclophilin D is the most characterized and undisputed molecular component in the 
mPTP. Preliminary evidence leading to the discovery of CypD as an important regulator 
in mPTP came from studies examining the effect of the immunosuppressive drug 
cyclosporine A (CsA) on mitochondrial functions. Fournier et al. observed that CsA 
inhibited mitochondrial respiration and caused a large amount of Ca2+ accumulation in 
the mitochondrial matrix [454]. Later, it was found that CsA was able to bind to and 
inhibit Ca2+-induced pore formation and mPT induction [455, 456]. Subsequent studies 
identified mitochondrial peptidyl-prolyl cis-trans isomerase (PPIase) as the target of CsA, 
and a model where CypD interacts with ANT in the presence of Ca2+ to cause pore 
opening was proposed [457]. Genetic studies further demonstrated CypD as an essential 
component of the mPTP. In 2005, two laboratories simultaneously reported that mice 
lacking CypD are protected from ischemia/reperfusion-induced cell death. Additionally, 
CypD-deficient mitochondrial are resistance to mPT and mitochondrial swelling induced 
by oxidative stress and Ca2+ overload [432, 458]. Since then, numerous loss-of-function 
studies have corroborated previous findings, supporting the notion that CypD is of critical 
importance in mPT regulation under both normal and pathological conditions [459, 460]. 
CypD is a mitochondrial matrix protein encoded by the peptidyl-prolyl cis-trans 
isomerase F gene (PPIF). Human PPIF gene is located on chromosome 10 and is 
composed of 6 exons and 5 introns (National Center for Biotechnology Information, 
Gene ID: 10105). More than 17 cyclophilins have been identified in the human genome. 
They all have protein-folding and protein chaperone-like functions and have high binding 
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affinity to CsA [461]. The full-length CypD protein consists of 207 amino acids including 
a 109-amino acid cyclophilin-like domain (CLD) conserved among members of the 
cyclophilin family [462]. The inherent peptidyl-prolyl cis-trans isomerase (PPIase) 
activity, imparted by the CLD, is essential for the immunosuppressive effects of CsA and 
CypD-dependent mPTP-induced necrotic cell death [432, 462]. It has been shown that 1-
29 residues in the N-terminal of CypD formed the mitochondrial targeting sequence [463, 
464]. Immunoblotting analyses of cellular subfractions using a CypD-specific antibody 
detected two isoforms: a full-length CypD with a molecular mass of 22 kDa in the 
cytosol and a protein of 18 kDa in the mitochondria [465]. Using [35S]-labeled CypD, 
Johnson et al. reported that the 22-kDa CypD was imported into mitochondria and 
localized to mitochondrial matrix [463, 464]. Thus it has been proposed that the truncated 
form of CypD (18 kDa) results from post-translational processing and cleavage of the N-
terminal targeting sequence of the cytosolic form (22 kDa) [463]. More recently, the 
crystal structure of human CypD in complex with CsA was defined. It was found that 
human CypD consists of eight β-strands, two α-helices, and one 310 helix. Intriguingly, 
the binding sites for CsA are well conserved in all human cyclophilins [466].  
Physiological functions of CypD and CypD-mediated mPT   
Studies using CypD null (Ppif -/-) mice provide solid evidence for a central role of CypD 
in necrotic cell death [431, 432, 458]. It has been shown that CypD-deficient cells are 
highly resistant to cell death induced by hydrogen peroxide-mediated oxidative stress and 
Ca2+ overload, whereas the deficient cells display similar susceptibility as wild-type cells 
to cell death induced by classical apoptotic stimuli such as staurosporine and tumor 
necrosis factor-alpha (TNF-α). These findings suggest that CypD is essential for some 
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forms of necrotic cell death, but are not required for apoptotic cell death. 
Apart from regulating necrotic cell death, CypD and CypD-mediated mPT have been 
implicated in the modulation of energy homeostasis. Metabolic changes have been 
observed in mice lacking CypD. For instance, CypD null mice showed elevated levels of 
mitochondrial matrix Ca2+ and enhanced activities of pyruvate dehydrogenase and α-
ketoglutarate dehydrogenase, suggesting altered capacity of tricarboxylic acid (TCA) 
cycle [467]. Similarly, a proteomics study in the heart of CypD null mice indicates 
changes in branched chain amino acid metabolism, pyruvate metabolism and the TCA 
cycle [468]. Moreover, metabolic profiling of the CypD-deficient mouse embryonic 
fibroblasts revealed enhanced glycolysis with transcriptional upregulation of genes 
involved in glucose metabolism [469]. Further, primary hepatocytes isolated from mice 
lacking CypD exhibited heightened glucose consumption and ATP production [469]. It 
was suggested that the metabolic reprogramming and improved glucose tolerance due to 
CypD deficiency protect mice against high-fat-diet-induced liver damage [469]. Taken 
together, these findings strongly support a crucial role of CypD in cellular metabolism. 
However, questions like how CypD-mediated mPT modulates energy homeostasis and 
whether the mPT-independent mechanism is involved remain to be addressed.   
In addition to energy production, mitochondria also play a major role in regulating 
cellular Ca2+ homeostasis. It has been hypothesized that the transient opening of the Ca2+-
dependent mPTP may provide mitochondria with a fast Ca2+ release channel, therefore 
preventing Ca2+ overload [470]. In support of this hypothesis, Altschuld et al. observed 
that CsA, which desensitized the mPTP,  inhibited mitochondrial Ca2+ efflux in isolated 
adult rat cardiomyocytes [471]. The hypothesis was refined by a model stating that Ca2+  
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fluxes generated by mitochondria during Ca2+ -induced release of Ca2+ was dependent on 
the transitory opening of the mPTP operating in a low-conductance mode [472-474]. 
Consistent with the proposed homeostatic function of the mPTP as a Ca2+ release 
channel, genetic ablation of CypD resulted in the accumulation of Ca2+ in the 
mitochondrial matrix and CsA-treated cardiomyocytes showed a significantly greater 
mitochondrial Ca2+ transient and prolonged time of decay after pacing [467]. 
Additionally, it was found that asynchronous transient mPTP openings allow membrane 
depolarization to extrude Ca2+ and then rapidly repolarization after pore closure [475]. In 
addition to cardiomyocytes, a similar role of CypD-mediated mPT in maintaining Ca2+ 
homeostasis was observed in cortical neurons from adult mice [476]. Collectively, these 
findings suggest CypD-mediated mPT is implicated in the physiological regulation of 
Ca2+ homeostasis by a transient Ca2+ release mechanism. 
CypD and CypD-mediated mPT in AD  
Given that oxidative stress, mitochondrial dysfunction and neuronal loss are common 
features of neurodegenerative disorders, it is not surprising that mPTP opening is 
implicated in the pathogenesis and progression of a vast variety of neurodegenerative 
disorders such as multiple sclerosis (MS) [477], amyotrophic lateral sclerosis (ALS) [459, 
478], Parkinson’s disease (PD) [479, 480], Huntington’s disease (HD) [481], and AD 
[58].  
Amyloid beta (Aβ), a major component of amyloid plaques, has been shown to directly 
perturb mPTP function in brain mitochondria. Aβ treatment significantly decreased 
mitochondrial membrane potential, reduced Ca2+ accumulation, induced mitochondrial 
swelling, the subsequent release of cytochrome c and apoptosis [58, 482, 483]. The 
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indirect effects of Aβ on mPTP function include dysregulated Ca2+ homeostasis and 
oxidative stress. Numerous studies have shown that Aβ peptides increase intracellular 
Ca2+ levels [484-486] and the production of oxygen free radicals [483, 487, 488] in 
cultured primary neurons.  Since both conditions favor the opening of mPTP, Aβ-induced 
Ca2+ overload and ROS generation may contribute to mPTP formation, mitochondrial 
dysfunction and neuronal loss. The target of Aβ in the mPTP was later identified as 
CypD. Co-immunoprecipitation analyses demonstrated that CypD-Aβ complexes exist in 
the cortical mitochondria from AD patients and transgenic mice overexpressing a mutant 
form of the human amyloid precursor protein (mAPP), as well as isolated brain 
mitochondria treated with Aβ [58]. The interaction of CypD with Aβ was also confirmed 
using surface plasmon resonance (SPR) spectroscopy. Recombinant human CypD protein 
was found to bind to different species of Aβ in a dose-dependent manner [58]. Given that 
CypD expression is enhanced in the AD brain [58], and mPTP is implicated in 
mitochondrial dysfunction and neuronal degeneration, CypD-mediated mPT may 
represent a potential therapeutic target for AD. Indeed, blockage of mPTP by genetic 
ablation or pharmacological inhibition of CypD protected neurons against Aβ-induced 
damage. Cortical mitochondria lacking CypD were resistant to mitochondrial swelling 
induced by Aβ [58]. CypD-deficient neurons were protected from Aβ-induced oxidative 
stress and synaptic loss [58, 489]. Similarly, CsA treatment prevented mitochondrial 
swelling, attenuated ROS production and inhibited apoptosis induced by Aβ. In line with 
the in vitro findings, mice lacking CypD showed preserved inner mitochondrial 
membrane potential, reduced ROS generation, attenuated mitochondrial respiratory 
dysfunction and neuronal death in the presence of mAPP. These data suggest that the 
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absence of CypD may confer neuroprotection by abolishing Aβ-induced mPTP opening 
[58]. Intriguingly, genetic deletion of CypD resulted in markedly improved synaptic 
function and spatial learning memory in mAPP mice, likely due to the attenuated 
oxidative stress and amelioration in mitochondrial dysfunction [58]. Further, the above-
mentioned neuroprotective effects associated with CypD deficiency were preserved in old 
mAPP mice, suggesting that the absence of CypD confers a persistent protection against 
Aβ toxicity during aging [490]. In addition to the perturbation on mitochondrial function, 
Aβ also induces defects in mitochondrial motility [70, 491]. Wild-type hippocampal 
neurons exposed to oligomeric Aβ showed decreased mitochondrial density and reduced 
number and velocity of mitochondrial movement in the axons. Since proper 
mitochondrial distribution and efficient mitochondrial transport are essential for 
maintenance of synaptic functions, perturbations in axonal mitochondrial trafficking may 
result in a loss of synaptic integrity [70]. Importantly, Aβ-induced defects in axonal 
mitochondrial movement and synaptic dysfunction were greatly attenuated in neurons 
lacking CypD [491]. Together, these results provide compelling evidence that 
interventions of CypD-mediated mPT could counteract mitochondrial dysfunction, 
synaptic impairment and cognitive deficits induced by Aβ.  
CypD and CypD-mediated mPT in diabetes 
Emerging evidence implicates CypD-mediated mPT in the pathogenesis and 
complications of diabetes. Fujimoto et al. reported that blocking mPTP opening with 
CypD inhibitor CsA or genetic deletion of CypD restored IMM electrochemical gradient 
and reduced β-cell death in a diabetic mouse model induced by pancreatic duodenal 
homeobox gene-1(Pdx1) deficiency [492]. Notably, in Pdx1-deficient mice maintained on 
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a high-fat diet, genetic ablation of CypD resulted in a lower fasting blood glucose and 
markedly increased insulin levels at baseline and in response to glucose challenge, 
suggesting that CypD deficiency rescues the characteristic diabetic phenotype of Pdx1 
insufficiency [492]. In adipose tissue, CypD-mediated mPTP opening was found to 
contribute to high-fat-diet-induced cell death [493]. More recently, studies on diabetic 
skeletal muscles suggest that CypD-mediated mPTP opening may serve as a link between 
mitochondrial dysfunction and insulin resistance [494]. Specifically, CypD-deficient mice 
were protected from high-fat-diet-induced glucose intolerance likely due to the elevated 
glucose uptake by skeletal muscles. Mitochondria isolated from CypD null muscle were 
resistant to diet-induced swelling and had improved Ca2+ retention capacity [494]. 
Importantly, in cell culture models of insulin resistance, treatment with CsA prevented 
insulin resistance, as evidenced by enhanced insulin-stimulated translocation of GLUT4. 
It was suggested that improved insulin sensitivity was attributed to the increase in 
mitochondrial Ca2+ retention and not alterations in insulin signaling or mitochondrial 
bioenergetics [494]. Together, these findings indicate CypD-mediated mPT is implicated 
in diabetes, particularly in impaired insulin secretion and insulin resistance. Whether 
CypD-mediated mPTP opening contributes to diabetes-associated mitochondrial 
dysfunction in the brain, synaptic impairment and cognitive dysfunction remain to be 







2.2.5 CypD inhibitors 
In preclinical studies, CsA is the most commonly used pharmacological inhibitor for 
CypD-mediated mPT. Studies have shown that administration of CsA protects against 
mPTP-induced mitochondrial perturbations in several animal models of 
neurodegenerative diseases [495-498]. CsA was initially discovered as an agent for 
immunosuppression following organ transplants. It acts by inhibiting calcineurin, a 
calcium/calmodulin-dependent protein phosphatase, thereby preventing the 
dephosphorylation of nuclear factors of activated T-lymphocytes, resulting in the 
suppression of T-cell activation and overall immune response [499]. In addition to its 
immunosuppressive effect, CsA is associated with severe toxic effects in liver and kidney, 
which significantly limits its clinical applications. Several non-immunosuppressive CsA 
derivatives such as N-Me-Val-4-cyclosporin A and N-Me-Ala-6-cyclosporin A, retain 
high potency in inhibiting PPIase activity of CypD, thus protect cells against mPTP 
opening and apoptosis [430, 500]. However, the efficacy and potential cytotoxic effects 
of these CsA analogs have not been evaluated in vivo. Sanglifehrin A (SfA), a novel 
immunophilin-binding agent was found to bind to CypD but at a different site from CsA 
[501]. SfA showed protection against ischemia-reperfusion-induced necrotic damage in 
isolated rat hearts, presumably through inhibition of PPIase activity of CypD, the 
conformational change of ANT, and subsequent mPTP formation [501]. Although SfA 
does not inhibit calcineurin, it exerts its immunosuppressive action through a distinct 
mechanism which is not well elucidated [502]. Another novel derivative of CsA, 
FR901459 exhibits greater potency than CsA in suppressing Ca2+-induced mitochondrial 
swelling and protecting against transient cerebral ischemia-induced neuronal cell death 
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[503]. Interestingly, it was thought that the immunosuppressive properties of FR901459, 
rather than its inhibitory effect on mPTP opening, plays a more important role in 
attenuating brain damage. More recently, antamanide (AA), a monocyclic decapeptide 
isolated from the poisonous mushroom Amanita phalloides, was found to prevent mPTP 
opening by targeting the PPIase of CypD, thus protecting cells against apoptosis caused 
by mPT inducers [504]. Although in vitro studies demonstrated the great potency of these 
inhibitors in the blockage of CypD-mediated mPT, the potential neuroprotective effects 
of these CypD inhibitors have not been evaluated in vivo. Additionally, these CypD 
inhibitors are large molecules which may significantly limit their brain uptake across the 
blood-brain barrier. Further, the immunosuppressive properties of some inhibitors may 
cause a number of side effects and tissue injuries. Therefore, a non-immunosuppressive 
agent which targets CypD in the brain may be an ideal drug candidate to combat 
mitochondrial dysfunction and cognitive impairment associated with diabetes. 
 
The goals of the second chapter of my dissertation were to investigate the potential role 
of CypD in diabetes-related mitochondrial dysfunction and cognitive impairment. Using 
a mouse model of type 1 diabetes, we evaluated the consequence of changes in CypD 
expression in brain mitochondrial function and cognitive abilities. Results from the 
current study provide new insights into the mechanisms underlying mitochondrial 
malfunction relevant to the pathogenesis of diabetes-associated cognitive deficits.  
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2.3 Materials and Methods 
2.3.1 Animals 
Animal studies have been approved by the Institutional Animal Care and Use Committee 
(IACUC) of the University of Kansas and followed National Institutes of Health 
guidelines for the care and use of laboratory animals. Cyclophilin D homozygous null 
mice (Ppif-/-) were generous gifts from Dr. Jeffery Molkentin [432]. These mice were 
backcrossed to C57BL6/J mice at least 10 times before the experiments to eliminate the 
potential effects of genetic background. For the second study, we used transgenic mice 
overexpressing a mutant form of the human amyloid precursor protein (mAPP) bearing 
both the Swedish (K670N/M671L) and the Indiana (V717F) mutations driven by the 
PDGF-β promoter (J-20 line). Only male mice were used in the current studies as female 
mice are relatively unresponsive to streptozotocin.  
 
2.3.2 Induction of Type 1 Diabetes 
Type 1 diabetes was induced by intraperitoneal administration of streptozotocin (STZ, 
Sigma, St. Louis, MO, USA). Specifically, 3-month-old male mice were treated with STZ 
(freshly prepared in 100 mM sterile citric acid, pH 4.5) at a dosage of 50 mg/kg for 5 
consecutive days. Control animals received injections of citrate buffer. Diabetes was 
monitored by measurements of blood glucose at 2 weeks, 1 month and 2 months after 
STZ injection. Blood glucose levels were determined using a glucose meter and blood 
samples obtained by tail snipping. Hyperglycemia was defined as fasting glucose 
concentration above 250 mg/dL. 2 months after diabetes induction, Morris water maze 
behavior task was performed for 7 days and then the mice were euthanized and processed 
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for brain mitochondria isolation, mitochondrial respiratory chain activity and immunoblot 
analysis as described below. 
 
2.3.3 Morris Water Maze task 
Mice were tested in the Morris Water Maze task to assess spatial learning and memory as 
described previously [505].  The apparatus is composed of a pool, which is 150 cm in 
diameter and 50 cm in height, a platform is placed in one of the fixed quadrants for mice 
to escape, and a camera above the center of the pool captures images of the swimming 
mice. The tank is filled with water kept at 23 ± 2 °C during the trials. The platform is 
hidden 0.5-1 cm below the water surface and the white paint was added to the water to 
make the platform less visible. In spatial acquisition session, mice were trained for 6 
consecutive days with 4 trials for each mouse per day.  A trial started with releasing one 
mouse facing the pool wall and the mouse allowed to swim freely and search for the 
escape platform. If the mouse cannot reach the platform within 60 seconds, it was guided 
to the platform and allowed to stay on for 15 seconds before the next trial. After all trials, 
mice were dried with paper towels and returned to their cages. The escape latency was 
analyzed by the behavior software system (HVS water 2020). On the 7th day, a probe 
trial was performed to assess the reference memory of mice. The platform was removed 
from the pool and the mice were allowed to swim freely for 60 seconds. The location of 
mice were recorded and data were analyzed by HVS water 2020.  
 
2.3.4 Mitochondrial Isolation  
Mitochondrial fractions prepared from brain tissues of mice as described previously [58]. 
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Briefly, cerebral cortex or hippocampus was dissected and homogenized in cold 
mitochondrial isolation buffer (225 mM D-mannitol, 75 mM sucrose, 2 mM K2HPO4, pH 
7.2).  Brain homogenates were centrifuged at 1,300 g for 5 min at 4 °C. The supernatant 
was centrifuged at 34,000g for 10 min after layering on 15% Percoll. The pellet was 
resuspended in 20 ml mitochondrial isolation buffer containing 0.01% digitonin, 
incubated on ice for 5 min, and centrifuged at 8,000 g for 10 min. After two washes with 
mitochondrial isolation buffer (1.5 mL each), final mitochondrial pellets were collected. 
 
2.3.5 Mitochondrial Electron Transport Chain Complex Activities 
NADH dehydrogenase (Complex I) Enzyme activity of NADH dehydrogenase was 
measured by the decrease of absorbance at 340 nm following the oxidation of NADH. 
Mitochondrial fractions containing 30 μg of protein were added to the reaction solution 
containing 50 mM KCl, 30 mM Tris-HCl pH 7.4, 6 mM EDTA, 5 mM MgCl2, 2 mM 
KCN, 0.13 mM NADH, 2 μg/mL antimycin A. The reaction was initiated by addition of 
CoQ1 and the enzyme activity was measured by the changes in absorbance at 340 nm for 
a total of 360 seconds with 20 seconds interval on Shimadzu (Kyoto, Japan) UV1200 
spectrophotometer. To exclude the rotenone nonspecific activity, 2 μg/mL rotenone was 
added at 180 seconds and NADH dehydrogenase activity was calculated by subtracting 
the reaction rate in the presence of rotenone from that in the absence of rotenone. An 
extinction coefficient of 6.2 mM–1 cm–1 for NADH was used for the calculation. Complex 
I specific activity was expressed as micromoles of NADH oxidized per min per mg 
protein.  
Succinate dehydrogenase (Complex II) Enzyme activity of succinate dehydrogenase was 
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measured by the decrease in absorbance at 600 nm due to the reduction of dichlorophenol 
indophenols (DCPIP).  Briefly, 40 μg of cortical mitochondria were incubated 1 mL 
reaction buffer (50 mM KCl, 30 mM Tris-HCl pH 7.4, 6 mM EDTA, 5 mM MgCl2, 20 
mM sodium succinate) and equilibrated in a water bath at 37°C for 10 minutes. The 
reaction was started by adding (2 mM KCN, 2 μg/mL rotenone, 2 μg/mL antimycin A) 
containing 50 μM DCPIP. Absorbance at 600 nm was recorded for 180 seconds with 20 
seconds interval on UV1200 spectrophotometer. Then CoQ2 was added to the reaction 
mixture and changes in absorbance at 600 nm was measured for an additional 180s with 
20 seconds interval. Succinate dehydrogenase activity was calculated by the difference in 
the reaction rate before and after the addition of CoQ2. Complex II specific activity was 
expressed as micromoles of DCPIP oxidized per min per mg protein using an extinction 
coefficient of 19.1 mM–1 cm–1. 
Ubiquinol-cytochrome c reductase (Complex III) Enzyme activity of ubiquinol-
cytochrome c reductase was measured by the increase in absorbance at 550 nm due to the 
reduction of cytochrome c. In brief, CoQ2 was added into the reaction solution 
containing 50 mM KCl, 30 mM Tris-HCl pH 7.4, 6 mM EDTA, 5 mM MgCl2, 2mM 
KCN, 15 μM oxidized cytochrome c, 2 μg/mL rotenone and 0.6 mM n-Dodecyl-β-d-
maltoside, to a final concentration of 32.5 μM. Baseline was measured for 1 min with 20 
seconds interval on Shimadzu UV1200 spectrophotometer. 80 μg of protein was added to 
the reaction mixture and enzyme-catalyzed reduction of cytochrome c was measured for 
180 seconds. Cytochrome c reductase activity was calculated by subtracting the baseline 
rate from the reaction rate after CoQ2 addition. Complex III specific activity was 
expressed as micromoles of cytochrome c reduced per min per mg protein using an 
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extinction coefficient of 18.7 mM–1 cm–1. 
Cytochrome c oxidase (Complex IV) Enzymatic activity of cytochrome c oxidase was 
measured in cortical mitochondria as previously described [58, 506].  The mitochondrial 
fraction containing 30 μg of protein and enzyme dilution buffer (10 mM Tris-HCl, pH 
7.0) were added into 950 μL of assay buffer (10 mM Tris-HCl and 120 mM KCl). The 
reaction was initiated by the addition of 50 µL ferrocytochrome c into the cuvette. The 
changes in absorbance at 550 nm was recorded for 60 seconds using a kinetic program 
with 3 seconds delay and 10 seconds interval on UV1200 spectrophotometer. Complex 
IV activity was expressed as micromoles of cytochrome c oxidized per min per mg 
protein using an extinction coefficient of 21.2 mM–1 cm–1. 
 
2.3.6 Immunoblotting Analysis 
Brain tissues from transgenic mice were homogenized in cell lysis buffer (Cell signaling, 
Danvers, MA, USA) supplemented with protease inhibitor cocktail (Calbiochem, San 
Diego, CA, USA). Protein samples were then separated on 10% SDS-PAGE gels and 
transferred to 0.45 μm nitrocellulose membranes (Amersham, Pittsburgh, PA, USA), 
followed by blocking with 5% nonfat dry milk (Santa Cruz Biotechnology, Dallas, TX, 
USA) in TBST buffer (20 mm Tris-HCl, 150 mm sodium chloride, 0.1% Tween-20) for 1 
hour at room temperature. Membranes were then incubated and gently shaken overnight 
at 4°C with primary antibodies. The following primary antibodies were used: mouse anti-
CypD (1:4000, Abcam, Cambridge, UK), rabbit anti-Hsp60 (1:6000, Enzo Life Sciences, 
Farmingdale, NY, USA), mouse anti-β-actin (1:8000, Sigma, St. Louis, MO, USA), rabbit 
anti-tubulin (1:10000, Sigma, St. Louis, MO, USA). The binding sites of primary 
142 
 
antibody were visualized with horseradish peroxidase-conjugated anti-rabbit IgG 
antibody (1:5000, Life Technology) or anti-mouse IgG antibody (1:5000, Life 
Technology) followed by addition of super signal west pico chemiluminescent substrate 
(Thermo Scientific) and a FluorChem HD2 image system (ProteinSimple, San Jose, CA, 
USA). The densitometry of the immunoblotting bands was quantified using NIH Image J 
software (National Institutes of Health, Bethesda, MD, USA). 
 
2.3.7 Statistical Analysis 
Data are expressed as mean ± standard error of the mean (SEM). All statistical analyses 
were performed using StatView (SAS Institute). Student’s t-test and one-way ANOVA 
with Fisher’s protected least significant difference post hoc test were used for 
comparisons of mean values of the experimental groups. p<0.05 was considered 





2.4.1 Cyclophilin D deficiency ameliorated diabetes-associated mitochondrial 
dysfunction and cognitive impairment  
2.4.1.1 Increased expression of cyclophilin D in STZ-induced diabetic mice 
To explore the potential role of cyclophilin D (CypD) in diabetes-related brain 
dysfunction, we first examined the expression of CypD in the brains of STZ-injected 
mice. Interestingly, CypD protein expression was significantly elevated in both 
hippocampus and cortex of STZ-treated mice compared with vehicle-treated mice (Fig 
2.4.1.1A). Because CypD is localized to the mitochondrial matrix, we also evaluated 
CypD expression in cortical mitochondria isolated from the diabetic mice. Immunoblot 
analysis indicated that CypD expression was increased by 1.6 fold in brain mitochondria 
from diabetic mice compared to non-diabetic mice (Fig.2.4.1.1B). The expression of 







2.4.1.2 Experimental induction of type 1 diabetes in transgenic cyclophilin D null 
mice  
Given that CypD expression was elevated in diabetic brain and CypD-mediated mPT has 
been implicated in diabetes-induced mitochondrial dysfunction, we sought to determine 
whether CypD deficiency could ameliorate diabetes-associated deficits in the brain. 3-
month-old nontransgenic mice (nonTg) and cyclophilin D null mice (Ppif-/-) were 
subjected to intraperitoneal injection of streptozotocin (STZ) for five consecutive days. 
Blood glucose concentration was determined to validate the establishment of diabetes. 
Compared with vehicle-injected groups, STZ injection resulted in significantly enhanced 
blood glucose levels in both nonTg and Ppif-/- mice 2 weeks after initiation of STZ 
injection (387.7 ± 17.8 mg/dL in nonTg STZ and 451.9 ± 15.6 mg/dL in Ppif-/- STZ mice, 
Fig. 2.4.1.2A). Blood glucose levels remained significantly high in the diabetic mice two 
months post injection (503.9 ± 38.0 mg/dL in nonTg STZ and 565.9 ± 15.4 mg/dL in 
Ppif-/- STZ mice, Fig.2.4.1.2A). Progressive body weight loss is a typical feature of type 1 
diabetes. Indeed, mice injected with vehicle displayed positive changes in body weight 
(4.2 ± 0.6 g in nonTg Veh and 2.9 ± 0.5 g in Ppif-/- Veh, Fig2.4.1.2B). In contrast, 
significant body weight loss was observed in nonTg mice injected with STZ (-3.7 ± 0.5 
g). STZ also induced body weight loss in CypD-deficient mice, albeit at a lower 
Fig. 2.4.1.1 Enhanced CypD expression levels in the brains of STZ-induced 
diabetic mice. A) Densitometric analysis of CypD immunoreactive bands in tissue 
homogenates of hippocampus and cortex from vehicle- and STZ-treated mice. Data 
were normalized to β-actin. B) CypD expression level in cortical mitochondria 
isolated from vehicle- and STZ-treated mice. Hsp60 was used as a mitochondrial 
marker. n= 3-5 mice per group, *p<0.05, **p<0.01 vs Veh group. 
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magnitude (-0.2 ± 0.3 g). Together, these results indicate that both nonTg and CypD-null 
mice developed type 1 diabetes as early as two weeks after STZ treatment and was 








Fig. 2.4.1.2 Induction of type 1 diabetes in nonTg and CypD null mice. A) Fasting 
blood glucose levels measured before STZ injection, 2 weeks, 1 month and 2 months 
after STZ treatment were shown for the indicated groups. B) Mean body weight 
change were assessed before and 2 months after STZ treatment. n=7-12 per group. 
*p<0.05 vs nonTg Veh group. #p<0.05 vs mAPP Veh group. 
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2.4.1.3 Cyclophilin D deficiency attenuated diabetes-induced mitochondrial 
dysfunction 
Given that CypD is a key regulatory component of mitochondrial permeability transition 
pore (mPTP) and the opening of mPTP results in mitochondrial dysfunction, we 
investigated whether genetic deletion of CypD could rescue diabetes-induced 
mitochondrial dysfunction. We evaluated mitochondrial function by measuring 
mitochondrial electron transport chain (ETC) complexes activities in both vehicle- and 
STZ- treated mice. No significant difference was detected in the enzymatic activity of 
NADH dehydrogenase (complex I), ubiquinol-cytochrome c reductase (complex III), and 
cytochrome c oxidase (complex IV) between nonTg mice treated with vehicle and those 
with STZ (Fig. 2.4.1.3B-D). Succinate dehydrogenase (complex II) activity was 
significantly decreased in the brain mitochondria from STZ-treated nonTg mice 
compared to vehicle-treated nonTg mice (FC = 0.78, p = 0.041) (Fig.2.4.1.3A). Notably, 
complex II activity was markedly improved in the CypD null mice injected with STZ (FC 
= 1.27, p = 0.038), suggesting that CypD deficiency attenuated mitochondrial respiratory 








2.4.1.4 Cyclophilin D deficiency ameliorated diabetes-induced cognitive impairment  
As mitochondrial function is closely associated with synaptic plasticity and cognitive 
function, we next examined the effect of CypD deficiency on diabetes-associated 
cognitive dysfunction. Morris Water Maze task (MWM) was performed to assess spatial 
learning and memory in nonTg and Ppif-/- mice treated with vehicle or STZ. During the 
Fig. 2.4.1.3 CypD deficiency rescued STZ-induced defects in mitochondrial 
respiratory function. A-D) Enzymatic activities of complex I-IV were determined in 
the mitochondrial fractions prepared from cortex of vehicle- and STZ- treated mice. 
Diabetic nonTg mice were not different from their non-diabetic littermates in complex 
I (B), complex III (C) or complex IV (D). Complex II activity (A) was reduced in 
nonTg STZ group; CypD deficiency restored complex II activity. Results were 
compared using one-way ANOVA with Fisher's Least Significant Difference post hoc 
test. n= 6-9 per group. *p<0.05 vs nonTg Veh group. #p<0.05 vs nonTg STZ group. 
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acquisition phase, vehicle-treated nonTg mice showed intact learning abilities as 
demonstrated by a day-to-day decrease in escape latency. STZ treatment resulted in an 
impairment in spatial learning as nonTg mice injected with STZ spent significantly 
longer time searching for the platform (nonTg Veh = 21.8 ± 2.7s, nonTg STZ = ± 2.6s on 
day 6) (Fig. 2.4.1.4A). For the probe trials, STZ-treated nonTg mice spent significantly 
less time in the target quadrant and achieved fewer times of platform crossings, 
suggesting diabetes-induced deficits in reference memory (Fig. 2.4.1.4C-D). Importantly, 
STZ-induced defects in learning and memory were greatly attenuated by genetic deletion 
of CypD, as evidenced by the reduction in escape latency (Ppif-/- STZ = 28.5 ± 2.9 s, 
nonTg STZ = 44.8 ± 2.6 s), increased target quadrant occupation (Ppif-/- STZ = 41.1 
±1.1%, nonTg STZ = 23.1 ± 3.3%), and enhanced number of platform crossings (Ppif-/- 
STZ = 4 ± 0.7, nonTg STZ = 1.2 ± 0.3) (Fig. 2.4.1.4A, C-D). In vehicle-treated groups, 
CypD null mice did not differ from their nonTg littermates in the MWM performance 
(Fig. 2.4.1.3A, C-D), suggesting CypD deficiency has no effect on hippocampus-
dependent spatial learning and memory. The average swimming speed was comparable 
among the four groups of mice, suggesting that the differences observed in MWM task 









Fig. 2.4.1.4 CypD deficiency ameliorated STZ-induced deficits in spatial learning 
and memory. A) Mean latency to escape to the hidden platform during each day of 
acquisition session. B) Average swimming speed were shown for the indicated groups. 
C) Percentage of time spent in the quadrant where the hidden platform locates. D) The 
mean number of mice crossing the target zone in probe trials. Representative images 
of swimming paths for groups indicated were shown in the bottom. Results were 
compared using one-way ANOVA with Fisher's Least Significant Difference test. n= 
5-9 per group. ****p<0.0001 vs nonTg Veh group. ###p<0.001 vs nonTg STZ group. 
150 
 
2.4.2 Synergistic exacerbation of mitochondrial dysfunction and cognitive 
impairment in an AD mouse model with diabetes 
2.4.2.1 Experimental induction of type 1 diabetes in mAPP mice 
nonTg and mAPP mice were injected with STZ for 5 successive days to induce type 1 
diabetes. Hyperglycemia was confirmed in STZ-treated groups two weeks after STZ 
injection and sustained more than 2 months (Fig. 2.4.2.1A). Significant body weight loss 
was observed in STZ-induced diabetic mice but not in vehicle-treated mice 
(Fig.2.4.2.1B). Collectively, these results indicate the successful induction of type 1 




Fig. 2.4.2.1 Induction of type 1 diabetes in nonTg and mAPP mice. A) Fasting 
blood glucose levels were measured before STZ injection (baseline), 2 weeks and 2 
months after STZ treatment for the indicated groups. B) Mean body weight changes 
were assessed before and 2 months after STZ treatment. n=5-10 per group. *p <0.01 
nonTg/Vehicle vs nonTg/STZ, # p <0.01 mAβPP/Vehicle vs mAβPP/STZ. Adapted 




2.4.2.2 Further enhancement of Cyclophilin D expression in diabetic mAPP mice 
Previous studies indicate that CypD expression is markedly elevated in the brains of 
mAPP mice at 6-12 months compared to age-matched nonTg mice. The diabetic brains 
also show increased CypD expression when compared to non-diabetic brains 
(Fig.2.4.1.1). To determine the effects of diabetes and AD on CypD expression, we 
examined CypD protein levels in the brains of diabetic mAPP mice. Consistent with 
previous findings, CypD expression was significantly higher in the hippocampus of 
vehicle-treated mAPP mice and STZ-treated nonTg mice when compared to vehicle-
treated nonTg mice. Intriguingly, CypD expression was further enhanced in diabetic 
mAPP mice, suggesting that diabetes and AD may have synergistic effects on the 
regulation of CypD expression (Fig. 2.4.2.2).  
 
Fig. 2.4.2.2 Expression of CypD was further enhanced in the brains of diabetic 
mAPP mice. CypD protein expression levels were determined in the hippocampal 
homogenates from mice in the indicated groups. Densitometry of CypD 
immunoreactive bands were shown on the upper panel. Tubulin was used as loading 
control. Representative immunoblots were shown on the bottom. n= 5 per group. 
*p<0.05 vs nonTg Vehicle group, #p<0.05 vs nonTg STZ group, $p<0.01 vs mAPP 
Vehicle group. Adapted from Wang, Yongfu et al. (2015) JAD 43.2  
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2.4.2.3 Exacerbation of mitochondrial dysfunction in diabetic mAPP mice 
Impaired mitochondrial function has been implicated in the pathogenesis and progression 
of AD and diabetes. To determine the effects of AD and diabetes on mitochondrial 
function, we measured mitochondrial ETC complexes activities in brain mitochondria of 
mice in the designated groups. Consistent with our previous findings, STZ-treated nonTg 
mice exhibited significantly lower complex II activity than vehicle-treated nonTg mice 
(FC = 0.62, p = 0.005). However, the diabetic mice did not differ from their vehicle-
treated counterparts in complex I and IV activity (Fig. 2.4.2.3). However, the activity of 
both complexes were significantly decreased in STZ-treated mAPP mice when compared 
to STZ-treated nonTg mice (FC = 0.42, p = 0.042 for complex I; FC = 0.79, p = 0.026 for 
complex IV). These results suggest that diabetes-induced deficits in mitochondrial 












Fig. 2.4.2.3 Diabetes-induced defects in mitochondrial respiratory function were 
exacerbated in diabetic mAPP mice. A-C) Complex I, II and IV activities were 
determined in the cortical mitochondria for the indicated groups. STZ-treated nonTg 
mice were not different from their vehicle-treated counterparts in complex I (A) or 
complex IV (C). Activities of both complexes were markedly reduced in the STZ-
treated mAPP mice. Results were compared using one-way ANOVA with Fisher's 
Least Significant Difference test. n= 4-7 per group. *p<0.05 vs nonTg Veh group. 
#p<0.05 vs nonTg STZ group. $p<0.05 vs mAPP Veh group. 
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2.4.2.4 Accelerated cognitive decline in diabetic mAPP mice 
Hippocampus-dependent cognitive deficits were observed in STZ-induced diabetic mice 
(Fig. 2.4.1.4) and mAPP mice as early as 6 months old. To evaluate the synergistic effects 
of type 1 diabetes and AD on spatial learning and memory function, we performed MWM 
on mAPP mice after 2 months of diabetes induction. Vehicle-treated nonTg mice had 
gradually decreased escape latency over the training period, suggesting they showed 
some spatial learning. In comparison, STZ-treated nonTg and vehicle-treated mAPP mice 
displayed a significantly prolonged escape latency (nonTg STZ = 41.5 ± 3.5s, mAPP Veh 
= 43.9 ± 5.2s vs nonTg Veh = 19.9 ± 3.3s), indicating deficits in spatial learning. STZ-
treated mAPP mice showed the worst performance as they failed to find the platform 
within the maximum testing time (Fig.2.4.2.4A). For the memory retention test, both 
diabetic nonTg mice and non-diabetic mAPP mice exhibited impaired performance 
compared to vehicle-treated nonTg mice, since they spent significantly less time 
searching in the target quadrant (nonTg STZ = 31.5 ± 1.8%, mAPP Veh = 38.0 ± 4.0% vs 
nonTg Veh = 57.2 ± 4.4%), and achieved fewer times of platform crossings (nonTg STZ 
= 2 ± 0.3, mAPP Veh = 2 ± 0.6 vs nonTg Veh = 5.4 ± 0.5) (Fig.2.4.2.4C-D). Notably, 
defects in reference memory were greatly exacerbated in diabetic mAPP mice. Shown in 
Fig 2.4.1.4 C-D, STZ-treated mAPP mice had the least percentage quadrant time (16.3 ± 
1.8%) and the lowest number of target zone crossings (0.6 ± 0.2). No significant 
difference in the average swimming speed was observed among the groups (Fig. 
2.4.2.4B). Taken together, these results indicate that diabetes-induced cognitive 








Fig. 2.4.2.4 Diabetes-associated cognitive decline was accelerated in diabetic 
mAPP mice. Mean escape latency to the hidden platform during 6 days of acquisition 
session (A),  average swimming speed (B), percentage of time spent in the target 
quadrant (C), and the number of platform crossings (D) were shown for the indicated 
groups. Representative images of swimming paths for groups indicated were shown in 
the bottom. Results were compared using one-way ANOVA with Fisher's Least 
Significant Difference test. n= 4-7 per group. ****p<0.0001, **p<0.01 vs nonTg Veh 





Mitochondrial dysfunction has been implicated in diabetes-associated brain damage. 
Compared with other cell types, neurons rely heavily on mitochondria for their functions 
and survival, primarily due to their exceptional cellular morphology. Proper 
mitochondrial distribution, efficient mitochondrial transport, normal mitochondrial 
dynamics and intact mitochondrial respiratory capacity are all critically important for the 
maintenance of synaptic function. Previously, we have shown that hyperglycemia-
induced ROS generation disrupted mitochondrial dynamics, resulting in alterations in 
mitochondrial morphology and defects in mitochondrial respiratory function [75]. 
Impaired mitochondrial function was accompanied by injured synaptic plasticity [75]. 
Notably, restoration of mitochondrial fission/fusion balance ameliorated hyperglycemia-
induced defects in mitochondrial respiratory function and synaptic plasticity, suggesting 
an intrinsic link between mitochondrial dysfunction and diabetes-induced cognitive 
impairment. In the current study, we demonstrated that CypD, a critical regulator of the 
mPT, plays a major role in diabetes-induced brain mitochondrial malfunction and 
cognitive impairment using a mouse model of type 1 diabetes.  
In the present study, we observed increased CypD protein expressions in both 
hippocampus and cerebellar cortex of diabetic mice (Fig.2.4.1.1). Additionally, STZ-
induced diabetic mice also showed deficits in synaptic plasticity [507], as reflected by the 
suppression of long-term potentiation (LTP), loss of synaptic integrity [507], as 
evidenced by reduced expression levels of postsynaptic proteins, as well as impairments 
in hippocampus-dependent learning and memory (Fig.2.4.1.4). It has been shown that the 
expression level of CypD is correlated with the susceptibility of mPTP opening. 
157 
 
Specifically, mitochondria with low CypD expression displayed higher calcium threshold 
toward mPT induction, therefore more resistance to mPTP opening [508]. In contrast, 
mitochondria with high CypD expression exhibited elevated sensitivity to mPTP opening 
[508, 509]. Therefore, diabetes-induced upregulation of CypD may enhance the 
probability of mPTP opening, leading to mitochondrial dysfunction, and subsequent 
synaptic injury and cognitive impairment.  In support of this notion, genetic deletion of 
CypD significantly improved mitochondrial function (Fig. 2.4.1.3), attenuated synaptic 
injury [507], restored synaptic function, and ameliorated learning and memory deficits in 
STZ-induced diabetic mice (Fig. 2.4.1.4). On the contrary, when the diabetes-induced 
increase in CypD was further enhanced in the presence of Aβ (Fig.2.4.2.2), diabetes-
related defects in mitochondrial function (Fig.2.4.2.3), synaptic plasticity[510] and 
learning and memory function (Fig.2.4.2.4) were significantly exacerbated. In addition to 
animal models of diabetes, enhanced protein levels of CypD were also observed in the 
brains of diabetic patients when compared to age-matched healthy subjects [507].  
Intriguingly, postmortem studies of diabetic brains demonstrate a negative correlation 
between CypD expression and score on the Mini-Mental State Examination (MMSE) 
[507].  Given that elevated brain CypD expression and cognitive decline were observed 
in both diabetic patients and STZ-induced diabetic mice, our data indicate the clinical 
relevance of CypD-mediated brain mitochondrial abnormalities in diabetes-associated 
cognitive dysfunction and dementia. 
CypD is a crucial regulatory component in the formation of mPTP in the presence of 
inducers such as ROS generation and Ca2+ overload. Genetic ablation or pharmacological 
inhibition of CypD by CsA prevents CypD-mediated mPTP opening, thus preserving 
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mitochondrial membrane potential, mitochondrial structure, and function, and preventing 
cell death. Its role in physiological regulation of Ca2+ homeostasis by transient Ca2+ 
release suggests CypD may function as a switch, which controls transient or prolonged 
opening of the mPTP [473]. Therefore, changes in CypD expressions may have a 
profound impact on the susceptibility and status of mPTP opening. In support of this 
assumption, single-channel patch clamp studies indicate that brain mitochondria isolated 
from STZ-induced diabetic mice displayed increased opening probability in CsA-
sensitive high-conductance channel when compared to non-diabetic mice [507]. In line 
with these findings, mitochondria isolated from diabetic brains also exhibited aggravated 
mitochondrial swelling and cytochrome c release induced by Ca2+ overload, which were 
attenuated by CsA treatment [507]. These results suggest that enhanced CypD expression 
contributes to the hypersensitivity of CypD-mediated mPTP opening, which may underlie 
diabetes-induced mitochondrial dysfunction and cognitive impairment. 
Despite being recognized as an essential component of mPTP, the precise mechanism by 
which CypD regulates mPTP formation is not clear. In addition to CypD, the molecular 
identity of mPTP remains controversial. Recent studies, however, suggest that F1F0 ATP 
synthase is the central core component of mPTP and CypD binds the lateral stalk of F1F0 
ATP synthase and modulates its hydrolytic activity [511-513]. Thus a question is raised as 
to whether CypD-F1F0 ATP synthase interaction is implicated in CypD-mediated mPTP in 
the diabetic brain? Co-immunoprecipitation analysis in brain mitochondrial lysates 
confirmed the interaction between F1F0 ATP synthase and CypD [507]. Interestingly, 
increased amount of CypD was found in the F1F0 ATP synthase immunoprecipitates in the 
brain mitochondria isolated from diabetic mice, suggesting an augmented CypD-F1F0 
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ATP synthase interaction in the diabetic brain [507], which may serve as a potential 
mechanism underlying CypD-mediated mitochondrial malfunction. Chronic 
hyperglycemia and consequent ROS production can trigger the translocation of CypD 
from the mitochondrial matrix to the IMM where it interacts with F1F0 ATP synthase to 
facilitate conformational change and pore formation.  mPTP opening leads to the collapse 
of the mitochondrial membrane potential, depletion of ATP, mitochondrial swelling, 
mitochondrial respiratory dysfunction, which will further exacerbate oxidative stress, 
forming a vicious feedback loop. In support of this hypothesis, blocking the interaction 
between CypD and F1F0 ATP synthase by genetic deletion of CypD ameliorated 
mitochondrial ROS generation and defects in the mitochondrial respiratory chain 
(Fig.2.4.1.3)[507]. Further, other presumed components of mPTP, such as ANT, PiC, and 
BH3 pro-apoptotic proteins, BAX and BAK, may also be implicated in the regulation of 
mPTP in the diabetic brain. Further investigations are needed to uncover the molecular 
basis of CypD-F1F0 ATP synthase interaction, its role in mPTP formation and how it is 
regulated under both physiological and diabetic conditions. 
Another potential mechanism underlying diabetes-induced mitochondrial dysfunction and 
cognitive impairment may implicate the interaction between CypD and Aβ.  Both in vitro 
and in vivo studies have demonstrated that hyperglycemia facilitates the production and 
processing of amyloid precursor protein, thus promoting Aβ generation [514-517]. In the 
current study, we did not observe significant difference in Aβ40 and Aβ42 levels between 
STZ-treated and vehicle-treated non-transgenic mice nor between STZ-treated and 
vehicle-treated AD transgenic mice (data not shown), which are consistent with previous 
findings that STZ-induced diabetes exacerbated Alzheimer-like cognitive dysfunction 
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without increasing brain Aβ load in presymptomatic AD transgenic mice [518]. However, 
recent studies suggest that induction of chronic diabetes facilitates cerebral Aβ 
accumulation. For instance, experimental induction of type 2 diabetes by high-fat diet 
treatment increased brain Aβ levels in the senescence-accelerated mouse model 
(SAMP8), which displays early pathological features of AD [519]. Obese mice 
overexpressing mutant human APP (mAPP) showed aggravated Aβ accumulation in the 
brain microvascular vessels when compared to non-diabetic mAPP mice [520]. In line 
with these findings, an increase in cerebellar Aβ42 level was observed in a mouse model 
of type 2 diabetes (db/db) (data not shown). It has been shown that Aβ can bind to CypD, 
promote CypD translocation to inner mitochondrial membrane and subsequent formation 
of mPTP [58]. Enhanced CypD and Aβ expression may synergistically contribute to an 
increased probability of mPTP opening, that exacerbates mitochondrial dysfunction, 
synaptic injury and cognitive impairment as observed in the brains of diabetic mAPP 
mice. 
In summary, we report CypD is a major player in brain mitochondrial perturbation and 
cognitive impairment related to diabetes. Enhanced CypD expression increases the 
brain’s susceptibility to hyperglycemia-induced oxidative damage, whereas CypD 
deficiency protects against hyperglycemic insults. While future mechanistic studies are 
necessary to elucidate the precise role of CypD in mPTP formation in the diabetic brain, 
this study provides evidence for a causal link between oxidative stress-induced 
mitochondrial dysfunction and cognitive impairment, thus providing further insights into 
the mechanisms underlying diabetes-associated CNS complications.  
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2.6 Future Directions 
In the present study, we provide evidence for the involvement of CypD-mediated mPTP 
in diabetes-associated mitochondrial dysfunction and cognitive impairment. However, 
several questions remain to be addressed. The first question is how diabetes regulates 
gene and protein expression of CypD. In contrast to its well-characterized role in mPTP 
formation, much less is known about how CypD expression is regulated. A recent study 
suggests hematopoietic-substrate-1 associated protein X-1 (HAX-1) inhibited oxidative 
stress induced-mPTP opening through downregulation of CypD levels in the cardiac 
mitochondria [521].  Mechanistic studies reveal that HAX-1 recruited heat shock protein-
90 (Hsp90) from CypD, rendering CypD susceptible to ubiquitin-proteasomal 
degradation [521]. Therefore, such Hsp90/HAX-1 interaction may also underlie the 
altered CypD protein levels in the brain mitochondria.  Examination of the expression 
levels of HAX-1, Hsp90, and their interaction may help to validate this assumption. 
Additionally, CypD expression may also be regulated at the transcriptional and post-
transcriptional levels. Further investigations are warranted to elucidate the molecular 
mechanisms underlying the regulation of CypD in brain mitochondria under both 
physiological and pathological conditions, particularly in diabetes and AD.  
Another question that remains to be addressed is which signaling pathway is responsible 
for the hyperglycemia-induced oxidative damage in diabetic brain. Previous studies have 
shown that oxidative stress activates several mitogen-activated protein kinase signaling 
pathways (MAPK) including p38 and ERK, as well as other signaling pathways such as 
cAMP-dependent protein kinase (PKA)/cAMP response element binding (CREB) signal 
transduction pathway. Additionally, the activation of glycogen synthase kinase-3 
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(GSK3β) has been implicated in hyperglycemia-induced perturbation in mitochondrial 
and synaptic function. Examination of the pathways mentioned above may help to 
elucidate the cellular processes that occur in brain mitochondrial dysfunction and 
synaptic deficit, thus providing insights into diabetes-associated cognitive dysfunction. 
Further, studies on rodent models of diabetes suggest the molecular mechanisms of 
diabetes-associated CNS disorder differ in type 1 and type 2 diabetes. The observations 
made in the present study were based on a mouse model of type 1 diabetes. We have 
previously reported hyperglycemia-induced oxidative stress, mitochondrial respiratory 
dysfunction and synaptic injury in the brains of mice with spontaneous type 2 diabetes 
(db/db). Since CypD-mediated mPTP induction represents a causal link between 
oxidative stress-induced mitochondrial perturbation and cognitive impairment, future 
studies are needed to examine the implication of CypD in cognitive dysfunction induced 




In summary, the results of the present study clearly demonstrate that CypD is a major 
player in diabetes-associated brain damage (Fig. 2.7.1).  The absence of CypD markedly 
improved brain mitochondrial respiration and cognitive function in mice with diabetes 
induced by STZ, whereas enhanced CypD expression exacerbated brain mitochondrial 
dysfunction and accelerated cognitive deficits in mice overexpressing mAPP and made 
diabetic.  The Cypd-mediated opening of mPTP may serve as one of the mechanisms 
underlying diabetes-induced defects in mitochondrial respiration, dynamics and motility, 
which contribute to synaptic injury and ultimately cognitive impairment. Therefore, 
inhibition of CypD-mediated mPTP opening by blocking the interaction of CypD and 
other components in the mPTP may represent a promising therapeutic strategy for the 









Fig. 2.7.1 CypD-mediated mPTP is implicated in diabetes-induced cognitive 
impairment including AD. Diabetes is typically accompanied by increased 
production of ROS and perturbed calcium homeostasis invoked by chronic 
hyperglycemia. In the context of AD, Aβ also elevates intracellular calcium and ROS 
generation. Increased CypD expressions have been observed in both diabetic and AD 
brains. These conditions favor the opening of mPTP, resulting in mitochondrial 
dysfunction including reduced mitochondrial electron transport chain (ETC) complex 
activities, impaired axonal mitochondrial trafficking and mitochondrial fragmentation. 
Severe mitochondrial perturbations lead to synaptic injury and ultimately deficits in 
learning and memory function. Blocking mPTP opening by pharmacological 
inhibition of CypD may represent a promising therapeutic strategy for treatment of 




In summary, the data presented in this dissertation indicate that perturbation in brain 
energy metabolism and resulting energy deficits may form the pathophysiological basis 
for brain disorders including AD and diabetes. However, in different diseases, distinct 
metabolic processes, and discrete mechanisms are affected. Results obtained from the 
first study suggest that three human ApoE isoforms differentially modulate glucose 
transport and glycolysis, with ApoE2-expressing brain exhibiting the most robust profile 
whereas ApoE4-expressing brain demonstrating a most deficient profile. The 
bioenergetic robustness associated with ApoE2 may underlie its protective properties 
against AD. By contrast, the defects in glucose metabolism associated with ApoE4 may 
lead to energy failure, rendering the brain vulnerable to aging and AD-related insults, 
which may underlie its increased susceptibility to AD. Notably, the introduction of 
ApoE2 completely reversed the bioenergetic deficits induced by ApoE4, suggesting that 
brain delivery of ApoE2 may represent a promising therapeutic approach for AD 
prevention or early intervention, particularly in the high-risk ApoE4 carriers.  
Results obtained from the second study reveal a pivotal role of CypD in brain 
mitochondrial perturbation and cognitive dysfunction related to diabetes. Intriguingly, 
CypD deficiency attenuated whereas enhanced CypD expression exacerbated diabetes-
induced defects in brain mitochondrial respiration and cognitive function. Given that 
CypD is a key regulatory component of mPTP, CypD-mediated opening of mPTP may be 
one of the mechanisms underlying diabetes-induced mitochondrial dysfunction and 
subsequent synaptic injury and cognitive impairment. Therefore, a therapeutic strategy 
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that could inhibit mPTP opening by blocking the interaction of CypD and other 
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